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Chapter 1
Introduction
Adapted from M.O. Canning, C. Ruwhof, H.A. Drexhage. Autoimmunity 2003; 36: 429 – 42
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I. THE SPECTRUM OF AUTOIMMUNE THYROID DISEASES IN THE HUMAN
Immune responses to thyroid specific autoantigens form the basis of autoimmune thyroid 
disease pathogenesis. Two polar forms of autoimmune reactivity of the thyroid gland exist in 
this disease spectrum: a catabolic form characterized by gradual inflammatory destruction of 
thyroid parenchyma leading to thyroid failure, and an anabolic form in which stimulation of 
the growth and metabolism of the thyroid parenchyma leads to goiter formation and hyper-
thyroidism. The catabolic form is best known as destructive autoimmune thyroiditis, whereas 
the anabolic form is generally referred to as Graves’ disease. 
Destructive Autoimmune Thyroiditis
Clinically the destructive autoimmune thyroiditis is sub-divided in Hashimoto goiter and atro-
phic thyroiditis. Both are characterized by infiltrates of immune cells, which destroy thyroid 
parenchyma, yet in Hashimoto thyroiditis there are re-growing thyroid follicles leading to 
goiter formation, while in atrophic thyroiditis re-growth is absent leading to a rapid atrophy.
Antibodies (Abs) involved in both subtypes are mainly directed toward the colloid and 
the thyroid cells, which themselves are players in the progression of the disease, expressing 
molecules of immunological interest such as HLA class I and II, CD40, adhesion molecules, 
cytokines and complement regulatory proteins (1). The most important target antigens of 
these autoantibodies are thyroperoxidase (TPO) and thyroglobulin (Tg) (Table I).
Table I.
Target Organ Antigens Indicative of (prevalence in disease) Autoantibody Prevalence and Predictive 
Clinical Outcome
Thyroid TPO/ TG Hashimoto’s Goiter        (80-100%) Healthy adults (5-15%) TPO antibody-positive
Thyroid Atrophy   (60-70%) Females exhibit (per year) in 2-3% of 
cases a progression toward (subclinical) 
hypothyroidism
TPO antibody-positive females with a serum 
TSH level > 6,0 mU/l* exhibit (per year) in 4-5% 
of cases a progression toward hypothyroidism
TSH-R Graves’ disease   (80-90%) Healthy adults (0,3%)
Thyroid Atrophy   (30-40%) The presence of antibodies always results 
in clinical manifestation of the disease. In 
pregnant females with (treated) Graves’ 
disease or Thyroid Atrophy and positive TSH-R 
antibodies
Congenital hyper- or hypothyroidism should be 
suspected in the neonate
Abs to TPO and Tg are found in high titre in the serum of 80-90% of patients with Hashimoto’s 
disease, of 60-70% of atrophic thyroiditis patients, and of on average 10% of the normal 
healthy population. This latter prevalence is age and gender dependent, with females from 
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50 to 70 years of age displaying the highest prevalence of around 15% positivity of serum 
TPO-Abs. Since serum TPO-Abs are reliable markers of an existing thyroid autoimmune 
inflammation, it can be concluded that the incidence of autoimmune thyroiditis is consid-
erable in the general population, particularly in “healthy” elderly women. This sub-clinical 
presence of autoimmune thyroiditis carries an increased risk of developing sub-clinical and 
overt thyroid failure (Table I). 
TPO-Abs have recently been found to be significantly more prevalent in patients with 
bipolar disorder (28%) than population controls and psychiatric inpatients (3-18%) (2). The 
presence of TPO-Abs in bipolar patients was associated with thyroid failure, but not with age, 
gender, mood state, rapid cycling or lithium exposure.
Destructive autoimmune thyroiditis is also associated with neuro-endocrine disorders 
other than bipolar disorder: type 1 diabetes patients also exhibit a higher prevalence of 
this disease (3). Prevalences of up to 40% positivity for TPO-Abs have been found in type 1 
diabetic patients and they develop thyroid failure in up to 10% of cases. This combination of 
type 1 diabetes and autoimmune thyroid failure is known as Polyglandular Syndrome (PGS) 
type 3a. Patients with atrophic gastritis/pernicious anemia have a high prevalence of TPO-Abs 
(30-50%) as well (3). Autoimmune thyroid failure occurs in 25% of patients with pernicious 
anemia; this combination is referred to as thyro-gastric disease or PGS type 3b. 
Although TPO-Abs are a good marker of the destructive autoimmune thyroid process, 
they are not the actual effectors of the autoimmune destruction. Macrophages activated by 
auto-antigen specific T helper-1 (Th1) cells, cytotoxic CD8+ T cells, and apoptotic interactions 
between thyrocytes and these inflammatory cells are believed to play a more prominent role 
in the actual destruction of the thyroid parenchyma (4).
Receptor Antibodies
Although Tg and TPO are the best-known thyroidal antigens, others can also be the target of 
a thyroid autoimmune reaction. These other thyroidal antigens are f.i. the TSH-receptor and 
the IGF-1 receptor (5). These antibodies bind to these receptors and either mimic the bind-
ing of the actual ligand perfectly or imperfectly. The perfect mimicking receptor antibodies 
will lead to activation of the thyrocytes, i.e. the stimulation of thyroid hormone synthesis 
and growth (the so-called thyroid hormone stimulating antibodies, TSAbs, and the thyroid 
growth stimulating antibodies, TGAbs). The non-mimicking receptor antibodies will block 
the receptor and will lead to the blockade of hormone synthesis and growth (the so-called 
thyroid blocking antibodies (TBAbs)). The goiter in Hashimoto’s disease results from the re-
growth of destroyed thyroid follicles via a raised plasma TSH and the additional stimulation 
via stimulating antibodies, the TSAbs and TGAbs. Thyroid atrophy is due to the inability of the 
destroyed follicles to re-grow and respond to the raised TSH due to the presence of blocking 
antibodies, the TSBAbs and TGBAbs. 
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Graves’  Disease 
The clinical picture in Graves’ disease is characterized by hyperthyroidism, a diffuse goiter 
and endocrine ophthalmopathy. This triad is referred to as the Merseberg triad. 
The TSH-receptor (TSH-R) is the most important autoantigen in Graves’ disease. Antibod-
ies to this receptor are found in over 90% of patients with active disease. These Abs of IgG 
class are considered to be the direct cause of the disease, since monoclonal Abs to the TSH-R 
stimulate cAMP in cultured thyrocytes and since cAMP is involved in both hormone produc-
tion and cellular proliferation of thyrocytes. Moreover, transplacentally transferred TSH-R Abs 
are able to induce Graves’ hyperthyroidism in the neonate. 
The antibody response to the TSH-R in Graves’ patients is polyclonal and heterogeneous, 
and directed to various, partly overlapping, non-linear (conformational) epitopes in the TSH-
binding as well as the non-TSH-binding domain of the TSH-R (5). In view of this heterogeneity 
of the TSH-R Abs and the coupling of the receptor to various 2nd messenger systems other 
than cAMP, it is not surprising that IgG fractions of Graves’ sera are also capable of stimulating 
2nd messenger systems belonging to the PLA2 and PLC pathways (6). There are even reports 
of Graves’ IgG fractions that stimulate either the cAMP or the PLA2 pathway (6). Both varieties 
of TSH-R Abs are capable of inducing in vitro thyrocyte proliferation and when these varieties 
are found together in the serum of Graves’ patients, these patients show the largest goiters 
and the most severe expression of hyperthyroidism (6).
There are also receptor antibodies that are not directed to the TSH-R but to another 
important receptor on thyrocytes, the IGF1-receptor (7,8,9). These antibodies are most likely 
synonymous with the previously described TGAbs in Graves’ disease contributing to goiter 
formation in the virtual absence of stimulating hormone production. 
The interactions of the various above described TSH-R and IGF1-R Abs may explain differ-
ences in symptom expression in Graves’ patients, such as a strong hyperthyroidism with a 
small-to-absent goiter or the opposite, a hugh goiter with mild hyperthyroidism. 
Ophthalmopathy is due to a retrobulbar autoimmune reaction, which has as its target the 
eye muscle and the retrobulbar pre-adipocytes (fibroblastic cells). Here again the main tar-
gets are considered to be the TSH-R and the IGF1-R on the retrobulbar pre-adipocytes (5).
II. ANIMAL MODELS OF AUTOIMMUNE THYROID DISEASE
Since the intensive and in depth study of patients has its obvious limitations, knowledge on 
the pathogenesis of autoimmune thyroid diseases has been gained also and often predomi-
nantly in studies on animal models of the disease. In the following paragraphs I would like to 
shortly introduce these animal models.
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The Autoimmune Thyroiditis of the Obese Strain (OS) Chicken 
One of the oldest models of endocrine organ-specific autoimmune disease is the Obese 
Strain (OS) Chicken, which suffers from a lymphocytic thyroiditis with a rapid onset of hypo-
thyroidism (10). For the last 40 years chickens of the OS strain have been used to study the 
disease, which resembles severe destructive autoimmune thyroiditis of the human in many 
clinical, histopathological, serological and endocrinological aspects. Mononuclear cell infil-
tration of the thyroid gland commences in the second week after hatching and leads to an 
almost complete destruction of the thyroid architecture by 1-2 months of age. Limitations for 
extensive and up-to-date research in this model are the scarcity of immunological reagents 
for chickens and the absence of avian-cloned thyroid-specific genes. 
The first genetic theory of endocrine organ-specific autoimmunity as a polygenic trait 
(1966) was proposed by Cole and based on breeding studies with this bird (11). The three-
locus model of immune response MHC and non-MHC genes and genes coding for a hypo-
thetical primary thyroid defect emerged from genetic analysis of OS families and from F2 
crosses between OS and Cornell Strain (CS) chickens. Crossing experiments with another CS 
inbred line unrelated to OS revealed the existence of about 5 genes regulating the full devel-
opment of the disease. Approximately three genes encode the susceptibility of the target 
organ to the attack by the immune system (one of them recessive) and the remaining one or 
two genes encode the hyper-reactivity of the immune system (12).
Iodine levels in food are an important environmental factor in the development of thyroid-
itis in the OS chicken, and the severity of the disease can be manipulated by iodine: Iodine 
deficiency attenuates, while iodine excess accelerates autoimmune thyroiditis (13). Iodine 
probably exerts these effects via inducing alterations in the metabolism of thyrocytes and 
even via toxic thyrocyte necrosis. Application of anti-oxidants delays the onset of the thyroid-
itis in the OS chicken, illustrating the importance of oxidative reactions in the toxicity of iodine 
(13). Iodine also has direct effects on the development and function of various immune cells 
(antigen-presenting cells, T cells and B cells) and the antigenicity of thyroglobulin (13,14). 
The role of the stress system in the development of the disease in the chickens is illustrated 
by an altered immuno-endocrine communication via the HPA-axis in this strain of birds (15). 
The OS chicken shows a hypo-responsiveness to glucocorticoids and in particular to inhibi-
tory factors released by this stress hormone in immune cells (15). Moreover, low levels of the 
central opioid peptide ß-endorphin have been shown in the hypothalamus of the OS chick-
ens before onset of the disease, i.e. already at the embryonic stage. A further decrease in this 
brain peptide was observed in correspondence with the first signs of thyroid mononuclear 
infiltration (16). 
The autoimmune thyroiditis of the BB-DP rat
The BB-DP rat is primarily a model for autoimmune diabetes (17). Inbred diabetes-prone BB 
(BB-DP) rats develop spontaneously a T cell-dependent, ketosis-prone diabetes and have a 
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profound T cell lymphopenia. BB-DP rats also suffer from a form of focal lymphocytic infiltra-
tions in the thyroid that under normal conditions do not lead to hypothyroidism (18). These 
focal lymphocytic infiltrations show a high degree of architecture similar to that of secondary 
lymphoid organs (spleen and lymph nodes) with T cell zones, B cell follicles and high endo-
thelial venules (HEV). These lymphocytic accumulations become more pronounced when the 
animals are fed a high iodine diet (19,20). Thyroid failure may become apparent after hemi-
thyroidectomy of such animals. 
There also exist sub-lines of the BB-DP rats, that are not lymphopenic and do not develop 
diabetes and thyroiditis. These lines are referred to as Diabetes Resistant or BB-DR. The lym-
phopenia of the BB-DP rat is primarily due to a lack of RT6+ T cells. RT6 is a marker for regula-
tory T cells. Transfers of RT6+ T cells from BB-DR rats to BB-DP rats prevent the development 
of diabetes and thyroiditis (17).
The autoimmune thyroiditis of the NOD mouse
The NOD mouse is – like the BB-DP rat - also predominantly studied for its autoimmune dia-
betes (21). NOD mice develop from an early age onwards (5 weeks) an initially non-destruc-
tive peri-insular accumulation of dendritic cells, accessory macrophages, T cells and B cells 
that persists for several weeks before it develops into a destructive form of insulitis (from 12 
weeks of age onwards). Mild diabetes follows.
In the majority of the NOD strains there is only occasionally an association of diabetes with 
thyroid infiltrations (unlike in the BB-rat). In general the incidence of thyroiditis is very low in 
the NOD mouse, however it varies from colony to colony (22). 
Certain dietary iodine regimens, however, have a triggering effect on thyroiditis devel-
opment. When mice are made iodine deficient they develop a hyperplastic goiter. A single 
administration of a high dose of iodide to such mice has a necrotic effect on the hyperplastic 
iodine-deficient glands. In normal mice such dietary manipulation does not lead to thyroid 
autoimmunity. In NOD mice, however, it does lead to a Th1-mediated destructive autoim-
mune thyroiditis following the phase of early iodine-induced toxic thyrocyte necrosis (22). 
This again shows – as in the OS chicken - the importance of a local environmentally-induced 
factor (iodine-induced necrosis with a coinciding high antigen release and inflammation), 
which has to act in combination with a dys-regulated immune system (NOD mouse back-
ground) to start a full-blown autoimmune thyroiditis (22,23).
There are many genetic loci (over 15) on different chromosomes that associate with dia-
betes in the NOD mouse. The most important diabetic loci are linked to the MHC complex: 
NOD mice express an unique I-A locus, i.e. I-A g7 (histidine as residue number 56 and serine as 
residue 57, homologous to “diabetogenic” HLA-DQ ß non-aspartic acid 57 containing alleles 
in the human), but lack expression of I-Ea (homologous to DR α in humans) (24). There also 
exists a sub-line of NOD mice characterized by an alternative MHC haplotype, viz. the I-Ak 
allele instead of the I-Ag7 on the NOD background, and the mice are called NOD-H2h4 mice. 
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These mice have under normal dietary conditions a prevalence of around 5% thyroiditis, but 
when kept on a continuously high iodine diet “spontaneously” develop autoimmune thyroid-
itis in virtually all animals (25). 
Mouse thymectomy models of autoimmune thyroiditis
Thymectomy of Balb/C mice at day 3 results in a variety of organ-specific autoimmune dis-
eases, including thyroiditis, gastritis, and oophoritis, but not insulitis (26). The inflammations 
are characterized by the presence of T cell infiltrates in the affected organs and the develop-
ment of organ-specific antibodies in the serum. There is a strict temporal relationship between 
the development of the autoimmune syndrome and the day of thymectomy, which has to 
occur between the second and the fifth day after birth (27). Classically the model has been 
used to study oöphoritis and autoimmune gastritis (28). Autoimmune thyroiditis has hardly 
been studied in this model. The recent interest in CD4+CD25+ T cells as a specific subpopula-
tion of thymus-derived suppressor or regulatory T cells has a clear historical association with 
the day 3 mouse thymectomy model (29,30). Day 3 neonatal thymectomy-induced autoim-
mune disease is due to a lack of CD4+CD25+ T cell migration into the periphery, since these 
regulatory cells typically migrate out of the thymus in this early period and since injection of 
purified CD4+CD25+ T cells into neonatally thymectomized mice prevents the development 
of autoimmunity, including autoimmune thyroiditis. 
Animal models for “experimental allergic” Graves’ disease
Classical models for the induction of organ-specific autoimmune disease are models that 
make use of immunizations with autoantigen in an adjuvant (the so-called “experimental 
allergic models”). A recent promising development in this area of experimental allergic 
diseases is the sensitization of mice with TSH-receptor (TSH-R) peptides, recombinant TSH-R 
preparations or with cDNA for the full-length human TSH-R cloned in an eukaryotic expres-
sion vector (genetic immunization) to create an animal model for Graves’ disease (31). In 
these experiments it appeared easy to induce TSH-R antibodies (Abs) in all mice strains used 
with all the mentioned regimens. However the majority of the regimens were without any 
effect on the histology or function of the thyroid in most of the cases: Whereas H-2b and H-2k 
animals did not develop thyroiditis or thyroid function abnormalities, H-2d (Balb/C) mice did 
and some of these mice had hypo-thyroxinemia. Also NOD mice (H-2g7) developed thyroid-
itis and TSH-R Abs, and particularly in the NOD mouse model the thyroiditis was destructive 
and of Th1 character leading to clear hypothyroidism (32). This shows that the TSH-R is also 
able to induce destructive autoimmune thyroiditis, depending on the genetic background 
of an organism. 
Hyper-thyroxinemia and orbital pathology (both clinical hallmarks of Graves’ disease) 
were more difficult to induce using the above-described protocols. However two protocols 
showed some success:
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1) immunizations of H-2k (AKR/N) mice intraperitoneally with MHC Class I identical 
fibroblasts double transfected with the TSH-R and MHC Class II led in 20% of cases to 
hyperthyroxinemia 
2) immunizations of outbred Balb/C mice with TSH-R cDNA vectors led in 10% of cases 
to hyperthyroxinemia and TSH-R Abs that were able to stimulate c-AMP in cultured 
fibroblasts.
Even more interesting is the observation that transferring T cells from the latter mice to naïve 
mice (after an in vitro restimulation of the T cells with a recombinant TSH-R preparation) led 
to a Th1 thyroiditis with no signs of eye muscle infiltration when a NOD mouse model was 
used throughout. It led to a Th2 type thyroiditis with mild signs of eye muscle infiltration 
when Balb/C mice were used (31). 
Recently it was shown that subcutaneous injections of dendritic cells, the most potent anti-
gen-presenting cells (see below), infected with recombinant adenovirus expressing the TSH-
R were able to induce a Graves’-like hyperthyroidism in female mice which was characterized 
by stimulating TSHR antibodies, elevated serum thyroxine levels and diffuse hyperplastic 
goiter (33). TSHR antibodies determined by ELISA were of both IgG1 (Th2-type) and IgG2a 
(Th1-type) subclasses, and splenocytes from immunized mice secreted interferon-gamma (a 
Th1 cytokine), not interleukin-4 (a Th2 cytokine), in response to TSHR antigen. Surprisingly, 
IFN-gamma secretion, and induction of antibodies and disease were almost completely sup-
pressed by co-administration of alum/pertussis toxin, a Th2-dominant adjuvant. These data 
challenge the concept of a Th2 dominance in Graves’ hyperthyroidism and provide support 
for the role of Th1 immune response in disease pathogenesis. 
Clearly these models of experimentally-induced Graves’ disease are promising and need 
further exploration, yet they can not be used to study the very early phases of “spontaneously 
developing” autoantigen presentation in “wild type-occuring” Graves’ disease. The models 
may, however, be useful in the study of effector mechanisms playing a role in the signs and 
symptoms of Graves’ disease.
III. RISK FACTORS FOR DEVELOPING THYROID AUTOIMMUNE DISEASE
Genotype
A genetic predisposition to autoimmune reactivity is associated with positivity for particular 
MHC class I and II haplotypes. Specifically, Graves’ disease is associated in whites with HLA B8 
and DR3, and in particular with DRB1*0304-DQB1*02-DQA1*0501 haplotype. MHC associa-
tion studies in destructive autoimmune thyroiditis have revealed less consistent results. In 
whites, an association has been reported with various HLA alleles, including B8, DR3, DR4, 
DR5, DQA1*0201/*0301 and DQB1*03 (34). 
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Also non-MHC linked gene polymorphisms play a role in the development of autoimmune 
thyroiditis, such as polymorphisms in the CTLA-4 gene.
Effects of Age and Gender
Table I gave the prevalences of TPO-Ab positivity in the general population and the risk for 
developing overt and/or subclinical thyroid disease in case of antibody positivity. Figure 1 
further illustrates the prevalence rates of TPO-Ab positivity in the general population as a 
function of age and gender. It is clear from this figure that thyroid autoimmunity has a predi-
lection for the older aged and the female gender.
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Figure 1. Prevalence of thyroperoxidase (TPO) antibody positivity in the normal population according to age and gender. TPO antibodies 
determined by Lumitest (Henning, Berlin, Germany). Black bars, females; white bars, males. n>150 in each age category.
The effect of ageing on the incidence of certain autoimmune diseases is generally ascribed to 
the decline in immune function in old age, so-called ‘immuno-senescence’. Signs of immuno-
senescence are thymus involution, and the involution and fibrosis of secondary lymphoid 
tissues. Interestingly, serum levels of dehydroepiandrostenedione (DHEA), which is quantita-
tively the most abundant adrenal steroid hormone, also show a steady decline with ageing 
(35). There are reports showing that when DHEA is administered to aged individuals, whether 
animals or humans, their immune function is activated: they become more resistant to infec-
tions, their secretion of T-cell cytokines is enhanced, and monocyte numbers are increased. 
There are, however, also reports that refute such immune stimulating action of pharmaco-
logical doses of DHEA (36). In this respect, it is worth noting that DHEA administration does 
not lead to an attenuation of autoimmune thyroiditis in the ageing BB-DP rat.
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With regard to the female preponderance in autoimmunity, the mode of action of sex ste-
roids in the spontaneous autoimmune models still remains to be elucidated. Experimental 
studies show that the course of these autoimmune diseases can be modulated by procedures 
interfering with sex steroid levels, such as by castration or administration of sex steroids 
(37). In chicken and mouse models for autoimmune thyroid disease, oestrogen treatment of 
female or male animals, as well as castration of male animals, results in increased autoanti-
body levels. When castrated animals are treated with testosterone, autoantibody levels and 
autoimmunity decrease again.
However, results differ between distinct animal strains. Also, extrapolation of concepts 
derived from such animal studies to the human situation is problematic, because animal 
studies in general are performed in a genetically homogeneous population. To illustrate this, 
we have collaborated in a study on male to female transsexuals; castration followed by treat-
ment with female hormones of these individuals did not lead to an increased prevalence of 
TPO antibodies up to the level found in the normal female population (38).
Effects of Environmental Factors
In addition to internal factors such as genotype, gender and age, environmental factors also 
play a role in the pathogenesis of thyroid autoimmune disease. The most important of these 
external factors are infectious agents, dietary intake, toxic agents and stress.
Infectious agents. Epidemiological studies have suggested a negative correlation between 
the pathogen weight in a population and the incidence of type 1-diabetes. In NOD mice 
and BB-DP rats, vaccination with Mycobacterium bovis, strain Bacillus Calmette–Guerin (BCG), 
or Mycobacterium tuberculosis- or QFA-containing preparations protect from developing 
diabetes in the animals, provided the treatment is initiated during the first 2 weeks of life 
(39). Staphylococcal enterotoxins have also been shown to prevent diabetes in NOD mice. 
Viruses can prevent diabetes too, and a plethora of viral strains such as EMCV-B, Lymphocho-
riomeningitis virus (LCMV) and others have been shown to interfere favourably with diabetes 
development in the rodent models of the disease (40). Although the mechanisms behind 
this protection are far from clear, it has been suggested that the viruses or bacteria act via 
antigenic competition, or via a direct superantigenic stimulation of T cells, releasing anti-
inflammatory cytokines.
Independently of these potential protective roles, viruses and bacteria can also play a dis-
ease-promoting role. At least four mechanisms may contribute to autoimmune pathogenesis 
in this respect:
1. A virus may specifically infect a beta cell or a thyrocyte, leading to destruction of the 
cell. In this way, a non-specific inflammation of the target is induced, attracting APCs, 
which subsequently trigger an autoimmune response in susceptible (immune dys-
regulated) hosts (see above). Insulinotropic viruses include EMCV-D, reoviruses, rubella 
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and various enteroviruses, most notably Coxsackie B virus (41). Thyrotropic viruses are 
less well known, yet reoviruses may infect thyrocytes (42). 
2. Viral or bacterial proteins sometimes share sequences with important organ-specific 
autoantigens. This has been suggested for Coxsackie B virus and glutamic acid decar-
boxylase (GAD), but has recently been disputed. Cross-reactivity (mimicry) has also 
been suggested between Yersinia enterocolitica serotype 3 and the thyroid-stimulating 
hormone receptor (43). Cross-reactive epitopes could bypass existing T-cell tolerance 
to autoantigens to give rise to autoimmune responses.
3. A virus could induce the expression of neoantigens by future target cells. Reovirus 
type 1 induces an antibody-positive lymphocytic thyroiditis in mice (42). The infec-
tion is thought to introduce new epitopes next to, or as part of, thyroid autoantigens. 
This makes an immune reaction possible to these new epitopes, additionally elicit-
ing an immune reaction to the coupled or adjacent thyroid autoantigen (bypass 
mechanism).
4. Finally, viruses and bacteria may directly influence the cells of the immune system, 
thus disturbing the delicate immune regulatory balance. Avian leucosis virus induces a 
lymphocytic thyroiditis with germinal centres in fetally infected chickens (44). The virus 
infects stem cells of the immune system, and has a direct effect on thymus and bursa 
development. Retroviruses and bacterial products might also disturb the immune 
balance by acting as superantigens, which cause expansion of subsets of T cells with 
T-cell receptors containing particular Vβ chains. It is conceivable that such T cells would 
include autoimmune reactive TH1 or TH2 cells.
Dietary factors. A second source of exogeneous factors contributing to autoimmune patho-
genesis is constituted of specific food components. Both iodine excess and iodine deficiency 
are capable of disturbing the tolerance for thyroid autoantigens that exists in the healthy 
state (23,45). This sometimes leads to clinically overt thyroid autoimmune disease. An acute 
excessive iodine intake (e.g. the iodine treatment after the Chernobyl incident) in individu-
als with a predisposition for thyroid autoimmune disease induces a rise in the titre of TPO 
and thyroglobulin antibodies, and an outburst of Hashimoto-like lymphocytic thyroiditis in a 
proportion of such individuals with increased susceptibility. 
Proposed pathogenic mechanisms are:
• An iodine-induced thyrocyte necrosis with a concomitant attraction of DCs and macro-
phages, and a release of autoantigens.
• A higher antigenicity of thyroglobulin due to a higher iodination grade.
• An enhanced maturation of accessory macrophages from monocytes due to a stimulat-
ing effect of iodinated compounds.
• A direct stimulation of B cells, T cells and macrophage peroxidase activity by iodine.
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Any of these mechanisms may, by it self or in combination, break the existing tolerance for 
thyroid autoantigens and may cause disease development. 
Iodine deficiency induces goitre formation and a diminished thyroid hormone production. 
In affected populations this leads to disease entities such as endemic goitre and endemic 
cretinism. In these environmentally induced thyroid disorders, local thyroid autoimmune 
phenomena have been described. These phenomena include a DC accumulation and cluster-
ing in the thyroid and a rise in the titre of anti-TPO and anti-thyroglobulin antibodies. In 
the BB-DP rat, a mild iodine deficiency leads to acceleration of the disease. Severe iodine 
deficiency leads, however, to a severe immunodeficiency in this animal, and hence to an 
ameloriation of the thyroid autoimmune response.
Toxic agents or drugs. Chemical toxins or drugs constitute a third source of pathogenic factors 
in the development of autoimmunity. Exposure to methylcholanthrene enhances the thyroid 
autoimmune response in Buffalo rats, a strain of rats genetically susceptible to experimentally 
induced autoimmune thyroid disease (46). Methyl-cholanthrene is thought to have a direct 
toxic action on the immune regulatory system rather than on the thyroid tissue of the rats.
Among other toxic factors, components from tobacco smoke have appeared to be most 
important in the development of Graves disease and autoimmune thyroiditis (45). In the UK, 
almost two-thirds of patients with Graves ophthalmopathy smoke cigarettes, in contrast to 
10–20% of the normal healthy population. The mechanisms behind the association are not 
clear. Smoking might lead to immune dysregulations akin to the alterations seen in inher-
ited forms of thyroid autoimmune disease. As such, smoking does lead to clear alterations 
in DC and macrophage function in the lung environment, and to an altered production of 
pro-inflammatory cytokines in the lung. Whether this is reflected in systemic monocyte, DC 
and macrophage dysfunction, or in a dysfunction of such cells in the thyroid, needs to be 
investigated. Alternatively, smoking might also lead to thyrocyte necrosis or thyroid meta-
bolic abnormalities, processes that might also be driving forces behind a thyroid-specific 
autoimmunization. 
Stress. A final putative external factor that modulates autoimmune pathogenesis is stress. BB 
rats exposed to daily stress, such as rotation, vibration or restraint stress, develop diabetes 
with a higher incidence than unaffected control animals. In contrast, in NOD mice, chronic 
stress introduced between 6 and 8 weeks of age, as well as repeated injections of saline, 
decreases the incidence of diabetes. Prenatal stress, however, accelerates the onset of dia-
betes (37). These examples illustrate the complex effects of stressors. It is suspected that 
stressors modulate the development of organ-specific autoimmunity by altering set points in 
the HPA axis and the IL-l system. This notion is supported by recent findings in patients with 
manic-depressive psychosis and severe melancholia. In these patients, the immune system is 
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severely dys-regulated, and the HPA axis and IL-1 system are grossly activated. Interestingly, 
the incidence of TPO antibodies is high in such patients.
Conclusion regarding the risk factors important for the development of autoimmune thyroid disease
Autoimmune diseases are complex, polygenic afflictions of which the penetrance is heavily 
dependent on various environmental influences. Only unfortunate combinations of genetic 
susceptibility and exogenous factors lead to full-blown disease.
IV. DENDRITIC CELLS (DC) AND THEIR HETEROGENEITY
In this thesis focus has mainly been on the role of antigen-presenting cells, such as the den-
dritic cells, in autoimmune thyroid diseases. The next section will therefore deal with a short 
introduction on the origin and function of dendritic cells. 
Although almost all cells can act as antigen presenting cells to some degree, there are cells 
in the immune system that excel in this function, specifically B cells, accessory macrophages 
and above all, the DC. DC are critically involved in the initiation of primary T cell responses 
and the generation of T cell dependent auto-antibody formation (47). 
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Figure 2. Developmental scheme of the various types of DC presently recognized
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It is now well-accepted that the Langerhans cells (LC) of the skin pick up foreign antigens, 
process these antigens and travel with these - as socalled veiled cells (VC) - via the lymph to 
the draining lymph nodes to populate the T cell areas of these nodes as interdigitating cells 
(IDC) (47,48). The IDC act in presenting the transported and processed antigens to the sur-
rounding T cells, and stimulate these lymphocytes to proliferate and to differentiate. LC, VC, 
IDC and similar antigen transporting and presenting cells (APC) from other sites are generally 
referred to as dendritic cells (DC), since the cells share many morphological and functional 
characteristics with the so-called dendritic cells of Steinman, originally isolated from the 
spleen of experimental animals, and playing a prime role in antigen presentation and T cell 
stimulation and skewing (47).
Cells belonging to the DC group are the most potent APC known, and have considerable 
potential for use in immunotherapy and tolerance induction. Therefore, there exists a great 
interest in generating sizeable numbers of such cells in vitro. Various methods have been 
devised for this, resulting in populations of accessory cells which differ in phenotype, func-
tional capability and level of maturity, depending on the starting population and method 
of generation used. This has historically raised many questions about the lineage of DC, 
especially regarding possible precursors and routes of differentiation/maturation (49-55). 
Presently it is well accepted that apart from CD34+ precursor cells, also early not-commited 
thymocytes and monocytes may give rise to dendritic APC populations (56) and that the DC 
population is very heterogeneous.
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Figure 3. The traffic of monocyte-derived DC through tissues. Mo = monocyte, mDC = mature DC, Ts = suppressor T cell, Te = T effector cell
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The “lymphoid” DC originate from pre T cells in the thymus and predominately populate 
the thymic cortico-medullary junction where the cell is instrumental in the deletion of erro-
neously created auto-reactive T cells (57). 
“Plasmacytoid” DC originate from plasmacytoid precursor cells in the peripheral blood, 
characterized by a strong production of IFN-a and a positivity for CD123 (58). 
The “myeloid” DC originate from a special CD34+ precursor in the peripheral blood (giving 
rise to epidermal S100+ Langerhans cells) and from CD14+ circulating monocytes (58). In the 
last decade culturing of monocytes for a week in the presence of GM-CSF and interleukin 
(IL)-4 (11) has become popular for generating large numbers of so-called monocyte-derived 
DC. The use of this methodology has resulted in the acceptance of blood monocytes as a 
major source of DC precursors.
The generally held current paradigm (47,59) is that the myeloid DC present in the inter-
stitium of peripheral tissues are in a so-called “immature” state, suitable for their sentinel 
function. The immature cells express various molecules instrumental in the uptake of foreign 
and damaged material (mannose receptors, Toll receptors). They have a high capability for 
endocytosis enabling the cells to capture and process antigens, i.e. to place antigenic pep-
tides in the grooves of the MHC-molecules in their endocytotic vesicles. Immature DC have a 
limited potency to stimulate T cells. 
In response to a local inflammatory stimulus (the so-called “danger signals”), such as endo-
toxin (LPS) and bacteria, interstitial DC undergo maturation (Figure 3). The cells lose their 
antigen-capturing capacity and acquire a strong T cell stimulatory capacity by directing the 
antigen-loaden MHC molecules to the cell membrane and by up-regulating their co-stimula-
tory molecules CD80 and CD86. During maturation the cells migrate via the lymph to the T 
cell areas of the draining lymph nodes. For the latter process they change their make-up of 
chemokine receptors: immature DC are characterized by CCR1 and CCR5, while mature DC 
are positive for CCR7, enabling the latter cells to home to the lymph nodes since the lymphat-
ics and the structures in the lymph node express the ligands for CCR7, i.e. CCL-15 and CCL-19. 
Fully mature lymph node DC are the initiators of immune responses in the draining lymph 
nodes (Figure 3). They are capable of giving strong proliferation signals to naïve antigen-
specific T cells accumulated in the T cell areas of the lymph nodes due to the high expression 
of MHC class II molecules and co-stimulatory molecules on their cell membranes.
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V. ABERRANT DENDRITIC CELLS IN THE ANIMAL MODELS OF SPONTANEOUS 
AUTOIMMUNE THYROIDITIS 
The Early Accumulation and Clustering of DC and Macrophages in the Thyroids of the Animal Models of 
Spontaneously Developing Autoimmune Thyroiditis
A small increase in the number of DC and a homotypic clustering of the cells in the intersti-
tium of the thyroid is one of the first signs of a developing thyroid autoimmune reaction in 
the Bio breeding diabetes prone (BB-DP) rat, the NOD mouse and the OS chicken (22,60,61). 
This local activation of DC precedes the T cell expansion and the production of auto-antibod-
ies in the regional lymph nodes. At these early stages of the autoimmune reaction, thyrocytes 
are negative for MHC class II (22,61). Such MHC class II negative thyrocytes are very poor 
stimulators of T cell expansion (62). The thyroidal DC, on the other hand, are excellent in T cell 
stimulation and equal spleen T cells in this function (62). These arguments provide, at least in 
the animal models, sufficient proof to reject the idea that an aberrant expression of MHC class 
II molecules is an event initiating the thyroid autoimmune process. 
In the BB-DP rat and OS chicken there are no signs of an early necrosis of thyrocytes attract-
ing macrophages and DC to the necrosis-induced inflammatory reaction (as in the iodine-
induced inflammation in the NOD model, see above). Interestingly, intrinsic disturbances in 
the growth and the differentiation of thyrocytes have been shown in both models, in the 
BB-DP rat leading to a high incidence of ultimo-brachial cysts and an altered production of 
IL-6 by thyrocytes (13,63). Whether such alterations are the cause of the early accumulation of 
DC is not known. In both models a high iodine diet does lead to acceleration of the autoim-
mune response and in the BB-DP rat to a higher influx of DC (13,20,64,65). With regard to 
relevant chemokines, MCP-1 does not seem to be involved in the early DC accumulation in 
the autoimmune thyroiditis of the BB-DP rat (63).
An abnormal differentiation of APC from precursors in the animal models of spontaneously developing 
autoimmune thyroiditis. A role in a defective tolerance induction?
Since the histology of thyroids to be affected by autoimmune disease clearly shows that DC 
are critically involved in the initiation of the autoimmune process and since normally steady 
state DC are involved in tolerance induction and not auto-sensitization (see above), it is 
important to note that there is accumulating evidence that the function and the differentia-
tion of DC from precursors is aberrant in the BB-DP rat and in the NOD mouse. 
Particularly in the NOD mouse studies have concentrated on the development of accessory 
macrophages and DC from bone-marrow precursors. This development has been found to 
be hampered in the majority of the studies, leading to the generation of DC in vitro with a 
lower grade of maturation and a lower capability to stimulate T cells (66,67). Contradictory 
findings have, however, also been made (68). This is probably due to the phenomenon that 
outcomes of DC differentiation studies from precursors are heavily dependent on the culture 
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conditions used, e.g. seeding concentrations of the cells, concentrations of growth factors 
and plastics used (Leenen, personal communication). Also in the BB-DP rat Sommandas et al 
have evidence that the generation of DC is hampered from bone-marrow precursors (to be 
published).
The differentiation abnormality from precursors leads to a deficit in APC with the appro-
priate grade of differentiation in the interstitium of peripheral tissues and in the draining 
lymphatic tissues, hence in the availability of the tolerogenic steady state DC at the appro-
priate places. In the BB-DP rat Simons et al found that in the very early thyroid infiltrates 
monocytic precursors are more abundant as compared to differentiated DC (62), and that 
lymph node and spleen DC of the BB-DP rat are still in a poorly differentiated state, show-
ing a low expression of MHC class II and co-stimulatory molecules and a low capability of 
homotypic clustering (21,22). In the NOD mouse functional studies on thyroid interstitial DC 
are lacking. With regard to the spleen and lymph nodes of the NOD mouse, Piganelli et al 
(69) found that a mixture of spleen accessory macrophages and spleen DC were defective in 
stimulating T cells. Dahlen et al (70) confirmed these findings and in addition showed that 
such NOD macrophages and dendritic cells expressed lower basal levels of CD86. This low 
CD86 expression was not dependent on the MHC haplotype or on diabetes development 
since the NOD-related, diabetes-free mouse strains NON (H-2nb1) and NOR (H-2g7) exhibited 
similar low levels of CD86 expression. Radosevic et al have studied purified DC populations of 
the spleen and the lymph nodes of the NOD mouse and could not confirm that these profes-
sional APC were defective. In their hands the cells had reached a normal state of maturation 
and were perfectly capable of stimulating T cells (71). In fact there was an excessive prolifera-
tion response of the NOD T cells, when stimulated with such DC in vitro. This is most likely 
due to a defect other than the DC maturation defects in the immune system of this animal, 
namely a defect in the mechanisms of apoptosis of T cells leading to a hampered Activation 
Induced T Cell Death (AITCD, see below, 71). 
Although it is not clear how precisely the above described differentiation defects of acces-
sory macrophages and DC in the BB-DP rat and the NOD mouse play a role in the defective 
ability of the animals to mount tolerance to auto-antigens, there are a few indications on the 
mechanisms of the failure of tolerance induction. The less well-differentiated lymph node 
and spleen DC of the BB-DP rat are in particular less capable of expanding an important sup-
pressor T cell population of the rat, the so-called RT6+ T cells (72). In the report of Dahlen et al 
(70) on the defective spleen APC of the NOD mouse the authors proposed that the low level 
of CD86 expression in the NOD mouse contributed to a defective regulation of autoreactive 
T cells by preventing a full activation of T cells and therefore the up-regulation of the CTLA-4 
induced switch-off signal. In the BB-DP rat a similar mechanism may play a role: When this 
animal is treated with a stimulating anti-CD28 antibody (thus correcting the poor stimulat-
ing activity of the animals APC and activating the T cells to express CTLA-4), autoimmunity 
does not develop (Whalen and Rozing, personal communication). Also in the NOD mouse 
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interventions in the activation pathway between functionally active DC and T cells (by delet-
ing CD80-CD28 interactions) disrupt tolerance induction by interfering in the generation of 
CD4+CD25+ T cells (73). Moreover transfers of in vitro fully differentiated and maturated DC 
prevent the development of type 1 diabetes in the NOD mouse (74,75). 
Collectively these data show that the hampered differentiation of the DC in the animal 
models might lead to an inability to generate suppressor T cells as well as an inability to exert 
AITCD.
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HOW DO IN VITRO GENERATED VEILED CELLS RELATE TO CLASSICAL 
DENDRITIC CELLS?
Kabel et al and Mooi et al previously reported on a method for the generation of Antigen 
Presenting Cells (APC) from monocytes with a morphology, movement behaviour, marker 
pattern and function reminiscent of those of lymph-borne veiled cells (VC) (1,2). The VC gen-
erated using this culture procedure were found - but note more than a decade ago - to be 
functionally equal in T cell stimulation to DC populations obtained following well-accepted 
methods of that time, e.g. the method of Knight (1,2). We thus concluded at that time that 
such monocyte-derived VC were as typical DC as those yielded by other methods (1,2). 
The hallmark of this method for the generation of VC from monocytes is that it results 
in the production of APC within twenty-four hours. It contrasts with other methods in that 
it employs strictly plastic non-adherent (polypropylene) culture conditions. To increase the 
yield of VC the monocytes are additionally exposed prior (and/or during) the culture period to 
iodinated compounds, such as metrizamide and thyroid hormones, and it was hypothesized 
that the active redox capacity of the iodonium atoms in these iodinated compounds may 
have affected the reactive-oxygen-species-generating system in the monocytes, and that 
this mechanism may have played a role in the enhanced generation of VC from monocytes 
(2). For the transition from monocytes to VC the presence of endogenous GM-CSF, TNF-α and 
IL-6 was also found to be essential in the culture system, although the extra addition of these 
cytokines was not needed (2). 
Since then the field has progressed, showing the enormous heterogeneity of the DC popu-
lations including cells with different abilities in cytokine production, T cell subset stimulation 
and marker expression (3,4,5). I therefore have extended Kabel and Mooi’s previous studies 
on the monocyte-derived VC and these are presented here in this thesis (Chapter 3). We firstly 
investigated the potential of two compounds (diphenyleneiodonium, DPI, and ascorbate 
with a known potent inhibitor activity for the reduced nicotinamide adeninedinucleotide 
phosphate (NADPH) oxidase, the major ROS producing membrane enzyme complex)(6,7,8) to 
enhance the transition of monocytes into VC. We also studied in greater detail the expression 
of recently-developed DC-specific markers and co-stimulating molecules on the generated 
VC, and their IL-12/IL-10 production and T cell-stimulating potential. 
CAN DC AND VC GENERATION AND FUNCTION BE MODULATED BY 
HORMONES?
Dehydroepiandrosterone (DHEA) and glucocorticoids. Dehydroepiandrosterone (DHEA) is 
quantitatively the most abundant adrenal steroid hormone in humans and other mammals 
(9,10). The hormone is uniquely sulfated (DHEA-S) before entering the plasma, and the sul-
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fated prohormone is converted to DHEA and its metabolites (11) in various peripheral tissues. 
No major endocrine functions have been ascribed to a direct action of DHEA-S and DHEA, 
although the hormones act as intermediaries in sex steroid synthesis (11). Both hormones, 
however, have been proposed as exerting important restoring effects on age-related pro-
cesses, such as fat depot distribution and neurodegeneration. These effects also include 
major stimulation of cells of the (aging) immune system (12,13,14). However, these effects of 
DHEA have also been disputed (15,16).
There are no reports on the effects of DHEA on dendritic cell development. Mooi and Hoek 
previously reported that the exposure of monocytes to hormones (in particular to triiodothy-
ronine) stimulated DC development from monocytes (2,17). We now have tested and report 
in this thesis (Chapter 4) the effects of exposure of monocytes to DHEA, prior to, and during, 
their differentiation into immature DC under the influence of GM-CSF and IL-4. 
In biological systems, the effects of DHEA-S and DHEA are often opposed by the other 
important adrenal steroid cortisol (18). The ratio DHEA/cortisol is abnormal in various patho-
logical conditions characterized by immune dysfunction, such as after thermal injury, in AIDS, 
in rheumatoid arthritis and in tuberculosis (19-23). The suppressive effects of glucocorticoids 
on T cells, B cells, monocytes and macrophages have extensively and in detail been studied 
(reviewed in 24, 25), but the reports on the effects of glucocorticoids on the function and 
differentiation of DC (26, 27) are relatively limited at the time and data in these reports are 
inconsistent regarding effects on marker expression, T cell-stimulatory capacity and cytokine 
production. We therefore contrasted our DHEA experiments with dexamethasone (DEX) 
experiments (Chapter 4) and tested the effect of this hormone on the process of transition 
from monocyte to immature DC also.
1α, 25-Dihydroxyvitamin D3 (1,25(OH)2D3). 1α, 25-Dihydroxyvitamin D3 (1,25(OH)2D3) is a 
steroid hormone known for its ability to regulate calcium metabolism. The presence of the 
vitamin D3 receptor in almost all types of immune cells and the ability of 1,25(OH)2D3 to affect 
immune cell function in vitro is indicative of other actions of this hormone. The ability of 
1,25(OH)2D3 to stimulate cell differentiation has been well characterized. For instance, this 
hormone can inhibit proliferation and induce differentiation of benign cells such as keratino-
cytes, malignant cells such as prostate, breast and colon adenocarcinoma cells and various 
leukemic cells.
1,25(OH)2D3 also plays a role in the differentiation of benign cells of the myeloid lineage. 
The differentiation of immature monocytes toward mature macrophages has been demon-
strated to be fostered by this hormone in many reports (28,29,30). The hormone enhances 
macrophage-type activities such as phagocytosis and killing of bacteria, adherence and 
chemotaxis (31,32). 1,25(OH)2D3 is also known for its capability to induce TGF-beta produc-
tion in monocytes and other cell types (33). Although TGF-beta is commonly considered as 
a tolerance-inducing or immunosuppressive cytokine, it has great plasticity and its action 
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on immune cells can be inhibiting or promoting, depending upon cell type, differentiation/
activation status and environment. (34). Thus, its manner of regulating immune function is 
heavily context dependent.
Data on the effects of 1,25(OH)2D3 on the accessory cell function of monocytes/macro-
phages demonstrate a decreased antigen presenting capability together with a reduced 
MHC class II antigen expression (11,12). In order to further investigate the effects of the 
immunoregulatory hormone 1,25(OH)2D3 on myeloid DC differentiation, I also studied for this 
thesis the generation of iDC from blood monocytes in the presence of GM-CSF and IL-4, with 
the addition of 1,25(OH)2D3 to the culture (Chapter 5). 
ARE THERE ABERRATIONS IN DC AND VC IN PATIENTS WITH AUTOIMMUNE 
THYROID DISEASE?
In a previous report Jansen et al found aberrancies in the monocyte-derived veiled cells of 
type-1 diabetes: the yield of such cells was lower and their T cell stimulatory capacity reduced 
(35). At that time Jansen et al were of the opinion that veiled cells were as prototypic DC as 
generated by others via other methodologies. They thus took this observation as supporting 
a concept that DC generation might be disturbed in human endocrine autoimmune diseases 
in a similar fashion as it was in the animal models. To strengthen this concept we carried out 
experiments on monocyte derived veiled cells in autoimmune thyroiditis patients. In Chapter 
6 the data of these studies are shown. 
By now we know that there are considerable differences between monocyte-derived VC 
and DC (see Chapter 3). We have therefore also completed a study with classical monocyte-
derived DC in autoimmune thyroiditis patients (addendum to Chapter 6). 
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ABSTRACT
Veiled cells (VC) present in afferent lymph transport antigen from the periphery to the drain-
ing lymph nodes. Although VC in lymph form a heterogenous population, some of the cells 
clearly belong on morphological grounds to the Langerhans cell (LC)/ dendritic cell (DC) 
series. 
Here we show that culturing monocytes for 24 hrs while avoiding plastic adherence (poly-
propylene tubes) and avoiding the activation of NADPH oxidase (blocking agents) results in 
the generation of a population of veiled accessory cells. The generated VC were actively mov-
ing cells like lymph-borne VC in vivo. The monocyte (mo)-derived VC population consisted of 
CD14dim/- and CD14bright cells. Of these the CD14dim/- VC were as good in stimulating allogeneic 
T cell proliferation as immature DC (iDC) obtained after one week of adherent culture of 
monocytes in granulocyte-macrophage-colony stimulating factor (GM-CSF)/interleukin (IL)-
4. This underscores the accessory cell function of the here-reported mo-derived CD14dim/- VC. 
Although the CD14dim/- VC had a modest expression of the DC specific marker CD83 and were 
positive for S100, expression of the DC specific markers CD1a, Langerin, DC-SIGN, and DC-
LAMP were absent. This indicates that the here generated CD14dim/- VC can not be considered 
as classical LC/DC. It was also impossible to turn the CD14dim/- mo-derived VC population into 
typical DC by culture for one week in GM-CSF/IL-4 or LPS. In fact the cells died under such 
circumstances, gaining some macrophage characteristics before dying.
The IL-12 production from mo-derived CD14dim/- VC was lower, whereas the production of 
IL-10 was higher as compared to iDC. Consequently the T cells that were stimulated by these 
mo-derived VC produced less IFNγ as compared with T cells stimulated by iDC.
Our data indicate that it is possible to rapidly generate a population of CD14dim/- veiled 
accessory cells from monocytes. The marker pattern and cytokine production of these VC 
indicate that this population is not a classical DC population. Rather, the cells might be 
related to the veiled macrophage-like cells also earlier described in afferent lymph. 
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INTRODUCTION
It is now well-accepted that the Langerhans cells (LC) of the skin pick up foreign antigens, 
process these antigens and travel with these - as veiled cells (VC) - via the lymph to the drain-
ing lymph nodes to populate the T cell areas of these nodes as interdigitating cells (IDC) 
(1, 2). The IDC act in presenting the transported and processed antigens to the surround-
ing T cells, and stimulate these lymphocytes to proliferate and to differentiate. LC, VC, IDC 
and similar antigen transporting and presenting cells (APC) from other sites are presently 
generally referred to as “dendritic” cells (DC), since the cells share many morphological and 
functional characteristics with the so-called dendritic cells of Steinman, originally isolated 
from the spleen of experimental animals, and playing a prime role in antigen presentation 
and T cell stimulation and skewing (2).
Cells belonging to the DC group are the most potent APC known, and have considerable 
potential for use in immunotherapy and tolerance induction. Therefore, there exists a great 
interest in generating sizeable numbers of such cells in vitro. Various methods have been 
devised for this, resulting in populations of accessory cells which differ in phenotype, func-
tional capability and level of maturity, depending on the starting population and method of 
generation used. This has historically raised many questions about the lineage of DC, espe-
cially regarding possible precursors and routes of differentiation/maturation (2-9). Presently 
it is well accepted that apart from CD34+ precursor cells, also early not-commited thymocytes 
and monocytes may give rise to dendritic APC populations (10). 
In the last decade culturing of monocytes for a week in the presence of GM-CSF and inter-
leukin (IL)-4 (11) has become popular for generating large numbers of so-called mo-derived 
DC. The use of this methodology has resulted in the acceptance of blood monocytes as a 
major source of DC precursors. These mo-derived DC express high levels of MHC-class-II and 
CD1a (11). The cells are considered ‘immature’, since these ‘immature’ DC can still take up 
and process antigens, and are able to increase their T cell accessory potential when cultured 
further (‘mature’) in the presence of lipopolysaccharide (LPS), IL-1, CD40 or TNFα (12-14). 
These then 'mature' DC show an increased T cell stimulating capacity (15). 'Mature' DC can 
be recognized by their increased expression of CD83 (13), while the costimulating molecules 
CD80 and CD86 are also markedly upregulated (12), as are the DC specific molecules DC-
SIGN (16) and DC-LAMP (17). The ‘immature’ mo-derived DC (iDC) are considered to be the in 
vitro counterpart of the peripheral DC residing in the tissues, such as the LC (expressing the 
specific marker Langerin (18)) and the DC of the gut and bronchial mucosa, while the mature 
mo-derived DC (mDC) are considered to represent the DC residing in the T cell areas of the 
lymph nodes and spleen, the IDC (19).
We previously reported on an alternative method for the generation from monocytes of 
cells with the morphology, movement behaviour, marker pattern and functions reminiscent of 
those of lymph-borne veiled cells (VC) (4, 20). The hallmark of our method for the generation 
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of VC from monocytes is that it results in the production of APC within twenty-four hours. It 
contrasts with other methods in that it employs strictly plastic non-adherent (polypropylene) 
culture conditions. To increase the yield of VC the monocytes are additionally exposed prior 
(and/or during) the culture period to iodinated compounds, such as metrizamide and thyroid 
hormones, and it was hypothesized that the active redox capacity of the iodonium atoms 
in these iodinated compounds may have affected the reactive oxygen species generating 
system in the monocytes, and that this mechanism may have played a role in the enhanced 
generation of VC from monocytes (20). For the transition from monocytes to VC the presence 
of endogenous GM-CSF, TNF-α and IL-6 was also found to be essential in the culture system, 
although the extra addition of these cytokines was not needed (20). 
The VC generated using this culture procedure were previously (more than a decade ago) 
found to be functionally equal in T cell stimulation to DC populations obtained following 
well-accepted methods of that time (e.g. the method of Knight) (4, 20). We thus concluded at 
that time that such mo-derived VC were as prototypic DC as those yielded by other methods 
(4, 21). 
Since then the field has progressed, showing the enormous heterogeneity of the DC popu-
lations including cells with different abilities in cytokine production, T cell subset stimulation 
and marker expression (10, 22). We therefore have extended our previous studies on the mo-
derived VC. We firstly investigated the potential of two compounds (diphenyleneiodonium, 
DPI, and ascorbic acid with a known potent inhibitor activity for the reduced nicotinamide 
adenine dinucleotide phosphate (NADPH) oxidase, the major reactive oxygen species (ROS) 
producing membrane enzyme complex) (23-25) to enhance the transition of monocytes into 
VC. We also studied in greater detail the expression of DC-specific markers and costimulating 
molecules on the generated VC, their IL-12/IL-10 production and their T cell-stimulating and 
T cell-skewing potential. 
Notable is the heterogeneity present in the expression of CD14 in the mo-derived VC pop-
ulation (4, 20). Since DC are generally regarded as CD14− cells, we also report here studies 
where we separated via MACS the CD14bright and CD14dim/- fractions to study these separately 
with respect to morphology, movement behaviour, marker expression, T cell stimulating 
and T cell-skewing capability and IL-10 and IL-12 production. The unseparated VC, as well as 
the CD14bright and CD14dim/- VC were compared to prototypic iDC obtained via the currently 
well-accepted method of culturing monocytes for one week in the presence of GM-CSF and 
IL-4. The CD14bright and CD14dim/- VC obtained after twenty-four hours and the iDC were also 
cultured for further periods under plastic adherent conditions with LPS or GM-CSF and IL-4 to 
study their capability to develop into ‘mature’ DC.
This report describes that although CD14dim/- mo-derived VC express S100 and higher levels 
of MHC class II and CD83 in comparison to their starting monocyte population and in addi-
tion are potent stimulators of allogeneic T cells (similar to iDC), that these cells lack important 
DC/ Langerhans cell markers like CD1a, Langerin, DC-LAMP and DC-SIGN. Also their survival 
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in GM-CSF/IL-4 was poor. We therefore presently consider this population as dissimilar from 
the classical DC. The cells are probably more related to the monocyte/macrophage series. 
Interestingly one of us (H.D.) reported almost two decades ago that the VC population in skin 
lymph of pigs is quite heterogenous, particularly after the application of a sensitizing agent. 
The population not only consisted of classical LC-like cells, but also of veiled macrophage-like 
cells reminiscent of those earlier described in lymphatics of sheep ().
MATERIALS AND METHODS
Isolation of monocytes from peripheral blood
Monocytes were isolated from the peripheral blood of healthy blood donors via well-
accepted methods: Heparinized blood diluted with an equal volume of phosphate buffered 
saline (PBS) was distributed over Ficoll Isopaque (density 1.077 g/ml, Pharmacia, Uppsala, 
Sweden) and centrifuged for 15 minutes at 1000 g. Cells collected from the interface and 
washed were then suspended in RPMI 1640 with 25 mM HEPES and L-glutamine (GIBCO, 
USA), supplemented with 100 U/ml penicillin G, 0.1 mg/ml streptomycin (both Seromed, Bio-
chrom, Berlin, Germany) and 10% FCS (Biowhitaker, Walkersville, MD, USA) (hereafter known 
as RPMI 1640+) added. This cell suspension was distributed over Percoll (density 1.063 g/ml, 
Pharmacia), then centrifuged for 40 minutes at 400 g. Cells collected from the interface were 
washed and suspended in RPMI 1640+. Monocyte purity was determined by non-specific 
esterase staining (NSE) (26). Cell suspensions containing 80% or more monocytes were frozen 
following standard procedures and stored in liquid nitrogen, providing a bank for experi-
ments. Monocytes purified by elutriator centrifugation (4) were also used in a limited series 
of experiments (courtesy of CLB, Amsterdam, the Netherlands) in order to confirm results 
obtained via Ficoll/Percoll gradient separation. 
Generation of VC 
Monocytes were removed from liquid nitrogen and quickly thawed in a 37°C water bath. These 
cells were then washed twice in RPMI 1640 (without FCS) (5 minutes, 500 g) and suspended 
under plastic-nonadherent conditions (polypropylene tubes, Falcon, Becton Dickinson, San 
Jose, CA, USA) at a concentration of 2x106/ml in RPMI 1640 (without FCS). Not only triiodothy-
ronine (T3) and reversed T3 (rT3) were used, but also the known potent inhibitors of NADPH 
oxidase DPI (Sigma, St. Louis, USA) or L-ascorbic acid (Sigma) were added in dose-response to 
the cell suspension. The monocyte suspension was thereafter exposed to these compounds 
at 37°C, 5% CO2, 100% humidity for 30 minutes. This was either followed by washing in RPMI 
1640+ (5 minutes, 500 g) or not, and further culturing in RPMI 1640+ at 37°C, 5% CO2, 100% 
humidity under plastic non-adherent conditions for 16 hours (overnight).
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Following the 16 hour culture period, cells were centrifuged (5 minutes, 500 g) and resus-
pended in RPMI 1640+. Cells were then examined under light microscopy at a magnification 
of 400x. VC were defined as large cells with actively moving cytoplasmic processes or veils. 
Viability was checked using trypan blue exclusion. Time-lapse cinematographic studies were 
also carried out. For this purpose cells were kept in a microincubator (37°C, 5% CO2) on an 
inverted microscope (Axiovert, Zeiss, Germany) attached to a video camera (Sony, Japan) and 
a time lapse video recorder (Panasonic, Matsushita Electric Industrial CO., Osaka, Japan). The 
video recording interval was set at 0.18 sec and the tape running speed at 2.599 mm/sec. 
After recording, the images were analyzed using a computer (Acorn Computers Ltd., Cam-
bridge, UK). 
The cell suspension was then further purified and separated using large cell columns and a 
mini-MACS (Magnetic Cell Separation System, Miltenyi Biotec GmbH, Bergisch Gladbach, Ger-
many) with mouse anti-human CD3 (Becton Dickinson, USA), CD19 (Coulter, Hialeah, Florida, 
USA), and CD56 (Becton Dickinson) monoclonal antibodies and goat anti-mouse magnetic 
beads (Miltenyi Biotec GmbH) to deplete contaminating T cells, B cells and NK cells. Separa-
tion into CD14bright and CD14dim/- cells was performed via mini-MACS using CD14 (Coulter) 
monoclonal antibody and goat anti-mouse magnetic beads (Miltenyi Biotec GmbH).
In a few experiments VC were further cultured (37°C, 5% CO2, 100% humidity) for 2 days 
under plastic adherent conditions (polystyrene tubes, Falcon, Becton Dickinson) and GM-
CSF and IL-4 added, as described below for the generation of DC to study the maturation 
potential of VC to become DC. Also VC were further cultured under adherent conditions with 
lipopolysaccharide (LPS 10 ng/ml) added.
Generation of DC by long-term adherent culture in GM-CSF and IL-4
Aside from generating VC, DC were obtained via the well-established method described by 
Ruppert et al. (27) and by Sallusto and Lanzavecchia (11). Briefly, monocytes were cultured 
for one week at 37°C, 5% CO2, 100% humidity at a concentration of 3x10
5 cells/ml in RPMI 
1640+ with 800 U/ml GM-CSF and 1000 U/ml IL-4. Feeding of the cultures took place every 
two days, by removing 500 µl culture fluid and replacing this with 1 ml of fresh medium with 
cytokines. 
Flow cytometry and immunocytochemistry
For analysis of marker expression by flow cytometry, all cell populations were stained by incu-
bating for 10 minutes with mouse anti-human FITC- or PE-conjugated monoclonal antibod-
ies, then washing three times. The monoclonal antibodies used were My4 (CD14, Coulter), 
CD1a (Coulter), B7.1 (CD80), B7.2 (CD86), Langerin (CD207), DC-LAMP (CD208) (all four from 
PharMingen, San Diego, CA, USA), and DC-SIGN (CD209) (R&D Systems, Minneapolis, USA). 
Immediately following the staining, cells were analyzed on a FACScan (Becton Dickinson). 
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The marker pattern of monocytes, VC and DC was also investigated by immunocyto-chem-
istry. Cytospins were prepared using a Cytospin apparatus (Nordic Immunological Labora-
tories, the Netherlands). These were air-dried for 1 hour, then fixed in 100% acetone (Merck, 
Darmstadt, Germany) for 10 minutes. Indirect immunoperoxidase staining was performed 
with the monoclonal antibodies My4 (CD14, Coulter), HLA-DR (Becton Dickinson), OKIa (Ortho 
Diagnostics, Raritan, NJ, USA), L25 (Dr. T. Takami, Gifu, Japan), Kim 6 (CD68, Behring, Marburg, 
Germany), RFD 7 and RFD 9 (gift of Dr. L.W. Poulter, London, UK). Application of rabbit-anti-
mouse IgG peroxidase-labelled conjugate (1:50, Dako A/S, Glostrup, Denmark) in 1% normal 
human pool serum followed incubation with the monoclonal antibodies (RT, 1h). Cytospins 
were developed with a 0.05% 3,3’- diaminobenzidine (DAB, Sigma) solution containing 0.01% 
hydrogen peroxide for 3-5 minutes.
Cytospin preparations were also used to determine the reactivity of the various cell popu-
lations to acid phosphatase. The cytospins were air-dried, then incubated for acid phospatase 
staining according to Katayama et al. (28), using naphtol AS-BI phosphate as substrate and 
hexarotised pararosanilin as coupling agent (37 °C, 30 min). Slides were counterstained with 
hematoxylin.
Anti-S100 staining was performed on monocytes, VC and DC with a rabbit polyclonal 
antiserum against cow S100 (diluted 1:500; Dakopatts, Glostrup, Denmark). Cytospins were 
fixed overnight with Zamboni fixative at 4°C. Swine anti-rabbit serum (Dakopatts) was used 
as the secondary antibody, and was diluted 1:50 and supplemented with 4% normal rabbit 
serum. Non-specific adsorption of the antibodies was minimized by blocking with 4% normal 
swine serum (Dakopatts) prior to incubation with the secondary antibodies. Staining was 
ultimately achieved by incubation with rabbit peroxidase-anti-peroxidase-complex (diluted 
1:50; Dakopatts) and diaminobenzidine HCI-nickel staining solution, essentially as described 
(21).
All cytospin preparations were mounted in DePeX mounting medium (Gurr, BDH Limited, 
Poole, England).
S100 enzyme immunoassay
The S100 protein concentrations in the media of monocyte- and VC cultures were measured 
using a double monoclonal antibody enzyme immunoassay (Sandwich EIA) (Inro/Medisera, 
Campro Scientific, Veenendaal, the Netherlands), essentially as described by Aurell et al. (29). 
Microtiter plates coated with a MoAb directed against S100 and an anti-S100 MoAb conju-
gated with β-galactosidase reacted with the S100 in the samples. O-nitrophenyl-β-galacto-
side was used as the staining substrate. Bovine S100 was used as the reference standard.
Mixed leukocyte reaction (MLR)
Allogeneic MLRs were performed in order to measure the accessory capability of the various 
APC populations generated. Responder T lymphocytes were obtained from healthy donors 
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and isolated following standard procedures with Ficoll-isopaque, Percoll density gradient 
centrifugation, and nylon wool adherence (Leuko-Pak, Fenwall Laboratories, IL, USA). Non-
adhering cells recovered were greater than 90% CD3 positive. 1.5x105 responder cells were 
cultured in 96-well, flat-bottom microtitre plates (Nalgene Nunc International, Rochester, NY, 
USA) with different numbers of irradiated (2000 rad) stimulator cells (monocytes, VC or DC) 
to achieve stimulator-to-T cell ratios of 1:5, 1:10, 1:20 and 1:40. The culture medium used 
was RPMI 1640 with 25 mM HEPES and L-glutamine, supplemented with 100 U/ml penicillin 
G, 0.1 mg/ml streptomycin and 10% human A+ serum, in a total volume of 200 µl per well. 
Controls used were monocytes, VC or DC alone, and lymphocytes in the presence of 10-50 
µg/ml phytoheamagglutinin (PHA) (Wellcome Diagnostics, UK). Cultures were performed in 
triplicate. On day 5, thymidine incorporation was measured by adding 0.5 µCi 3H-thymidine 
(specific activity = 185 GBq/mmol) to each well, then harvesting 16 hours later. Scintillation 
was counted on an LKB 1205 Betaplate liquid scintillation counter (Wallac, Turku, Finland).
T cell skewing capacities
The capacity of VC and DC to prime IFNγ-producing T cells (Th1 cells) was tested to demon-
strate the T cell skewing capacities of these cell types. T cells were obtained out of the cell pel-
let generated after Percoll density gradient centrifugation of peripheral blood. This cell pellet 
was purified by removing contaminating B cells and NK cells, and monocytes via negative 
miniMACS selection using and anti-human CD-19, -56, and –14 magnetic beads (Miltenyi Bio-
tec GmbH). 0.15 x 106 Irradiated (2000 rad) VC or DC (stimulator cells) were cultured in 24-well 
plates (Nalgene Nunc) with 1.5 x 106 T cells (1:10) (responder cells). The culture medium used 
was RPMI 1640 with 25 mM HEPES and L-glutamine, supplemented with 100 U/ml penincil-
lin, 0.1 mg/ml streptomycin and 10% human A+ serum. Controls used were T lymphocytes 
alone. On day 2, T cells were collected via miniMACS using MS+ columns and anti-human 
CD3 (Miltenyi Biotec GmbH) to deplete VC and DC from the culture. The obtained T cells were 
placed in 24-well plates at a concentration of 1 x 106/ml and stimulated for 16-18 h by calcium 
ionophore (1000 ng/ml) and tetradecanoylphorbol acetate (TPA; 2 ng/ml) in Yssel’s medium 
supplemented with 2.5% FCS. The next day, supernatants were collected and tested for the 
presence of IFN-γ by ELISA as indicated by the manufacturer (BioSource). The production of 
IFN-γ by T cells cocultured with VC or DC were corrected for the basal production of IFN-γ by T 
cells alone. The production of IFN-γ by T cells can be used as a measure of T cell skewing since 
Th1 cells predominantly produce IFN-γ, whereas Th2 cells produce IL-4, -5, -10, and –13 (30).
Phagocytosis
The ability of monocytes, VC and DC to phagocytose bacteria was tested using the Phagotest 
kit (Orpegen Pharma, Heidelberg, Germany). Cells were first cooled for fifteen minutes in an 
ice-water bath. E. coli-FITC was added, and the cells were then incubated for ten minutes in a 
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37°C water bath. The manufacturer's instructions were then followed regarding quenching, 
lysing and DNA staining. Analysis was performed on a FACScan (Becton Dickinson, USA).
IL-12/IL-10 production
Monocytes, VC and DC were placed in 24-well plates (Nalgene Nunc) at a concentration of 
5x105 cells/ml and cultured for 24 hours in RPMI+ containing ultraglutamine (2 mM, Biow-
hitaker), penicillin/streptomycin (100 U/ml, 100 μg/ml, Biowhitaker) and serum free medium 
supplement (SF-1; Corning Costar Europe, Badhoevedorp, the Netherlands). To stimulate 
IL-10 production, the culture fluid contained staphylococcus aureus cowan 1 strain (SAC) 
(1:5000, Calbiochem, La Jolla, CA, USA). The IL-12 production was stimulated by SAC (1:5000) 
and γ-IFN (1000 U/ml, Biomedical Primate Research Centre, Rijswijk, the Netherlands). The 
production was measured by ELISA as indicated by the manufacturer (IL-10: ELISA Pelikine, 
CLB, Amsterdam, the Netherlands and the IL-12 (p 70): Eli-pair, Diaclone, Besançon, France).
RESULTS
Accessory cells with a movement pattern of lymph-borne VC are generated by overnight plastic non-adherent 
culture of monocytes after exposure to NADPH oxidase blocking compounds.
We confirmed our previously-described observations that the procedure using monocytes 
cultured overnight under non-adherent conditions (polypropylene-tubes) after exposure 
and in the presence of the iodinated compounds T3 or rT3 yielded 40 – 60% (n ≥ 30) of cells 
with a veiled morphology, and a movement pattern in time-lapse cinematography character-
istic of lymph-borne veiled cells (Fig. 1). 
Figure 1. Time-lapse cinematographic pictures of a living monocyte-derived veiled cell (a-d) and an original monocyte (e-h). Pictures are taken 
20-30 seconds apart. Magn.x1000. Note the constant changes in shape of the veiled cell extending and withdrawing long, thin cytosplasmic 
extensions (a-d), this in contrast to the rigid round shape of the monocyte (e-h).
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The VC suspension also showed a marked improved stimulatory capacity in the MLR as com-
pared to the original monocytes (Fig. 2) (e.g. T3 as iodinated compound 14,218 ± 4307 cpm, 
DC: T cell ratio 1:20), and a reduced reactivity with the enzyme acid phosphatase (9 ± 4%).
Markers (as measured by immunocytochemistry on cytospins) that were upregulated in 
the VC population as compared to the original monocytes were HLA-DR (OK1a, 44 ± 17% vs 
8 ± 5%), and the HLA-DQ related molecules RFD1 (61 ± 23% vs 6 ± 5%) and L25 (32 ± 14% 
vs 9 ± 8%). The DC specific marker CD83 was also upregulated, but to a lesser extent (9 ± 1% 
vs 3 ± 2%). Importantly there was almost no expression of DC-SIGN (a specific DC marker 
(16)), DC-LAMP (a specific IDC marker (17)) and Langerin (a specific Langerhans cell marker 
(18)) in the mo-derived VC population. There were no differences in results acquired from 
monocytes obtained by Percoll gradient separation or by elutriation in a limited series of 
experiments (n=3). For reasons of convenience, only Percoll-purified monocytes were used 
in further experiments. 
With regard to DPI and ascorbate, Table I gives the data (plus total yield of cells). As can be 
seen DPI and ascorbate were equally as good as T3 in accelerating the transition of monocytes 
into VC. When exposed to these compounds and further cultured under plastic non-adherent 
Figure 2. The T cell stimulatory capacity in alloMLR of the various antigen presenting cell (APC) populations studied. Mean cpm x 1000 (± s.d.) 
are given for various APC:T cell ratios (1:20; 1:10; 1:5). : original monocytes (n=13); : thyroid hormone-activated monocytes cultured 
overnight under nonadherent conditions (n=13); : as , but MACS-separated into CD14dim/− VC (VC) (n=22); : as , but MACS-separated 
into CD14bright VC (n=12) and : monocytes cultured for 7 days under plastic-adherent conditions in GM-CSF and IL-4 (DC) (n=6).
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conditions monocytes turned for more than 40% into VC when optimal concentrations were 
used. In the presence of ascorbate the total yield of cells was slightly higher (45%, see Table I) 
as compared to DPI and T3, these latter conditions yielding in total around one third of the 
cells.
Table I. The generation of veiled cells (percentages ± standard deviation (upper part)) and total cell numbers (yield in percentages ± standard 
deviation (lower part) (n>5) from monocytes after exposure of the monocytes to agents which block NADPH-oxidases and further culture under 
non-plastic adherent conditions.
Concentration
Nil 10-12 M 10-9 M 10-6 M
Triiodothyronine 24 ± 9 40 ± 12 a 30 ± 10 -
Diphenylene iodonium 24 ± 9 42 ± 8 a 36 ± 4 a 35 ± 6 a
Ascorbate 24 ± 9 42 ± 13 a 68 ± 10 a 52 ± 3 a
Cell Yield
Nil 10-12 M 10-9 M 10-6 M
Triiodothyronine 29 ± 9 32 ± 9 - -
Diphenylene iodonium 29 ± 9 32 ± 10 24 ± 9 35 ± 11
Ascorbate 29 ± 9 34 ± 7 42 ± 8 45 ± 5 a
a Significantly different from nil value, p<0.05. T test EXCEL computer program.
To see whether the monocytes cultured in the presence of GM-CSF/IL-4 and under plastic-
adherent conditions also yielded any VC after one day, we examined monocytes exposed to 
these conditions and compared them to VC generated under above described conditions. 
After one day of culture, only few of the monocytes plastic adherent-cultured in GM-CSF 
and IL-4 displayed a veiled morphology (20 ± 5%) and the cells lacked movement patterns of 
lymph-borne VC. They also hardly stimulated T cells in the mixed leukocyte reaction (e.g., at a 
stimulator-to-T cell ratio of 1:20 1,000 ± 100 cpm). 
CD14dim/- and CD14bright monocyte-derived VC
Since the VC obtained were clearly heterogeneous with respect to negative, dull and bright 
CD14 expression, and since classical DC are CD14−, we further purified the population on 
this basis. For the outcomes of the following experiments it did not matter which was the 
blocking compound used to generate the CD14dim/- and CD14bright VC, since marker expres-
sion, capabilities to stimulate T cells, to produce cytokines or to phagocytose were found 
predominantly linked to the separated populations itself. 
Two different VC populations could be obtained using the mini-MACS with a mouse anti-
human CD14 monoclonal antibody: CD14dim/- and CD14bright VC. The morphology and cinema-
tography of the CD14dim/- and CD14bright VC was markedly similar, with 73 ± 8% and 82 ± 8% of 
the cells, respectively, displaying actively moving, long veils. In cytospin analysis HLA-DR was 
expressed by high numbers of both CD14dim/- and CD14bright VC, i.e. over 80%. RFD1 expression 
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was 74 ± 13% and 66 ± 19%, respectively. Noteworthy the CD14dim/- VC and CD14bright VC were 
both acid phosphatase negative (monocytes were largely positive).
Further flow cytometric analysis of surface markers (Fig. 3 and Table II) of these two MACS-
separated populations revealed that the majority of the CD14dim/− fraction (Fig. 3) indeed 
expressed no CD14: there was a bright expression of CD14 on only 13 ± 8%, and a dim expres-
sion of CD14 by 38 ± 21%. The CD14bright VC brightly expressed CD14 in 76.1 ± 18.5% of the 
cells. The MFI data on CD14 (Table II) corroborated these numerical findings.
The DC specific marker CD83 was expressed by 21 ± 4% of the CD14dim/- VC, and the MFI 
level of CD83 expression was clearly above that of monocytes and CD14bright VC (Table II and 
Fig. 4) and comparable to that of iDC. Langerin, DC-SIGN and DC-LAMP did not come to 
expression in CD14dim/- VC (Table II). Only a small percentage of the CD14dim/- VC expressed 
CD1a (8 ± 7%) and CD80 (7 ± 3%) with a weak expression (Fig. 3 and Table II); 64 ± 25% of the 
CD14dim/- VC expressed CD86 (Fig. 3), and the MFI of CD86 expression was clearly above that of 
monocytes and CD14bright VC, but lower than that of iDC (Table II). CD40 also came to a higher 
expression on CD14dim/- VC than on monocytes and CD14bright VC (Table II). 
CD14bright VC expressed almost no CD1a and CD80. CD83 was expressed by only 3 ± 1% 
of these cells, and at a low level (Table II and Fig. 4). The cells lacked expression of DC-SIGN, 
DC-LAMP, and Langerin. Of note is that fewer CD14bright VC expressed CD86 as compared to 
monocytes, but the positive cells had a higher level of expression (yet lower as compared to 
Figure 3. The CD14bright, the CD1a, the CD80 and CD86 expression as determined by FACS analysis of original monocytes (mo, n=5), CD14bright 
VC (VC, n=4), CD14dim/- VC (n=4) and 7 day cultured DC (DC) (n=5). Mean (± s.d.) of percentage positive cells are given; only large cells - the 
fraction containing veiled/DC - were included. For abbreviations see legend Fig. 1.
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CD14dim/- VC, Table II). There was an equal expression of CD40 by the CD14bright VC as compared 
to the original monocytes (Table II). 
Classical mo-derived iDC after seven days in plastic adherent culture with GM-CSF and IL-4 
formed a population of cells that contained large numbers of cells with a typical dendritic 
morphology. Of note is that CD14bright expression was clearly reduced (Fig. 3 and Table II) 
as compared to the original monocytes, while at the same time CD1a and CD80 expression 
were markedly increased, both being higher than in the CD14dim/- and CD14bright VC (Fig. 3 and 
Table II). Also the intensities (MFI) of CD86 and CD83 expression were clearly upregulated in 
comparison to monocytes, but not statistically significantly higher than in the CD14dim/- VC 
population (Table II). CD 40, DC-LAMP and DC-SIGN expression was markedly upregulated as 
compared to monocytes, CD14dim/- VC and CD14bright VC (Table II).
The generated VC and DC were also tested for immunoreactivity and production of the cal-
cium-binding protein S100 by immunocytochemistry and EIA. Using immuno-cytochemistry, 
71 ± 11% of the CD14dim/- VC were positive for S100, as compared to 25 ± 9% of the CD14bright 
VC and 22 ± 6% of the original monocytes (n=2). The percentage of the unseparated VC 
positive for S100 was 62 ± 5% (n=2). Immature DC were S100+ in <1%, although many of the 
cells were faintly stained. These immunocytochemical data correlated well with S100 protein 
concentrations in the media of the various cell populations in culture, resulting in the highest 
concentration of S100 in the CD14dim/- VC (1.64 ng/ml, n=1) followed by the unseparated VC 
(1.34 ng/ml, n=1), CD14bright VC (1.11 ng/ml, n=1) and the starting monocyte population (0.97 
ng/ml, n=1). The immature DC were not tested in this respect.
Functional capabilities (accessory/skewing function, IL-12/IL-10 production, phagocytosis) of VC generated by 24 
hr non-adherent culture of monocytes as compared to GM-CSF/IL-4-induced monocyte-derived DC
Accessory function. Firstly, the two VC populations, the original blood monocytes and the iDC 
generated by culturing monocytes under adherent conditions in GM-CSF and IL-4 for seven 
Table II. FACS analysis of monocytes, CD14bright VC, CD14dim/- VC and iDC (n=6 populations of 6 different donors). The mean fluorescence intensity 
and standard deviation are given.
Marker Monocytes CD14bright VC CD14dim/- VC  iDC
CD14 2925 ± 1095 2295 ± 743 674 ± 350a  280 ± 230a
HLA-DR  212 ± 113  403 ± 96a 910 ± 359a  870 ± 570a
CD83   12 ± 6   24 ± 9 101 ± 32a  150 ± 63a
CD1a    9 ± 2   19 ± 7  16 ± 4  270 ± 350a
CD80    7 ± 3   27 ± 10  37 ± 31  290 ± 130a
CD86   55 ± 13  154 ± 42a 291 ± 73a  400 ± 270a
CD40   89 ± 40  124 ± 63 215 ± 81a  710 ± 297a
DC-LAMP   19 ± 2   28 ± 3  23 ± 4  276 ± 189a
DC-SIGN   36 ± 9    7 ± 20  44 ± 12 7775 ± 809a
Langerin    7 ± 3   10 ± 2   9 ± 7   59 ± 37
a Significantly different from monocytic value, p<0.05. T test EXCEL computer program.
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days were cocultured with allogeneic T cells in the MLR to study their accessory capability. 
Different numbers of stimulatory cells were cultured with a fixed number of allogeneic T cells, 
resulting in stimulatory-to-T cell ratios of 1:5, 1:10, and 1:20 (Fig. 2). At all ratios tested the 
CD14dim/- VC were as good stimulators of T cell proliferation as iDC: at a ratio of 1:5 71,380 ± 
43,730 vs 64,183 ± 22,844 cpm, respectively; at a ratio of 1:10 39,143 ± 27,175 and 44,849 
± 14,421 cpm, respectively, and at a ratio of 1:20 23,094 ± 22,644 and 17,678 ± 8,491 cpm, 
respectively. In contrast, CD14bright VC were relatively poor stimulators of T cell proliferation: 
13,656 ± 18,559 cpm at a stimulatory-to-T cell ratio of 1:5, comparable to monocytes (18,118 
± 13,440 cpm), and almost non-stimulatory at a ratio of 1:20: 1,993 ± 2,265 cpm. 
A B 
C D 
Figure 4. A representative example of the CD83 expression as determined by FACS analysis of monocytes and their descendent CD14bright 
VC, CD14dim/- VC, and iDC. Histogram profiles of the expression of CD83 of monocytes (a), of thyroid hormone-activated monocytes cultured 
overnight under nonadherent conditions and MACS-separated into CD14+ VC (b), of thyroid hormone-activated monocytes cultured overnight 
under nonadherent conditions and MACS-separated into CD14dim/- VC (c), and of monocytes cultured for 7 days in GM-CSF/IL-4 (iDC) (d). 
Percentages of cells positive for CD83 are indicated in the plots.
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Figure 5. T cell skewing capacities of the various APC populations studied. The induction of IFN-γ-producing T cells (Th1 cells) by VC and DC 
populations cocultured for 2 days with T cells at a concentration of 1:10. Mean (± s.e.) of IFN-γ production by T cells was calculated as the ratio 
of IFNγ production by T cells cocultured with VC or DC corrected for the basal production of T cells.  : monocytes cultured for 7 days under 
plastic-adherent conditions in GM-CSF and IL-4 (iDC);  : thyroid hormone-activated monocytes cultured overnight under nonadherent conditions 
MACS-separated into CD14dim/− VC; , thyroid hormone-activated monocytes cultured overnight under nonadherent conditions MACS-separated 
into CD14bright VC.
IL-12/IL-10 production. The CD14bright and CD14dim/- VC populations were also tested for the 
production of IL-10 and IL-12, and compared to the original monocyte population and the 
GM-CSF/IL-4- induced iDC (Fig. 6). Monocytes and the CD14bright VC produced the greatest 
amounts of IL-10 (3106 ± 503 pg/ml, n=21 and 3472 ± 1046 pg/ml, n=10, respectively) (mea-
surements are for 0.5 x 104 cells). The production by the CD14dim/- VC was similar at 2347 ± 
754 pg/ml (n=10). In contrast, the iDC exhibited a very low IL-10 production (326 ± 82 pg/ml, 
n=8), which had clearly decreased from the original monocyte population (875 ± 316 pg/mL, 
n = 8 vs. 333 ± 76, n = 17, respectively, p = 0.02).
With regard to IL-12, a shut-down in production occurred in the CD14bright VC population (74 
± 29 pg/ml, n=5) when compared to IL-12 production by monocytes (333 ± 76 pg/ml, n=17, 
p=0.02). CD14dim/- VC had a production of IL-12 equal to that of the original monocytes. The 
level of IL-12 production had increased in the DC as compared to their original monocyte 
populations (875 ± 316 pg/ml, n=8 vs. 333 ± 76, n=17, respectively, p=0.02). 
Skewing function. Furthermore, the VC and DC populations were tested for their T cell skew-
ing capacities by their capability to prime T cells that produce IFNγ (a Th1 cytokine). As shown 
in Figure 5 DC stimulated the production of IFNγ by T cells by 4.6-fold (s.e. 1.9), whereas both 
CD14dim/- VC and CD14+ VC stimulated the production of IFNγ by T cells just 1.2-fold (s.e. 0.4). 
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Taken both VC populations together, the VC were significantly (p=0.05) less potent in gener-
ating Th1 cells as compared to iDC.
Phagocytosis. The APC populations generated under non-adherent and plastic-adherent 
conditions were finally tested and compared to monocytes for their ability to perform phago-
cytosis. During a ten minute incubation with E.coli, 54 ± 23% of the monocytes phagocytosed 
these bacteria. Both the CD14dim/- and CD14bright VC (24 ± 12%, p=0.06 and 33 ± 11%, p=0.03, 
respectively) were less capable of phagocytosing E. coli than were monocytes. The iDC only 
had a minor capability to phagocytose E. coli (0.8 ± 0.7% immature DC phagocytosed E.coli).
Phenotype of the CD14dim/- and CD14bright VC obtained from non-adherent-cultured monocytes 
after further long-term culture under plastic adherent conditions in the presence of GM-CSF/IL-4 
or LPS
Figure 6. The IL-12 and IL-10 production of original monocytes (mo, n=17), CD14bright VC (VC, n=10), CD14dim/− VC (n=10) and 7 day cultured DC 
(n=8). Mean (± s.d.) of production (pg/ml/106 cells) are given. a p<0.01 vs. orginal monocytes.
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To see if our VC could become iDC or, like iDC, become mature DC we cultured the CD14dim/- 
and CD14bright VC under plastic adherent conditions in the presence of GM-CSF and IL-4, or 
LPS (Table III). After culturing under these conditions, however, the viability of the two VC 
populations greatly decreased. 
Of the CD14dim/- VC, only 50-65% (GM-CSF/IL-4) or 25-50% (LPS) were viable after two days. 
When cultured with GM-CSF/IL-4, the CD14dim/- VC exhibited a decrease in CD14 expression 
before dying (12 ± 7% positive cells) as compared to the original population (26 ± 14% posi-
tive cells). There was however no increase in CD1a expression (3 ± 2% positive cells on day 
3, as compared to 4 ± 3% positive cells on day 1) and even a decrease in CD80 expression (6 
± 6% positive cells on day 3, as compared to 18 ± 7% positive cells on day 1). Expression of 
CD86 was reduced from 43 ± 28% positive cells on day 1 to 16 ± 15% positive cells on day 
3. Hence there were absolutely no signs of further maturation into the direction of DC-like 
cells. These signs were also absent during culture with LPS. Under these conditions the cells 
in fact changed to rounded-up macrophage-like cells before dying (Table III): the cells lost 
their veils and became acid phosphatase positive (dotted macrophage-like patterns) while 
losing CD14 expression. 
When the CD14+ VC were cultured in GM-CSF/IL-4 or LPS there was also a considerable 
death of cells (though slightly less than with the CD14dim/- DC), and viability results of 50-55% 
(GM/CSF/IL-4) and 60-70% (LPS) were found after two days of culture. When cultured with 
GM-CSF/IL-4, the CD14bright VC clearly lost their CD14 expression: 30 ± 23% positive on day 3 
of culture as compared to 81 ± 8% initially. This however was not combined with noteworthy 
increases in CD1a expression (6 ± 3% positive cells on day 3, as compared to 3 ± 1% positive 
cells on day 1) and CD80 expression (9 ± 5% positive cells on day 3, as compared to 4 ± 1% 
positive cells on day 1). CD86 expression was even slightly decreased (33 ± 16% positive cells 
on day 3, as compared to 46 ± 13% positive cells on day 1). Hence there were again no signs 
of “maturation”. Also in the presence of LPS the CD14bright VC did not acquire a typical mature 
DC phenotype. 
DISCUSSION
This study shows that based upon the avoidance of plastic adherence (culture in polypropylene 
tubes) and avoidance of NADPH oxidase activation (via exposure to blocking agents) a heteroge-
neous population of accessory cells with long actively moving protrusions could be generated 
from blood monocytes within 24 hours. 
These rapidly in vitro-generated mo-derived veiled cells resembled in a number of aspects 
the veiled cells described in lymph: the cells displayed a movement behaviour known of 
lymph-borne VC, they were MHC class II and S100 positive and they were acid phosphatase 
negative. 
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Two major populations of in vitro-generated mo-derived veiled accessory cells could 
be distinguished based upon the expression of CD14: a CD14bright fraction and a CD14dim/- 
fraction. These populations differed from each other and from classical DC in functional 
capacity, marker expression and survival capability. The CD14dim/- fraction had a clearly 
increased T cell stimulatory capacity as compared to monocytes and were the far better 
stimulators of allogeneic T cell proliferation as compared to the CD14bright fraction. In fact, 
they were comparable in allogeneic MLR to iDC which also formed a more or less CD14negative 
homogeneous population, as is also known from literature. However, the CD14dim/- VC did 
not or hardly express CD1a, Langerin, DC-SIGN and DC-LAMP, and CD80 only to a limited 
extent. They were however clearly positive for S100 and a considerable proportion for CD83. 
Although the strong S-100 positivity of our in vitro generated VC is reminiscent of that of 
various peripheral subsets of DC-like cells such as those of the skin (31), lung (32), gut (33) 
and endocrine glands (21, 34, 35), we nevertheless do not consider our cells as classical DC. 
The absent to lower level of expression of CD1a, Langerin, DC-SIGN and DC-LAMP and CD80 
by our in vitro generated CD14dim/- mo-derived veiled accessory cells and the lower level of 
production of IL-12 and greater production of IL-10 in comparison to mo-derived DC indicate 
that the CD14dim/- veiled accessory cells must be accessory cells separate from classical DC. To 
investigate the possible potential of our CD14dim/- VC to mature into classical DC, we tried to 
culture them for an additional week using the same culture conditions as has been reported 
for the generation of immature and mature DC, and added GM-CSF, IL-4 or LPS to the cultures. 
We found that the CD14dim/- VC do not remain viable under these culture conditions where, 
also in our hands, iDC do remain viable and gain in MHC class II, CD83 and CD80 expression. 
In fact, the CD14dim/- VC did not gain in CD1a or CD80 expression at all, and even became 
macrophage-like cells before dying in LPS culture conditions. This underscores the separate 
character of the CD14dim/- VC from classical DC, and indicates that the cell is mainly related to 
the monocyte-macrophage series. It is thus likely that our CD14dim/- mo-derived VC require 
other factors than GM-CSF/IL-4 and LPS for their sustenance, and we recently found that IL-3 
is such a factor (to be published).
Interestingly Randolph et al (36) created a population of veiled/dendritic cells from mono-
cytes somewhat reminiscent of ours using a system of reverse transmigration. When mono-
cytes were cultured with endothelium on a collagen matrix the reversed transmigrated cells 
differentiated within 2 days into a subset of CD14-CD1a-CD83- veiled/dendritic cells. These 
veiled/dendritic cells generated from monocytes during the process of reversed transmigra-
tion reverted in part to macrophages when exposed to LPS or particles in the subendothelial 
collagen (36), the remaining part was however able to transform -in contrast to our cells- into 
mature DC expressing CD83. 
Since the CD14dim/- veiled macrophage-like cells were equally good T cell stimulators as 
the iDC (as measured in the MLR) and good producers of IL-10, while their CD80 expression 
and IL-12 production were low, it was tempting to speculate that these CD14dim/- VC do not 
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stimulate Th1 cells. Indeed we found that our CD14dim/- VC induced T cells that produced less 
IFNγ as compared to iDC. It is further worthy to note that S100-expressing accessory cells 
with a similar costimulatory molecule expression and cytokine production profile as our 
CD14dim/- VC population have been described in vivo in lung digests (38) and in the broncho-
alveolar lavage fluid (39). These human airway-associated APC have also been suggested to 
be predominantly Th2-stimulatory cells (38, 39), since airway APC of the rat with a similar 
immature marker pattern were proven to stimulate Th2 pathways (40). 
Apart from CD14dim/- VC, there was the CD14bright population. Although veiled and actively mov-
ing, these VC hardly expressed DC related markers and costimulatory molecules, and had the 
same low T cell stimulatory capacity as monocytes. We therefore do not consider this popula-
tion as specialized in expanding T cell populations. This poses the question of what the function 
of these (still largely monocytic) VC might be. Our studies show that their prime role does not 
lie in phagocytosis, as is also indicated by their low acid phosphatase content. CD14bright veiled 
monocytic cells were, however, very actively moving cells and formed large homotypic clusters 
as well as clusters with T cells (cinematographic studies, not shown here), suggesting a role for 
this population in immunoregulation. Noteworthy in this respect are its very low IL-12 produc-
tion, combined with a high IL-10 production and moderate MHC-class-II expression. This profile 
suggests that the CD14bright VC population might provide signals for anergy induction, but this 
assumption clearly needs further investigation. It is also worthy to note that the CD14bright cells 
did not change into more typical DC-like cells after a further culture in GM-CSF/IL-4 or LPS. Again 
the viability of the cells was a problem.
In conclusion, what is evident from this body of work, is that within 24 hours a heterog-
enous population of veiled cells can be generated from monocytes when avoiding plastic 
adherence and avoiding the activation of NADPH oxidase. Of this population particularly the 
CD14dim/- fraction has acessory capabilities in T cell stimulation. However, the marker pattern 
and cytokine production of these VC indicate that this population is not a classical DC population. 
The cells might earlier be related to veiled macrophage-like cells also described in afferent lymph 
in the 1970-1980s; however detailed studies on such lymph-borne cells using markers developed 
in the last decades are required to strengthen or refute such view. 
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ABSTRACT
Background: Dehydroepiandrosterone (DHEA) has been suggested as an immunostimulat-
ing steroid hormone, of which the effects on the development of dendritic cells (DC) are 
unknown. The effects of DHEA often oppose those of the other adrenal glucocorticoid, cor-
tisol. Glucocorticoids (GC) are known to suppress the immune response at different levels 
and have recently been shown to modulate the development of DC, thereby influencing the 
initiation of the immune response. Variations in the duration of exposure to, and doses of 
GC (particularly dexamethasone (DEX)) however, have resulted in conflicting effects on DC 
development.
Aim: In this study, we describe the effects of a continuous high level of exposure to the 
adrenal steroid DHEA (10-6 M) on the generation of immature DC from monocytes, as well as 
the effects of the opposing steroid DEX on this development.
Results: The continuous presence of DHEA (10-6 M) in GM-CSF/IL-4-induced monocyte-
derived DC cultures resulted in immature DC with a morphology and functional capabilities 
similar to those of typical immature DC (T cell stimulation, IL-12/IL-10 production), but with 
a slightly altered phenotype of increased CD80 and decreased CD43 expression (markers of 
maturity). 
The continuous presence of DEX at a concentration of 10-6 M in the monocyte/DC cultures 
resulted in the generation of plastic-adherent macrophage-like cells in place of typical imma-
ture DC, with increased CD14 expression, but decreased expression of the typical DC markers 
CD1a, CD40 and CD80. These cells were strongly reactive to acid phosphatase, but equally 
capable of stimulating T cell proliferation as immature DC. The production of IL-12 by these 
macrophage-like cells was virtually shut down, whereas the production of IL-10 was signifi-
cantly higher than that of control immature DC.
Conclusion: The continuous presence of a high level of GC during the generation of 
immature DC from monocytes can modulate this development away from DC towards a 
macrophage-like cell. The combination of a low CD80 expression and a shutdown of IL-12 
production suggests the possibility of DEX-generated cells initiating a Th2-biased response. 
These effects by DEX on DC development contrast with those by DHEA, which resulted in a 
more typical DC although possessing a phenotype possibly indicating a more mature state 
of the cell.
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INTRODUCTION
Dehydroepiandrosterone (DHEA) is quantitatively the most abundant adrenal steroid hor-
mone in humans and other mammals (1, 2). The hormone is uniquely sulfated (DHEA-S) before 
entering the plasma, and the sulfated prohormone is converted to DHEA and its metabolites 
(3) in various peripheral tissues. No major endocrine functions have been ascribed to a direct 
action of DHEA-S and DHEA, although the hormones act as intermediaries in sex steroid 
synthesis (3). Both hormones, however, have been proposed as exerting important restoring 
effects on age-related processes, such as fat depot distribution and neurodegeneration.
These effects also include major stimulation of cells of the (aging) immune system (4-6). 
However, these effects of DHEA have also been disputed (7, 8).
Dendritic cells (DC) are antigen-presenting cells par excellence, and the only cells capable 
of stimulating naïve T cells and thus capable of initiating primary immune responses (9). A 
well-accepted method of generating DC from monocytes is the culture of monocytes in the 
presence of the cytokines GM-CSF and IL-4 for 7 days (10). This procedure yields the socalled
`immature’ DC, with a retained capability for uptake and processing of antigens but with 
a relatively low capability to stimulate T cells. A further exposure of `immature’ DC to pro-
inflammatory stimuli (e.g. IL-1, lipopolysaccharide (LPS)) generates mature forms of
the cell with an enhanced capability to stimulate T cells, but an almost lost capability for 
antigen uptake and processing (11).
There are no reports on the effects of DHEA on dendritic cell development. We previously 
reported that the exposure of monocytes to hormones (in particular to triiodothyronine) 
stimulated DC development from monocytes (12, 13). We now have tested and report here 
the effects of exposure of monocytes to DHEA, prior to, and during, their differentiation into 
immature DC under the influence of GM-CSF and IL-4. 
In biological systems, the effects of DHEA-S and DHEA are often opposed by the other 
important adrenal steroid cortisol (14). The ratio DHEA/cortisol is abnormal in various patho-
logical conditions characterized by immune dysfunction, such as after thermal injury, in AIDS, 
in rheumatoid arthritis and in tuberculosis (15-19). Although the suppressive effects of glu-
cocorticoids on T cells, B cells, monocytes and macrophages have extensively been studied 
(reviewed in 20, 21), there is a growing, but still limited number of reports on the effects of 
glucocorticoids on the function and differentiation of DC (22-26). Data in these reports are 
inconsistent regarding effects on marker expression, T cell-stimulatory capacity and cytokine 
production. We therefore contrasted our DHEA experiments with dexamethasone (DEX) and 
tested the effect of this hormone on the process of the transition from monocyte to imma-
ture DC also.
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MATERIALS AND METHODS
Isolation of monocytes from peripheral blood
Monocytes were isolated from the peripheral blood of healthy blood donors via well-accepted 
methods. Heparinized blood diluted with an equal volume of phosphate buffered saline (PBS) 
was distributed over Ficoll Isopaque (density 1.077 g/ml, Pharmacia, Uppsala, Sweden) and 
centrifuged for 15 min at 1000 g. Cells were collected from the interface and washed and then 
suspended in RPMI1640with 25 mMHEPES and L-glutamine (GIBCO, LifeTechnologies, Breda, 
the Netherlands), supplemented with 100U/ml penicillinG, 0.1 mg/ml streptomycin (both 
Seromed, Biochrom, Berlin, Germany) and 10% FCS (Bio Whitaker, USA) (hereafter knownas 
RPMI 1640+) added. This cell suspension was distributed over Percoll (density 1.063 g/ml, 
Pharmacia, Uppsala, Sweden), then centrifuged for 40 min at 400 g. Cells collected from the 
interface were washed and suspended in RPMI 1640+. Monocyte purity was determined by 
non-specific esterase staining (NSE) (27). Cell suspensions containing 80% or more monocytes 
were frozen following standard procedures and stored in liquid nitrogen, providing a bank 
for experiments. Monocytes purified by elutriator centrifugation were also used (courtesy of 
CLB, Amsterdam), in order to confirm results obtained via Ficoll/Percoll gradient separation.
Culture of DC from peripheral blood monocytes
DC were obtained via the well-established method first described by Sallusto and Lanzavec-
chia (10). Briefly, monocytes were cultured for 1 week at 37 ˚C, in 5% CO2 and 100% humidity 
at a concentration of 3 x 105 cells=ml in RPMI 1640+ with 800 U/ml GM-CSFand 1000 U/ml IL-4. 
The cultures were fed every 2 days, by removing 500 μl culture fluid and replacing this with 1 
ml of fresh medium containing cytokines. In order to test the effects of exposure to DHEA and 
DEX on the monocyte-to-DC transition, these hormones were added at an optimal concen-
tration of 10-6 M to monocytes in RPMI 1640 culture medium (without FCS) and incubated for 
30 min at 37 ˚C, 5% CO2, 100% humidity after which FCS (10%), GM-CSF (800 U/ml) and IL-4 
(1000 U/ml) were added to the culture. DHEA and DEX were also fed to the cultures every 2 
days along with fresh medium and cytokines. All culture medium used was tested and found 
to be free of endotoxin. Both hormones were purchased free from endotoxin contamina-
tion.
Flow cytometry and immunocytochemistry
For analysis of marker expression by flow cytometry, all cell populations were stained by incu-
bating for 10 min with mouse anti-human FITC- or PE-conjugated monoclonal antibodies, fol-
lowed by three washes. The monoclonal antibodies used were My4 (CD14, Beckman Coulter, 
Hialeah, FL, USA), CD1a (Beckman Coulter, Hialeah, FL, USA), B7.1 (CD80, Becton Dickinson, 
San Jose, CA, USA), B7.2 (CD86, PharMingen, Los Angeles, CA, USA), CD 40 (Serotec, Oxford, 
UK), CD43 (Biosource, Camarillo, CA, USA) and CD83 (Immunotech, Marseilles, France). Imme-
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diately following the staining, cells were analyzed on a FACScan (Becton Dickinson, San Jose, 
CA, USA). 
The reactivity of the various monocyte/DC populations to acid phosphatase was deter-
mined using cytospins prepared on a Cytospin apparatus (Nordic Immunological Laborato-
ries, the Netherlands) Cytospins were air-dried, then incubated for acid phosphatase staining 
according to Katayama et al. (28), using naphtol AS-BI phosphate as substrate and hexarotised 
pararosanilin as coupling agent (37 ˚ C, 30 min). Slides were counterstained with hematoxylin. 
Preparations were mounted in DePex mounting medium (Gurr, BDH Ltd, Poole, UK).
Mixed leukocyte reaction
Allogeneic mixed leukocyte reactions (MLRs) were performed in order to measure the 
accessory capability of the various DC populations generated. Responder T lymphocytes 
were obtained from a healthy donor and isolated following standard procedures with Ficol-
lisopaque,
Percoll density gradient centrifugation, and nylon wool adherence (Leuko-Pak, Fenwall 
Laboratories, IL, USA). Non-adhering cells recovered were greater than 90% CD3 positive. A 
total of 1.5 x 105 responder cells were cultured in 96-well, flat-bottom microtitre plates (NUNC 
A/S International, Denmark) with different numbers of irradiated (2000 rad) stimulator cells 
(monocytes or DC) to achieve stimulator-to-T cell ratios of 1:5, 1:10, 1:20 and 1:40. The culture 
medium used was RPMI 1640 with 25 mM HEPES and L-glutamine, supplemented with 100 
U/ml penicillin G, 0.1 mg/ml streptomycin and 10% human A+ serum, in a total volume of 200 
μl per well. The controls used were monocytes or DC alone, and lymphocytes in the presence 
of 10-50 μg/ml phytohemagglutinin (PHA) (Wellcome Diagnostics, Zeist, the Netherlands). 
Cultures were performed in triplicate. On day 5, thymidine incorporation was assayed by add-
ing 0.5 μCi [3H]-thymidine to each well. Cells were harvested 16 h later and the radioactivity 
counted on an LKB 1205 Betaplate liquid scintillation counter (Wallac, Turku, Finland).
IL-12/IL-10 production
The DC were placed in 24-well plates (NUNC) at aconcentration of 5 x 105 cells/ml and cul-
tured for 24 h in RPMI+ containing ultraglutamine (2 mM, BioWhitaker), penicillin/strepto-
mycin (100 U/ml, 100 μg/ml, BioWhitaker) and serum free medium supplement (Pepro Tech, 
Rocky Hill, NJ, USA). To stimulate IL-10 production, the culture fluid contained Staphylococcus 
aureus cowan 1 strain (SAC) (1:5000, Calbiochem, La Jolla, CA, USA). The IL-12 production 
was stimulated by SAC (1:5000) and γ-IFN (1000 U/ml, Biomedical Primate Research Centre, 
Rijswijk, the Netherlands). The production was measured by ELISA as indicated by the manu-
facturer (for IL-10, ELISA Pelikine, CLB, Amsterdam, the Netherlands; IL-12, Eli-pair, Diaclone, 
Besançon, France).
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RESULTS
DHEA and DEX influence the phenotype of DC in culture
Dose-response curves were carried out to determine the optimal concentration of DHEA to 
add to the monocytes in culture. On the basis of our previous experience using various hor-
mones to generate veiled cells (12, 13), the optimal concentration was determined to be that 
which resulted in the greatest number of cells displaying a veiled morphology. The optimal 
concentration for DHEA was found to be 10-6 M. In the case of DEX, we had previously carried 
out dose ± response curves and have shown that although concentrations of 10-9 M were 
already effective, a concentration of 10-6 M added to DC obtained from bronchial alveolar 
lavage was optimal for obtaining a decreased function as well as a decrease in costimula-
tory molecule expression (29). We have therefore used 10-6 M DHEA and 10-6 M DEX in our 
subsequent experiments.
The addition of DHEA and DEX to the cultures resulted in the generation of DC with sig-
nificantly different phenotypes than those generated with cytokines alone (Fig. 1), while not 
affecting cell viability or cell survival, as determined by cell recovery numbers and trypan 
blue exclusion.
Adding DHEA to the cultures resulted in a DC population with a marked upregulation of the 
costimulatory molecule CD 80 (45 ± 9% vs 22 ± 8% positive cells in the control culture, P = 
0.05). This was contrasted by a sharp downregulation of CD80when DEX was added (1 ± 0% 
vs. 22 ± 8% positive cells in the control culture, P = 0.05). Moreover, in the presence of DEX the 
morphology of the cells had changed, appearing as largely adherent macrophage-like cells 
with blunted cytoplasmic processes. The expression of the co-stimulatory molecule CD86 
remained constant, regardless of exposure to either DHEA or DEX. 
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Figure 1a. The CD80, CD86, CD43, CD40, CD1a, CD83 and CD14 expression as determined by FACS analysis of control monocyte-derived DC and 
DC derived from monocytes in the continuous presence of 10-6 M DHEA (DHEA DC) or 10-6 M dexamethasone (DEX DC).
Means (±s.d.) of percentage positive cells are given; only large cells were included. P values are as indicated, n = at least five separate 
experiments.
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Figure 1b. The CD80, CD86, CD43, CD40, CD1a, CD83 and CD14 expression as determined by FACS analysis of control monocyte-derived DC and 
DC derived from monocytes in the continuous presence of 10-6 M DHEA (DHEA DC) or 10-6 M dexamethasone (DEX DC).
Overlapping histogram profiles of the expression of each marker in a representative experiment. Control DC are represented by fine line, DHEA 
DC are represented by a dotted line and DEX DC are represented by a thick line.
Both hormones decreased the expression of the antiadhesion molecule CD43 (a marker of 
immature DC, see Discussion) from 49 ± 8% positive cells in the control culture to 27 ± 2% 
positive cells in the DHEA culture (P = 0.04) and 27 ± 4% positive cells in the DEX culture (P 
= 0.04). Whereas DHEA had no effect on CD40 expression, the addition of DEX to the culture 
significantly downregulated its expression (96 ± 2% positive cells in the control culture vs 52 
± 7% positive cells in the dexamethasone culture, P = 0.04). Both CD43 and CD40 play a role 
in the further maturation of immature DCs by inducing homotypic interactions (see Discus-
sion) or when ligated by CD40 ligand on T cells respectively. 
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The expression of CD1a was also downregulated by DEX from 49 ± 18% positive cells in the 
control culture to 1 ± 1% positive cells in the DEX culture (Fig. 1). The presence of DHEA in the 
culture also resulted in a slight decrease in CD1a expression, from 49 ± 18% positive cells in 
the control culture to 32 ± 0% in the DHEA culture (Fig. 1). 
The expression of the mature DC marker CD83 was extremely low in all cultures, underscor-
ing the immature status of all DC populations under study.
As expected, most dendritic cells from the control cultures were CD14 negative. A signifi-
cant increase in CD14 marker expression was seen in cells from cultures containing DEX (74 
± 8% positive cells vs 12 ± 11% positive cells in control cultures, P = 0.04). Cells from the 
cultures containing DHEA did not express CD14 in significantly higher amounts than those 
from the control cultures. Moreover, staining of cytospin preparations revealed that cells 
from the DEX cultures were strongly reactive with acid phosphatase in contrast to those from 
the DHEA- and control cultures which reacted weakly with acid phosphatase.
Thus, in summary, the addition of DHEA enforced the DC-character of the cells with a high 
CD80 and low CD43 expression, whereas DEX in fact changed the phenotype of the cells into 
more macrophage-like CD14+ cells, lacking CD1a CD80 and CD40 expression.
Functional differences induced by DHEA and DEX in DC culture
Dendritic cells were co-cultured with allogeneic T cells in mixed leukocyte reactions in order 
to measure their capacity for stimulating T cell proliferation (Fig. 2). Dendritic cells gener-
Figure 2. The T cell stimulatory capacity in allo-MLR of the various DC populations studied. Mean c.p.m. x 1000 (± s.d.) are given for various DC:
T cell ratios (1:40; 1:20; 1:10) 
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ated under the influence of DHEA stimulated T cell proliferation as successfully as the control 
immature dendritic cells. Dendritic/macrophage-like cells generated under the influence 
of DEX were also able to stimulate T cell proliferation at a comparable level to the control 
dendritic cells; however, a non-significant difference at a stimulator-to-T cell ratio of 1:10 
may suggest that these DCmay be slightly inferior at higher ratios. As the number of mixed 
leukocyte reactions performed was limited (n = 3); further experimentation should elucidate-
whether or not DC generated in the presence of DEX are truly as capable of stimulating Tcell 
proliferation (at all ratios) as control immature DC. The ability of all DC populations generated 
to stimulate T cell proliferation at a stimulator-to-T cell ratio of 1:40 was comparable to the 
control PHA response. At a stimulator-to-T cell ratio of 1:10, this response was three times 
that of the PHA control.
Dendritic cells generated in the presence of DHEA produced IL-10 and IL-12 in not signifi-
cantly higher amounts than the control DC (Fig. 3). Dendritic/ macrophage-like cells gener-
ated under the influence of DEX, however, produced significantly more IL-10 than the control 
DC (1825 ± 503 pg/ml vs. 323 ± 114 pg/ml respectively; mean ± S.E.M.; P = 0.05) and virtually 
shut down their production of IL-12, in contrast to the control DC (0 ± 0 pg/ml vs. 831 ± 490 
pg/ml respectively; mean ± S.E.M.; P = 0.05).
DISCUSSION
Glucocorticoids are well known for their potent immunosuppressive effects when given in 
pharmacological doses. There are numerous reports of such suppressive effects on T cells, 
B cells and macrophages (reviewed in 20, 21). With regard to DC, various studies indicate 
that exposure to glucocorticoids decreases the function and number of DC in vivo (30-32). 
Literature on the effects of glucocorticoids on the in vitro generation of immature and mature 
DC from their precursors, or on the T cell stimulatory capability of glucocorticoidexposed DC 
is increasing (22-26). These reports until now collectively show that the function of DC and 
Figure 3. The Il-10 and IL-12 production of control DC, DHEA DC and DEX DC (see Figure 1 for abbreviations). Means (± s.d.) of production 
(pg/mL/106 cells) are given. P values are as indicated, n = at least five separate experiments.
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the generation of immature and mature DC from monocytes is negatively influenced by the 
in vitro addition of glucocorticoids. Nevertheless, the precise data on the effects of glucocor-
ticoids on DC marker expression, function and maturation are inconsistent. The reasons for 
the differences among observations are largely unclear, yet it is likely that they include the 
different maturation states of the DC used and the different exposure times to different doses 
of glucocorticoids in these experiments. When Van den Heuvel et al. (24) exposed GM-CSF/IL-
4-cultured human monocytes not continuously, as in this report, but only for brief periods to 
DEX (early or late in the culture period), a population of immature DC was generated with a 
decreased accessory capability. This difference in function occurred in these experiments in 
the absence of changes in the expression of co-stimulatory molecules. Piemonte et al. (23) 
exposed GM-CSF/IL-4-cultured human monocytes not for brief periods, but continuously to 
DEX; they however used a lower concentration of DEX than in this report (i.e. 10-8 M). These 
authors again induced cells with a DC morphology, but with a lower expression of CD86, 
CD40 and CD1a, a higher expression of MHC-class II, adhesion molecules and CD14, as well 
as an enhanced antigen uptake via the mannose receptor. The cells again had a poor T cell 
stimulatory capability. Vieira et al. (22) reported that when they similarly produced immature 
DC in relatively low concentrations of glucocorticoids, they were poor in the production of 
IL-12 p-70, tumor necrosis factor (TNF)-α and IL-6 (when stimulated with LPS); however, these 
authors found a normal expression of CD80 and CD86, a normal antigen uptake, and a normal 
T cell stimulatory capability of such cells. 
Vanderheyde et al. (25) used already-generated immature monocyte-derived DC and 
exposed these cells to methyl-prednisolone GM-CSF/IL-4 (100 μg/ml) for 24 h. The cells 
enhanced their antigen uptake and downregulated their basal expression of CD86 and their 
T cell stimulation potential. The treatment also prevented LPS-induced maturation, but had 
limited effects on CD40-induced further maturation. A recent study by Matasic et al. (26) also 
exposed alreadygenerated immature monocyte-derived DC to DEX. The authors confirmed 
that 500 nM DEX prevented further DC maturation. In fact, the treatment redirected the dif-
ferentiation of the DC to a more monocyte-macrophage type of cell (high CD14, high CD68, 
low T cell stimulatory potential). 
Here we describe that a continuous exposure of monocytes to a high concentration of DEX 
(10-6 M) completely abolished the generation of cells with an immature phenotype and mor-
phology of DC from monocytes, and induced a set of largely plastic-adherent macrophage-
like cells, expressing increased levels of CD14 and decreased levels of `typical’ DC markers 
such as CD1a, CD40 and CD80. These cells were also strongly reactive to acid phosphatase, 
yet had a T cell stimulating potential in allo-MLR similar to that of ‘immature’ DC. They did 
not, however, produce IL-12 but did produce high quantities of IL-10. The CD80 expression of 
these macrophage-like cells was very low. In combination with the virtual shutdown of IL-12 
production, this suggests that these cells could possibly initiate a Th2-biased response. In 
vivo studies also indicate that exposure to glucocorticoids is able to increase the numbers of 
Opposing eff ects on the generation of monocyte-derived dendritic cells 77
(suppressor) macrophages (31, 33). Our data are in line with such an effect, suggesting that 
the MØ/DC balance is affected by glucocorticoids, which skew this dynamic equilibrium in a 
macrophage direction when monocytes are continuously exposed to DEX during DC matura-
tion. During this exposure, DEX passively diffuses through the cell membrane, binding to the 
resting glucocorticoid receptor (GR). The resulting activation of the GR causes it to bind to 
glucocoticoid-responsive elements (GRE) in the nucleus, influencing gene transcription.
Taken together, a picture is emerging in which glucocorticoids have multiple effects on DC 
biology. Besides the previously reported negative effects on DC trafficking (34), function (25, 
30) and increases in apoptosis of DC (35), glucocorticoids also have shown in many studies 
variable `suppressive’ and `altering’ effects on the maturation of DC. This probably depends 
on the dose and time schedule of exposure, and the maturation state of the target DC popu-
lation. 
Serum DHEA-S levels show a steady decline with aging, coinciding with the decline in 
immune function in old age (`immunosenescence’). When aged individuals, being it experi-
mental animals (36-38) or humans (39) are administered DHEA, their immune function has 
been claimed to be restored; they become more resistant to infections, their secretion of T 
cell cytokines (e.g. IL-2) is enhanced, whereas monocyte numbers are increased. Hence, DHEA 
is viewed by some as an immunostimulating hormone. However, data are also accumulating 
that such effects of DHEA are minimal or absent (7, 8). 
Our data on the effects of DHEA on DC development are in line with the view that DHEA 
has a modest potentiating effect on immune function. DHEA synergized in our hands with 
GM-CSF and IL-4 to generate DC with a higher expression of the co-stimulating molecule 
CD80 (whereas the expression of CD86 remained equal to that of the control immature DC) 
and a lower expression of CD43. The sialoglycoprotein CD43 (sialophorin/leukosialin) is a 
negatively-charged anti-adhesion molecule. When human DC are treated with an antibody 
to CD43, their clustering capability is enhanced and their phenotypic and functional matura-
tion is mediated (40, 41). Thus, the downregulation of CD 43 expression by DHEA-induced DC 
reported here may indicate a somewhat greater level of maturation than that of the control 
DC, which would be in accordance with the higher CD80 expression of these cells. However, 
CD83 expression was still low after DHEA exposure. An argument against their higher state 
of maturation is that the DC generated in the continuous presence of DHEA produced IL-10 
and IL-12 in similar amounts to the control DC. Their T cell stimulatory capacity was, however, 
somewhat higher, although this was not statistically significant. Despite this seeming lack of 
significant functional differences, the phenotypic profile of the DHEA-induced DC (high CD80 
expression) could signal the potential of these DC to direct the development of naý»ve Th 
cells toward a Th1 phenotype (42). DHEA would then be the first hormone known to possess 
this capability, which until now has only been demonstrated by pro-inflammatory cytokines 
such as IL-1 and TNF, and substances like LPS (43). 
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In saying so, we must be aware that it is still a matter of debate whether immune cells (or 
any other cells) possess specific receptors for DHEA. The effects of DHEA might not be exerted 
via DHEA-specific receptors, but rather via receptors for active androgenic metabolites of 
DHEA-S and DHEA generated in immune cells (44). Specifically leukocytes, including macro-
phages, possess the sulphatases and other enzymes important in this conversion (45, 46).
In conclusion, the data reported here show that the adrenal hormones DHEA and gluco-
corticoids both have effects on monocyte-to-immature DC maturation, though in a largely 
opposite manner. The DC maturation data as presented here are suggestive of DHEA inducing 
somewhat more mature DC with a possible Th1-skewing potential, whereas glucocorticoids 
induce macrophage-like APC with a possible Th2-skewing potential. Similar opposing effects 
of DHEA and cortisol on the Th1-Th2 balance in vivo have been suggested (47, 48) and refuted 
(49, 50) before.
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INTRODUCTION
In chapter 3 of this thesis we described that apart from classical DC, a population of veiled 
accessory cells could also be generated from monocytes.
Culturing monocytes for 24 hrs while avoiding plastic adherence (polypropylene tubes) 
and avoiding the activation of NADPH oxidase (blocking agents) resulted in the generation of 
a population of veiled accessory cells (VC). The generated VC were actively moving cells like 
lymph-borne VC in vivo. The monocyte (mo)-derived VC population existed of CD14dim/- and 
CD14bright cells. Of these the CD14dim/- VC were as good in stimulating allogeneic T cell prolif-
eration as immature DC (iDC) obtained after one week of adherent culture of monocytes in 
granulocyte-macrophage-colony stimulating factor (GM-CSF)/interleukin (IL)-4. This under-
scores the superb accessory cell function of the mo-derived CD14dim/- VC.
Although the CD14dim/- VC had a modest expression of the DC specific marker CD83 and 
were positive for S100, expression of the DC specific markers CD1a, Langerin, DC-SIGN, and 
DC-LAMP were absent. This indicates that the here generated CD14dim/- VC cannot be consid-
ered as classical LC/DC. The IL-12 production from mo-derived CD14dim/- VC was also lower, 
whereas the production of IL-10 was higher as compared to iDC. Consequently the T cells 
that were stimulated by these mo-derived VC produced less IFNγ as compared with T cells 
stimulated by iDC.
It was impossible to turn the CD14dim/- mo-derived VC population into typical DC by culture 
for one week in GM-CSF/IL-4 or LPS. In fact the cells died under such circumstances, gaining 
some macrophage characteristics before dying. We also found that culturing the cells in IL-3 
let them survive while the cells now gained clear macrophage characteristics as an adhesive 
capacity and acid phosphatase activity, underscoring the actual macrophage character of 
the cells.
We concluded that the veiled macrophage-like cells might form part of the veiled cell 
population in afferent lymph draining to peripheral lymph nodes and described in the 1970-
1980s, since similar cells formed part of this heterogeneous population. However detailed 
studies on such lymph-borne cells using markers developed in the last decades are required 
to strengthen or refute such view. 
Since dexamethasone had clear suppressing effects on the generation of classical DC from 
monocytes (see chapter 4) we studied here whether exposure of monocytes to dexametha-
sone would influence their capability to turn into veiled accessory macrophages.
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MATERIALS AND METHODS
Isolation of monocytes from peripheral blood
Monocytes were isolated from the peripheral blood of healthy blood donors via well-accepted 
methods: Heparinized blood diluted with an equal volume of phosphate buffered saline (PBS) 
was distributed over Ficoll Isopaque (density 1.077 g/ml, Pharmacia, Uppsala, Sweden) and 
centrifuged for 15 minutes at 1000g. Cells collected from the interface and washed were then 
suspended in RPMI 1640 with 25 mM HEPES and L-glutamine (GIBCO, USA), supplemented 
with 100 U/ml penicillin G, 0.1 mg/ml streptomycin (both Seromed, Biochrom, Berlin, Ger-
many) and 10% FCS (Biowhitaker, Walkersville, MD, USA) (hereafter known as RPMI 1640+) 
added. This cell suspension was distributed over Percoll (density 1.063 g/ml, Pharmacia), 
then centrifuged for 40 minutes at 400g. Cells collected from the interface were washed and 
suspended in RPMI 1640+. Monocyte purity was determined by non-specific esterase stain-
ing (NSE) (26). Cell suspensions containing 80 % or more monocytes were frozen following 
standard procedures and stored in liquid nitrogen, providing a bank for experiments. Mono-
cytes purified by elutriator centrifugation (4) were also used in a limited series of experi-
ments (courtesy of CLB, Amsterdam, the Netherlands) in order to confirm results obtained via 
Ficoll/Percoll gradient separation. 
Generation of VC 
Monocytes were removed from liquid nitrogen and quickly thawed in a 37°C water bath. 
These cells were then washed twice in RPMI 1640 (without FCS) (5 minutes, 500g) and sus-
pended under plastic-nonadherent conditions (polypropylene tubes, Falcon, Becton Dick-
inson, San Jose, CA, USA) at a concentration of 2x106/ml in RPMI 1640 (without FCS). The 
monocyte suspension was thereafter exposed to dexamethasone at a concentration of 10-6M 
at 37°C, 5% CO2, 100% humidity for 30 minutes. This was followed by washing in RPMI 1640
+ 
(5 minutes, 500 g) and further culturing in RPMI 1640+ at 37° C, 5 % CO2, 100% humidity under 
plastic non-adherent conditions for 16 hours (overnight).
Following the 16 hour culture period, cells were centrifuged (5 minutes, 500g) and resus-
pended in RPMI 1640+. Cells were then examined under light microscopy at a magnification 
of 400x. VC were defined as large cells with actively moving cytoplasmic processes or veils. 
Viability was checked using trypan blue exclusion. Time-lapse cinematographic studies were 
also carried out. For this purpose cells were kept in a microincubator (37°C, 5% CO2) on an 
inverted microscope (Axiovert, Zeiss, Germany) attached to a video camera (Sony, Japan) and 
a time lapse video recorder (Panasonic, Matsushita Electric Industrial Co., Osaka, Japan). The 
video recording interval was set at 0.18 sec and the tape running speed at 2.599 mm/sec. 
After recording, the images were analyzed using a computer (Acorn Computers Ltd., Cam-
bridge, UK).
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The cell suspension was then further purified and separated using large cell columns and a 
mini-MACS (Magnetic Cell Separation System, Miltenyi Biotec GmbH, Bergisch Gladbach, Ger-
many) with mouse anti-human CD3 (Becton Dickinson, USA), CD19 (Coulter, Hialeah, Florida, 
USA), and CD56 (Becton Dickinson) monoclonal antibodies and goat anti-mouse magnetic 
beads (Miltenyi Biotec GmbH) to deplete contaminating T cells, B cells and NK cells. Separa-
tion into CD14bright and CD14dim/- cells was performed via mini-MACS using CD14 (Coulter) 
monoclonal antibody and goat anti-mouse magnetic beads (Miltenyi Biotec GmbH).
Flow cytometry and immunocytochemistry
For analysis of marker expression by flow cytometry, all cell populations were stained by incu-
bating for 10 minutes with mouse anti-human FITC- or PE-conjugated monoclonal antibodies, 
then washing three times. The monoclonal antibodies used were My4 (CD14, Coulter), CD1a 
(Coulter), B7.1 (CD80), B7.2 (CD86), (both from PharMingen, San Diego, CA, USA). Immediately 
following the staining, cells were analyzed on a FACScan (Becton Dickinson). 
The marker pattern of monocytes, VC and DC was also investigated by immunocyto-chem-
istry. Cytospins were prepared using a Cytospin apparatus (Nordic Immunological Labora-
tories, the Netherlands). These were air-dried for 1 hour, then fixed in 100% acetone (Merck, 
Darmstadt, Germany) for 10 minutes. Indirect immunoperoxidase staining was performed 
with the monoclonal antibodies My4 (CD14, Coulter) and HLA-DR (Becton Dickinson). Appli-
cation of rabbit-anti-mouse IgG peroxidase-labelled conjugate (1:50, Dako A/S, Glostrup, 
Denmark) in 1% normal human pool serum followed incubation with the monoclonal anti-
bodies (RT, 1h). Cytospins were developed with a 0.05% 3,3’- diaminobenzidine (DAB, Sigma) 
solution containing 0.01% hydrogen peroxide for 3-5 minutes.
All cytospin preparations were mounted in DePeX mounting medium (Gurr, BDH Limited, 
Poole, England).
Mixed leukocyte reaction (MLR)
Allogeneic MLRs were performed in order to measure the accessory capability of the various 
APC populations generated. Responder T lymphocytes were obtained from healthy donors 
and isolated following standard procedures with Ficoll-isopaque, Percoll density gradient 
centrifugation, and nylon wool adherence (Leuko-Pak, Fenwall Laboratories, IL, USA). Non-
adhering cells recovered were greater than 90% CD3 positive. 1.5x105 responder cells were 
cultured in 96-well, flat-bottom microtitre plates (Nalgene Nunc International, Rochester, NY, 
USA) with different numbers of irradiated (2000 rad) stimulator cells (monocytes, VC or DC) 
to achieve stimulator-to-T cell ratios of 1:5, 1:10, 1:20 and 1:40. The culture medium used 
was RPMI 1640 with 25 mM HEPES and L-glutamine, supplemented with 100 U/ml penicillin 
G, 0.1 mg/ml streptomycin and 10% human A+ serum, in a total volume of 200 µl per well. 
Controls used were monocytes, VC or DC alone, and lymphocytes in the presence of 10-50 
µg/ml phytoheamagglutinin (PHA) (Wellcome Diagnostics, UK). Cultures were performed in 
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triplicate. On day 5, thymidine incorporation was measured by adding 0.5 µCi 3H-thymidine 
(specific activity = 185 GBq/mmol) to each well, then harvesting 16 hours later. Scintillation 
was counted on an LKB 1205 Betaplate liquid scintillation counter (Wallac, Turku, Finland).
IL-12/IL-10 production
Monocytes and VC were placed in 24-well plates (Nalgene Nunc) at a concentration of 5x105 
cells/ml and cultured for 24 hours in RPMI+ containing ultraglutamine (2 mM, g/ml, Biowhita-
ker) and Biowhitaker), penicillin/streptomycin (100 U/ml, 100 serum free medium supplement 
(SF-1; Corning Costar Europe, Badhoevedorp, the Netherlands). To stimulate IL-10 production, 
the culture fluid contained staphylococcus aureus cowan 1 strain (SAC) (1:5000, Calbiochem, 
La Jolla, CA, USA). The IL-12 production was stimulated by SAC (1:5000) and γ-IFN (1000 U/ml, 
Biomedical Primate Research Centre, Rijswijk, the Netherlands). The production was mea-
sured by ELISA as indicated by the manufacturer (IL-10: ELISA Pelikine, CLB, Amsterdam, the 
Netherlands and the IL-12 (p 70): Eli-pair, Diaclone, Besançon, France).
RESULTS
Exposing monocytes to dexamethasone prior to an overnight non-adherent culture resulted 
– similar to T3 exposure – in a population of CD14 dim/negative and a population of CD14 
positive VC. The CD14 positive cells were – as in the case of T3 exposure – poor stimulators in 
(allogeneic) MLR and we therefore concentrated on the CD14 dim/negative VC.
Figure 1 shows the FACS analysis of the cells. The DEX- exposed cells had a significant lower 
HLA-DR, CD86 and CD83 expression as compared to T3-exposed cells and mean fluorescence 
indexes (MFI) of 618, 107 and 39 versus 910, 290 and 100 (averages, p<0.05, n=7) were respec-
tively found. CD14 was higher expressed, but not statistically significant.
Figure 2 shows the allogeneic T cell stimulatory capacity of the VC generated from DEX-, T3- and 
DHEA-exposed monocytes as compared to the original non-exposed monocytes. It can clearly be 
seen that the T cell stimulatory capacity of all the CD14dim/negative populations is higher than 
the non-exposed monocytes, but the DEX-VC were clearly much lower than the T3-VC, while 
the DHEA-VC reached the highest T cell stimulatory capacity (yet this experiment was only 
performed 3 times and significances could therefore not be calculated).
Fig. 3 shows the IL-10 and IL-12 production of the DEX-VC and T3-VC as compared to this 
cytokine production of the original monocytes.
The IL-10 production capability of the CD14 dim/negative VC populations was higher 
than that of the original monocytes and was practically equal in the case of DEX- and T3-VC. 
Interesingly the IL-12 production capability of the DEX-VC was almost completely shut down, 
while that of the T3-VC was comparable to that of the original monocytes (yet again this 
experiment was only performed 3 times and significances could again not be calculated).
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Figure 1. The FACS analysis of the CD14 negative/dim veiled cells. Means of the mean fluorescence intensities (MFI) and standard deviations are 
shown. Black bars represent dexamethasone stimulated cultures, white bars represent cultures in the absence of dexamethasone.
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Figure 2. The T cell stimulatory capacity of CD14 negative/dim veiled cells. The increase in T cell stimulatory capacity is shown relative to the 
original monocytes. Black bars represent dexamethasone exposed cells, gray bars represent T3 exposed cells and white bars represent DHEA-
exposed cells.
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CONCLUSIONS
Dexamethasone exposure of monocytes prior to a non-adherent overnight culture resulted 
in veiled cells that
a. had a lower expression of the DC specific marker CD83 and a low expression of the 
stimulatory MHC class II and CD86 molecules (as compared to T3-exposed cells)
b. had a lower accessory capability in allogeneic MLR (as compared to T3- and DHEA-
exposed cells), and
c. had a very low IL12 production capability (as compared to T3-exposed cells).
These veiled cells generated after exposure of monocytes to dexamethasone lend support to 
the view that this hormone hampers the generation of immunostimulatory APC from mono-
cytes (see chapter 4). 
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Figure 3. The cytokine production of veiled cells (VC) exposed to dexamethasone (DEX) or T3 in comparison to that of the original monocytes. 
The black bars represent the IL-10 production, while the black bars represent the IL-12 production. Means and standard deviations are shown.
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ABSTRACT
Objective: To study the effects of the active metabolite of vitamin D3, 1,25(OH)2D3, an immu-
nomodulatory hormone, on the generation of so-called immature dendritic cells generated 
from monocytes (Mo-iDC). 
Design and methods: Human peripheral blood monocytes were cultured to iDC in the pres-
ence of GM-CSF and IL-4 for one week, with or without the extra addition of 10-8 M 1,25(OH)2D3 
to the culture. We examined their phenotype (CD14, CD1a, CD83, HLA-DR, CD80, CD86 and 
CD40 expression) by FACS analysis and their T cell stimulatory potential in allogeneic MLR 
(allo-MLR). Additionally we investigated their in vitro production of IL-10, IL-12 and TGF-ß by 
ELISA.
Results: 1,25(OH)2D3, when added to monocytes in culture with GM-CSF and IL-4, hampered 
the maturation of Mo-iDC. Firstly the phenotype of the 1,25(OH)2D3-differentiated DC was 
affected with a impaired down-regulation of the monocytic marker CD14 and a impaired 
upregulation of CD1a, CD83, HLA-DR, CD80 and CD40. CD86 was expressed on more 
1,25(OH)2D3-differentiated DC. Secondly, the T cell stimulatory capability of 1,25(OH)2D3-dif-
ferentiated DC was upregulated from that of the original monocytes to a lesser degree than 
DC differentiated without 1,25(OH)2D3 when tested in allogenic mixed lymphocyte reaction 
(MLR). With regard to the production of cytokines, SAC-induced IL-10 production, although 
not enhanced, remained considerably high in 1,25(OH)2D3-differentiated DC, whereas it was 
strongly downregulated in DC generated in the absence of 1,25(OH)2D3. SAC/IFNγ-induced 
IL-12 production was clearly upregulated in both types of DC from that of the original mono-
cytes and TGF-ß production downregulated.
Conclusion: Our data confirm earlier reports that 1,25(OH)2D3 hampers the maturation of 
fully active immunostimulatory MHC-classII+,CD1a+,CD80+ DC from monocytes. Our data 
supplement the other reports in showing that the expression of CD86 was upregulated in 
1,25(OH)2D3-differentiated DC, while the capability for IL-10 production remained high. Col-
lectively, this is in line with earlier descriptions of suppressive activities of this steroid-like 
hormone regarding the stimulation of cell-mediated immunity.
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INTRODUCTION
1α, 25-Dihydroxyvitamin D3 (1,25(OH)2D3) is a steroid hormone known for its ability to regulate 
calcium metabolism. The presence of the vitamin D3 receptor in almost all types of immune 
cells and the ability of 1,25(OH)2D3 to affect immune cell function in vitro is indicative of 
other actions of this hormone. The ability of 1,25(OH)2D3 to stimulate cell differentiation has 
been well characterized. For instance, this hormone can inhibit proliferation and induce dif-
ferentiation of benign cells such as keratinocytes, malignant cells such as prostate, breast and 
colon adenocarcinoma cells and various leukemic cells.
1,25(OH)2D3 also plays a role in the differentiation of benign cells of the myeloid lineage. The 
differentiation of immature monocytes toward mature macrophages has been demonstrated 
to be fostered by this hormone in many reports (4,5,6). The hormone enhances macrophage-
type activities such as phagocytosis and killing of bacteria, adherence and chemotaxis (7,8). 
1,25(OH)2D3 is also known for its capability to induce TGF-beta production in monocytes 
and other cell types (9). Although TGF-beta is commonly considered as a tolerance-induc-
ing or immunosuppressive cytokine, it has great plasticity and its action on immune cells 
can be inhibiting or promoting, depending upon cell type, differentiation/activation status 
and environment. (10). Thus, its manner of regulating immune function is heavily context 
dependent.
Data on the effects of 1,25(OH)2D3 on the accessory cell function of monocytes/macro-
phages demonstrate a decreased antigen presenting capability together with a reduced MHC 
class II antigen expression (11,12). Dendritic cells (DC), highly specialized antigen presenting 
accessory cells (APC) capable of stimulating naïve T cells, can be generated from monocytes 
by culturing for one week under plastic-adherent conditions in the presence of GM-CSF and 
IL-4. The resulting socalled immature DC (iDC) express dendritic-type markers such as CD1a, 
CD83, MHC Class II, CD40, CD80 and CD86, while downregulating the expression of CD14. 
Their accessory cell function is also greatly increased. Recent reports indicate that the dif-
ferentiation of DC is inhibited by 1,25(OH)2D3. Markers typical of iDC (CD1a, MHC Class ll) 
are expressed to a lesser degree, and T cell stimulatory capability is reduced. However, con-
flicting data exists regarding the expression of some costimulatory molecules. Piemonti (2) 
found that the expression of CD86 was inhibited in the presence of 1,25(OH)2D3, while that of 
CD80 was not significantly affected. This is in contrast to data from Berer (3), who found that 
CD86 expression was unaffected by 1,25(OH)2D3 while upregulation of CD80 was prevented. 
Immature DCs can be further differentiated into mature DCs in vitro by culturing with LPS, 
TNF-α, IL-1 or CD40-ligand (13,14). In this mature stage, the capacity for antigen uptake is 
lost, and the cell becomes an expert at antigen presentation (15,16). Maturing DCs are also 
reportedly affected by 1,25(OH)2D3: decreases in IL-12 production and an increase in IL-10 
production have been reported (1,2), however there are –to date- no accounts regarding the 
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effect of 1,25(OH)2D3 on the production of IL-10 and IL-12 in iDCs. The effect of 1,25(OH)2D3 on 
the production of the immunoregulatory growth factor TGF-ß by DCs is also unknown.
In order to further investigate these effects of the immunoregulatory hormone 1,25(OH)2D3 
on myeloid DC differentiation, we cultured human peripheral blood monocytes to iDC in the 
presence of GM-CSF and IL-4 for one week, with the addition of 1,25(OH)2D3 to the culture. 
We examined the phenotype (CD14, CD1a, CD83, HLA-DR, CD80, CD86 and CD40 expres-
sion) and T cell stimulatory potential in allogeneic MLR (allo-MLR) of these immature DC, and 
investigated their production of IL-10, IL-12 and TGF-ß while still in their immature state.
MATERIALS AND METHODS
Isolation of monocytes from peripheral blood
Monocytes were isolated from the peripheral blood of healthy blood donors via well-accepted 
methods: Heparinized blood diluted with an equal volume of phosphate buffered saline 
(PBS) was distributed over Ficoll Isopaque (density 1.077g/ml, Pharmacia, Uppsala, Sweden) 
and centrifuged for 15 minutes at 1000 g. Cells collected from the interface and washed were 
then suspended in RPMI 1640 with 25mM HEPES and L-glutamine (GIBCO, USA), supple-
mented with 100U/ml penicillin G, 0.1 mg/ml streptomycin (both Seromed, Biochrom, Berlin, 
Germany) and 10% FCS (Bio Whitaker, USA) (hereafter known as RPMI 1640+) added. This cell 
suspension was distributed over Percoll (density 1.063 g/ml, Pharmacia, Uppsala, Sweden), 
then centrifuged for 40 minutes at 400 g. Cells collected from the interface were washed and 
suspended in RPMI 1640+. Monocyte purity was determined by non-specific esterase staining 
(NSE) (27). Cell suspensions containing 80% or more monocytes were frozen following stan-
dard procedures and stored in liquid nitrogen, providing a bank for experiments. Monocytes 
purified by elutriator centrifugation were also used (courtesy of CLB, Amsterdam), in order to 
confirm results obtained via Ficoll/Percoll gradient separation.
Culture of DCs from peripheral blood monocytes
DC were obtained via the well-established method first described by Sallusto and Lanzavecchia 
(13). Briefly, monocytes were cultured for one week at 37°C, 5% CO2, 100% humidity at a con-
centration of 3x105 cells/ml in RPMI 1640+ with 800 U/ml GM-CSF and 1000 U/ml IL-4. Feeding of 
the cultures took place every two days, by removing 500 µl culture fluid and replacing this with 
1 ml of fresh medium with cytokines. In order to test the effects of exposure to 1,25(OH)2D3 on 
the monocyte-to-DC transition, this hormone as added at an optimal concentration of 10-8 M to 
monocytes in RPMI 1640 culture medium (without FCS) and incubated for thirty minutes at 37°C, 
5% CO2, 100% humidity after which FCS (10%), GM-CSF (800U/ml) and IL-4 (1000 U/ml) were 
added to the culture. 1,25(OH)2D3 was also fed to the cultures every two days along with fresh 
medium and cytokines.
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Flow cytometry and (immuno)cytochemistry
For analysis of marker expression by flow cytometry, all cell populations were stained by 
incubating for 10 minutes with mouse anti-human FITC- or PE-conjugated monoclonal 
antibodies, then washing three times. The monoclonal antibodies used were My4 (CD14, 
Beckman Coulter, Hialeah, Florida, USA), CD1a (Beckman Coulter, Hialeah, Florida, USA), HLA-
DR (Becton Dickinson, USA) B7.1 (CD80, Becton Dickinson, San Jose, CA, USA), B7.2 (CD86, 
PharMingen, Los Angeles, CA, USA), CD83 (Immunotech, Marseilles, France) and CD40 (Sero-
tec, Oxford, England). Immediately following the staining, cells were analyzed on a FACScan 
(Becton Dickinson).
Mixed leukocyte reaction (MLR)
Allogeneic MLRs were performed in order to measure the accessory capability of the various 
DC populations generated. Responder T lymphocytes were obtained from healthy donors 
and isolated following standard procedures with Ficoll-isopaque, Percoll density gradient 
centrifugation, and nylon wool adherence (Leuko-Pak, Fenwall Laboratories, Il, USA). Non-
adhering cells recovered were greater than 90% CD3 positive. 1.5x105 responder cells were 
cultured in 96-well, flat-bottom microtitre plates (NUNC A/S International, Denmark) with 
different numbers of irradiated (2000 rad) stimulator cells (monocytes or DC) to achieve 
stimulator-to-T cell ratios of 1:5, 1:10, 1:20 and 1:40. The culture medium used was RPMI 1640 
with 25mM HEPES and L-glutamine, supplemented with 100U/ml penicillin G, 0.1 mg/ml 
streptomycin and 10% human A+ serum, in a total volume of 200 µl per well. Controls used 
were monocytes or DC alone, and lymphocytes in the presence of 10-50 µg/ml phytohe-
amagglutinin (PHA) (Wellcome Diagnostics, UK). Cultures were performed in triplicate. On 
day 5, thymidine incorporation was measured by adding 0.5 µCi 3H-thymidine to each well, 
then harvesting 16 hours later. Scintillation was counted on an LKB 1205 Betaplate liquid 
scintillation counter (Wallac, Turku, Finland).
IL-12, IL-10 and TGFβ production
DC were placed in 24-well plates (Nunc) at a concentration of 5.105 cells/ml and cultured for 
24 hours in RPMI+ containing ultraglutamine (2mM, BioWhitakker), penicillin/streptomycin 
(100 U/ml, 100 mcg/ml, BioWhitakker) and serum free medium supplement (Pepro Tech). 
To stimulate IL-10 production, the culture fluid contained staphylococcus aureus cowan 1 
strain (SAC) (1:5000, calbiochem, La Jolla, CA, USA). The IL-12 production was stimulated by 
SAC (1:5000) and γ-IFN (1000U/ml, Biomedical Primate Research Centre, Rijswijk, the Nether-
lands). The production of cytokines was measured by ELISA as indicated by the manufacturer 
(IL-10 ELISA Pelikine, CLB, Amsterdam, the Netherlands; the IL-12 Eli-pair, Diaclone, Besançon, 
France; and the TGFβ1 ELISA, Biosource, Europe SA).
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STATISTICAL ANALYSIS
Data were collected in an Excell File. Statistical analysis was carried out between sets of measure-
ments (n=>6, see for exact details the result section and the legends of the table and figures) in 
the presence or absence of 10-8 M 1,25(OH)2D3 using the parametric T test (two-tailed, unpaired) 
provided by this computer programme.
RESULTS
1,25(OH)2 D3 influences the morphology and phenotype of DC
Dose response curves revealed that an optimal dose of 10-8M 1,25(OH)2D3 reduced the per-
centage of cells with cellular protrusions(veils and dendrites) from 84±8% (non-vit D-exposed 
cultures) to 63±9% in the culture to which 1,25(OH)2D3 was added (mean ± sd, p=0.002, 
n=10). 
The phenotype of the DC in culture was also affected by the addition of 1,25(OH)2D3 
(Table 1), resulting in a still high expression of the monocyte marker CD14 (typically down-
regulated during culture in GM-CSF and IL-4 alone). The expression of the DC markers CD1a 
and CD83 (typically upregulated during culture in GM-CSF and IL-4 alone) was still low in DC 
differentiated in the presence of 1,25(OH)2 D3. The intensity of the expression of the antigen-
presenting molecule HLA-DR (typically upregulated during culture in GM-CSF and IL-4 alone) 
remained low in 1,25(OH)2D3-differentiated cells (Table 1). The addition of 1,25(OH)2D3 to the 
culture also resulted in significant changes in the expression of the costimulatory molecules 
CD80 (lower expression), CD86 (higher expression) and CD40 (lower expression). In sum, the 
phenotype of the vit D3-generated DC more or less still resembled that of the original mono-
cytes with a persistent high CD14, low CD1a, low CD83, low CD80 and low CD40 expression. 
The high CD86 expression of vit D3-generated DC is remarkable: the percentage of CD86+ 
DC remained significantly higher and comparable to that of monocytes, while their mean 
fluorescence intensity was much higher than that of monocytes, which only have a dull 
expression (Table 1).
Functional differences induced by 1,25(OH)2D3 in DC culture
Dendritic cells were co-cultured with allogeneic T cells in mixed leukocyte reactions (MLR) 
in order to assess their capability to stimulate T cell proliferation. Dendritic cells generated 
under the influence of 1,25(OH)2D3 displayed a greatly reduced capability to stimulate T cells 
to proliferate (Fig. 1). At a stimulator-to-T cell ratio of 1:5, the capability of 1,25(OH)2 D3-gen-
erated DC to stimulate T cell proliferation was significantly lower than that of the control. 
This impairment of stimulatory ability was evident at all ratios tested (p values ranging from 
p=0.01 to p=0.02, n=7-8). It is also worthy to note that the T cell stimulating capacity of the 
original monocytes was clearly and significantly lower than that of both DC populations.
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Figure 1. The T cell stimulatory capacity in allo-MLR of the original monocytes () and monocyte-derived DCs generated in the absence () 
or presence () of 1,25(OH)2D3. Mean counts per minute (c.p.m.) of [
3H]thymidine incorporation are given (± s.d.) for various DC:T cell ratios 
in allo-MLR, i.e. 1:40, 1:20, 1:10 and 1:5. Differnces between the three conditions are statistically significant at all ratios (P values varying from 
0.01 to 0.02, n = 7-8 experiments using a different donor in each experiment; t-test, EXCEL computer program). 
IL-10, IL-12 and TFGβ production
When stimulated for 24 hrs with staphylococcus aureus cowan strain 1 (SAC), a well known 
inducer of IL-10 production, dendritic cells generated in the presence of 1,25(OH)2D3 pro-
duced more of the immunosuppressive cytokine IL-10 than the control, non-Vit D-exposed 
DC (1227±221 pg/ml vs 337±83 pg/ml, respectively; mean±sem; p<0.01, n=13 and 9 experi-
Table 1. Effect of 1,25(OH)2D3 on the phenotype of monocyte-derived dendritic cells
Percentage of positive cells Mean Fluorescence Intensity 
Monocytes Dendritic cells  Monocytes Dendritic cells
–Vit D3 +Vit D3 –Vit D3 +Vit D3
CD14 76 ± 5 14 ± 4b 49 ± 6 2980 ± 712 280 ± 230b 640 ± 414b
CD83  3 ± 2  8 ± 4  4 ± 2   75 ± 40 150 ± 63 b 116 ± 38
CD1a  2 ± 2 24 ± 8b  3 ± 1   19 ± 13 270 ± 356 b  60 ± 25a,b
HLA-DR 73 ± 6 80 ± 9 68 ± 9  285 ± 97 870 ± 570 b 490 ± 350
CD80  5 ± 1 28 ± 6b 15 ± 4   50 ± 34 290 ± 130 b 134 ± 102a,b
CD86 75 ± 5 54 ± 5b 64 ± 6a   84 ± 24 400 ± 270 b 595 ± 600b
CD40 82 ± 7 94 ± 2 71 ± 12a   84 ± 32 710 ± 297b 320 ± 230a,b
FACS analysis of immature DC populations (n=10 populations for each condition of 10 different donors) generated in the absence or presence of 
1,25(OH)2D3; FACS analysis was also performed on the original monocyte populations (n=7). Not only the mean percentage of positive cells (i.e. 
cells with a signal over that of the IgG control) is given, but also the mean fluorescence intensity ± standard deviation. a p<0.05 vs dendritic cells 
in the absence of vit D3
 b p<0.05 vs original monocytes, T test Excel computer programme.
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ments and donors respectively) (Fig. 2). The IL-10 production of the original monocytes was 
under such circumstances 1540 ± 534 pg/ml (mean ± sem, n=12) (Fig. 2). When SAC was not 
used IL-10 production was in all instances considerably lower and variable, and therefore 
tested in fewer cases. Differences stayed more or less the same, allthough not reaching statis-
tical significance anymore due to the rather high variability between experiments. Values for 
VitD3 exposed DC were 94±27 pg/ml (mean±sem, n=4), non-exposed DC 26±26 pg/ml (n=6), 
while monocytes produced 174 ± 56 pg/ml (n=8) Il-10.
The presence of 1,25(OH)2D3 in the culture during differentiation of DC from monocytes 
did not significantly affect their capability to produce IL-12. Under conditions of a 24 hr 
stimulation by SAC and interferon gamma (IFN-γ) (wellknown inducers of IL-12 production) 
1088±351 pg/ml IL-12 were produced by control DC vs 1056±652 pg/ml by DC generated 
under the influence of 1,25(OH)2D3 (mean±sem, p=0.31, n=10 and 7 respectively) (Fig. 2).
The original monocytes produced less IL-12 under these conditions, i.e. 301 ± 129 pg/ml 
(mean ± sem, n=17) (Fig. 2). Omitting SAC and IFN-γ from the cultures led to an almost nil 
production of IL-12 in all instances (< 10 pg/ml).
The TGFβ production of 1,25(OH)2D3-generated and control DC did also not differ, and was 
in both instances very low when compared to the original monocytes: 1,25(OH)2D3-gener-
ated DC produced 98 ± 65 pg/ml TGFβ (mean ± sem) (n=4) over a 24 hr period, control DC 121 
± 57 pg/ml (n=4), and original monocytes 1680 ± 500 pg/ml (n=7). SAC stimulation during 
the 24 hr production period had no effects.
Figure 2. The SAC-stimulated Il-10, the Sac/IFN-γ-stimulated IL-12, and the TGF-β production of original monocytes (white bars) and of 
monocyte-derived DCs generated in the absence (light grey bars) or presence (dark-grey bars) of 1,25(OH)2D3. Production rates are given as 
mean pg/mL/5x105 cells (± s.e.m.). a, P < 0.05 versus original monocytes; b, P < 0.05 versus DCs generated in the absence of 1,25(OH)2D3. For 
the exact number of experiments see the text (n= 9-13); t-test, EXCEL computer program.
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DISCUSSION
Recent reports indicate a role of 1,25(OH)2D3 on DC development. When monocytes are 
exposed to 1,25(OH)2D3 during their differentiation to immature DC, the resulting cells are 
less capable of stimulating T cell proliferation (1,2,3). High expression of the monocyte 
marker CD14 is maintained, while CD1a expression is reduced (2,3). The upregulation of 
MHC Class ll and CD40 is prevented, while conflicting results have been reported regarding 
the effects of 1,25(OH)2 D3 on the costimulatory molecules CD80 and CD86. While Piemonti 
(3) found that CD86 expression was inhibited and CD80 expression was unaffected by the 
presence of 1,25(OH)2D3, Berer et al (2000) found that CD86 expression was not affected by 
1,25(OH)2D3 while upregulation of CD80 was prevented. Differences in the endocytic activity 
of DCs diferentiated in the presence of 1,25(OH)2D3 were also reported by these two groups. 
There are no reports on the effects of 1,25(OH)2D3 on IL-10 and IL-12 production by immature 
DCs, however maturing DCs were affected by the presence of 1,25(OH)2D3, as reflected in 
decreases in IL-12p75 and IL-12p70 production upon exposure to CD40 ligand (1,2), and an 
upregulation in IL-10 production (1). This suppressive action of 1,25(OH)2D3 on DC devel-
opment is in accordance with the numerous reports of a downregulation of MHC Class II 
expression in mononuclear cells exposed to this hormone (11,12,17). There are no previous 
reports indicating whether or not this suppressive action of 1,25(OH)2D3 is reflected in the 
TGF-ß production by DCs.
Our data are largely in accordance with this picture of 1,25(OH)2 D3 as an immunosuppres-
sive agent for DC development. We confirmed that 1,25(OH)2D3 hampers the differentiation 
of monocytes into DC, generating a population of immature DC with a reduced capability to 
induce T cell proliferation. These immature DC generated whilst being exposed to 1,25(OH)2D3 
differed in phenotype from classical immature DC. A significant reduction in expression of 
the CD1a and CD40 antigens was seen in the 1,25(OH)2D3-exposed cells. Expression of the 
costimulatory molecule CD80 was inhibited, as has been reported by Piemonti (3), however 
expression of the costimulatory molecule CD86 was increased, in contrast to Piemonti’s and 
Berer’s reports of an unchanged and decreased level of expression of this marker in the 
presence of 1,25(OH)2D3 respectively. A significantly higher CD14 expression was seen in 
the 1,25(OH)2D3-exposed cells, which concurs with a high level of CD14 antigen expression 
in mononuclear phagocytes exposed to 1,25(OH)2D3, noted by numerous investigators. A 
reduction in CD1a antigen expression was also reported by Dam (18) in experiments apply-
ing calcipotriol to normal human skin. 
Although 1,25(OH)2D3 has been shown to inhibit IL-12 production by activated mac-
rophages and mature DC (19), contributing to the immunosuppressive capability of this 
hormone, we did not find such an effect in immature DC. IL-10 secretion by maturing DC 
was recently reported to be enhanced when 1,25(OH)2D3 was added to the culture during 
LPS-induced maturation (1). In our experiments we used SAC as a stimulus and also found a 
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higher production of IL-10 in 1,25(OH)2D3-differentiated iDC comparable to the production 
of their original monocyte precursors. In contrast SAC-induced IL-10 production by DC gen-
erated without 1,25(OH)2D3 was clearly downregulated as compared to that of the original 
monocytes. Although it has been demonstrated that calcitriol inhibits epithelial cell growth 
possibly by inducing the synthesis of TGF-ß (20), and 1,25(OH)2D3 displays identical actions 
on cell growth and differentiation as TGF-ß, we saw no increase but rather a decrease in the 
production of TGF-ß by both DC populations in comparison to monocytes. Mercier et al (21) 
have reported an inhibition in rat liver epithelial cell growth by calcitriol, which was accom-
panied by a reduction in TGF-ß synthesis. In our hands, the presence of 1,25(OH)2D3 appeared 
to have no effect on TGF-ß production by immature DC, giving no evidence for the existence 
of a paracrine/autocrine loop in the inhibitory effect of 1,25(OH)2D3. 
Much in vitro investigation has shed light on the presence and role of 1,25(OH)2D3 in 
immune regulation. Monocytes, macrophages and activated lymphocytes all express the 
vitamin D receptor (VDR). 1,25(OH)2D3 is also produced by activated monocytes and macro-
phages, and has been demonstrated to enhance the antimicrobial function of macrophages 
(7,8). Natural killer cell activity is enhanced as well by this hormone (8). 1,25(OH)2D3 has also 
been demonstrated as stimulating T suppressor cell function, in vivo as well as in vitro (22,23), 
and is known to inhibit both T- and B lymphocyte proliferation (24,25,26) as well as Ig produc-
tion (25). 1,25(OH)2 D3 also inhibits the production of the growth-promoting lymphokine IL-2 
(24,27,28), which was discovered to be the mechanism mediating the inhibition of lympho-
cyte proliferation (26,29). Activated T lymphocytes can serve as direct targets for 1,25(OH)2D3 
(30,31), however the effects of 1,25(OH)2D3 on these cells are also the results of its actions 
on monocytes and macrophages in their role as APCs (32). 1,25(OH)2D3 has been demon-
strated as both inhibiting (27,33) and promoting (28) the IL-1 production of monocytes and 
macrophages. The production of IL-12, important in the development of Th1-biased immune 
responses, has been found to be inhibited by 1,25(OH)2 D3 in both monocytes (34) and acti-
vated macrophages and mature DC (19). With regard to in vivo effects, immune-modulat-
ing properties of 1,25(OH)2D3 and its analogues have been demonstrated in various animal 
models for autoimmunity. For instance, Mathieu et al (23,35,36) showed that 1,25(OH)2D3 and 
several of its analogues are able to reduce the incidence of type 1 diabetes in the NOD mouse. 
Similarly, using the murine model for multiple sclerosis, experimental allergic encephalitis 
(EAE), 1,25(OH)2D3 was shown to prevent the initiation of disease by myelin basic protein 
(37). Although the use of 1,25(OH)2D3 in organ transplantation has not been highly successful 
in preventing graft rejection (partly due to complications of hypercalcaemia at the required 
dosage), various analogues of 1,25(OH)2D3 have been demonstrated to be highly effective in 
prolonging graft survival without the hypercalcaemic effect of 1,25(OH)2D3 itself (38,39,40).
In conclusion, exposure to the immunoregulatory hormone 1,25(OH)2D3 during monocyte-
to-DC maturation results in our hands in immature DC with a reduced expression of CD1a, 
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CD80 and CD40, a reduced capability in the MLR and a remaining high capability for IL-10 
production, all factors likely accounting for the immunosuppressive nature of this hormone 
in T cell stimulation. Apparently (also considering the data previously reported in the litera-
ture on the effects of this hormone) 1,25(OH)2D3 skews monocyte differentiation away from 
APC development and toward the direction of mature phagocytosing macrophages. This 
hormone thus likely favours the development of a strong aspecific, innate immune reaction, 
over that of an antigen-specific immune response.
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Chapter 5A
The effects of 1,25 (OH)2 Vitamin D3 exposure on the generation 
of veiled accessory macrophages from monocytes
M O Canning, C Ruwhof, Bram van de Velde, H J de Wit and H A Drexhage
Department of Immunology, Erasmus University Rotterdam, the Netherlands
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INTRODUCTION
In chapter 3 of this thesis we described that apart from classical DC, a population of veiled 
accessory cells could be generated from monocytes. 
In chapter 4A, we examined the effects of a short exposure of dexamethasone on the gen-
eration of these veiled accessory cells from monocytes. After seeing clear effects compatible 
with the immunosuppressive nature of this hormone, and since 1,25(OH)2Vitamin D3 had 
clear effects on the generation of classical DC from monocytes, we studied here whether 
exposure of monocytes to 1,25(OH)2Vitamin D3 would influence their capability to turn into 
veiled accessory macrophages.
MATERIALS AND METHODS 
Isolation of monocytes from peripheral blood
Monocytes were isolated from the peripheral blood of healthy blood donors via well-
accepted methods: Heparinized blood diluted with an equal volume of phosphate buffered 
saline (PBS) was distributed over Ficoll Isopaque (density 1.077 g/ml, Pharmacia, Uppsala, 
Sweden) and centrifuged for 15 minutes at 1000 g. Cells collected from the interface and 
washed were then suspended in RPMI 1640 with 25 mM HEPES and L-glutamine (GIBCO, 
USA), supplemented with 100 U/ml penicillin G, 0.1 mg/ml streptomycin (both Seromed, Bio-
chrom, Berlin, Germany) and 10% FCS (Biowhitaker, Walkersville, MD, USA) (hereafter known 
as RPMI 1640+) added. This cell suspension was distributed over Percoll (density 1.063 g/ml, 
Pharmacia), then centrifuged for 40 minutes at 400 g. Cells collected from the interface were 
washed and suspended in RPMI 1640+. Monocyte purity was determined by non-specific 
esterase staining (NSE) (26). Cell suspensions containing 80% or more monocytes were frozen 
following standard procedures and stored in liquid nitrogen, providing a bank for experi-
ments. Monocytes purified by elutriator centrifugation (4) were also used in a limited series 
of experiments (courtesy of CLB, Amsterdam, the Netherlands) in order to confirm results 
obtained via Ficoll/Percoll gradient separation. 
Generation of VC 
Monocytes were removed from liquid nitrogen and quickly thawed in a 37°C water bath. These 
cells were then washed twice in RPMI 1640 (without FCS) (5 minutes, 500 g) and suspended 
under plastic-nonadherent conditions (polypropylene tubes, Falcon, Becton Dickinson, San 
Jose, CA, USA) at a concentration of 2x106/ml in RPMI 1640 (without FCS). The monocyte 
suspension was thereafter exposed to 1,25(OH)2D3 at a concentration of 10-8M at 37°C, 5% 
CO2, 100% humidity for 30 minutes. This was followed by washing in RPMI 1640
+ (5 minutes, 
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500 g) and further culturing in RPMI 1640+ at 37°C, 5% CO2, 100% humidity under plastic 
non-adherent conditions for 16 hours (overnight).
Following the 16 hour culture period, cells were centrifuged (5 minutes, 500 g) and resus-
pended in RPMI 1640+. Cells were then examined under light microscopy at a magnification 
of 400x. VC were defined as large cells with actively moving cytoplasmic processes or veils. 
Viability was checked using trypan blue exclusion. Time-lapse cinematographic studies were 
also carried out. For this purpose cells were kept in a microincubator (37°C, 5% CO2) on an 
inverted microscope (Axiovert, Zeiss, Germany) attached to a video camera (Sony, Japan) and 
a time lapse video recorder (Panasonic, Matsushita Electric Industrial CO., Osaka, Japan). The 
video recording interval was set at 0.18 sec and the tape running speed at 2.599 mm/sec. 
After recording, the images were analyzed using a computer (Acorn Computers Ltd., Cam-
bridge, UK). 
The cell suspension was then further purified and separated using large cell columns and a 
mini-MACS (Magnetic Cell Separation System, Miltenyi Biotec GmbH, Bergisch Gladbach, Ger-
many) with mouse anti-human CD3 (Becton Dickinson, USA), CD19 (Coulter, Hialeah, Florida, 
USA), and CD56 (Becton Dickinson) monoclonal antibodies and goat anti-mouse magnetic 
beads (Miltenyi Biotec GmbH) to deplete contaminating T cells, B cells and NK cells. Separa-
tion into CD14bright and CD14dim/- cells was performed via mini-MACS using CD14 (Coulter) 
monoclonal antibody and goat anti-mouse magnetic beads (Miltenyi Biotec GmbH).
Flow cytometry and immunocytochemistry
For analysis of marker expression by flow cytometry, all cell populations were stained by incu-
bating for 10 minutes with mouse anti-human FITC- or PE-conjugated monoclonal antibodies, 
then washing three times. The monoclonal antibodies used were My4 (CD14, Coulter), CD1a 
(Coulter), B7.1 (CD80), B7.2 (CD86), (both from PharMingen, San Diego, CA, USA). Immediately 
following the staining, cells were analyzed on a FACScan (Becton Dickinson). 
The marker pattern of monocytes, VC and DC was also investigated by immunocyto-chem-
istry. Cytospins were prepared using a Cytospin apparatus (Nordic Immunological Labora-
tories, the Netherlands). These were air-dried for 1 hour, then fixed in 100% acetone (Merck, 
Darmstadt, Germany) for 10 minutes. Indirect immunoperoxidase staining was performed 
with the monoclonal antibodies My4 (CD14, Coulter) and HLA-DR (Becton Dickinson). Appli-
cation of rabbit-anti-mouse IgG peroxidase-labelled conjugate (1:50, Dako A/S, Glostrup, 
Denmark) in 1% normal human pool serum followed incubation with the monoclonal anti-
bodies (RT, 1h). Cytospins were developed with a 0.05% 3,3’- diaminobenzidine (DAB, Sigma) 
solution containing 0.01% hydrogen peroxide for 3-5 minutes.
All cytospin preparations were mounted in DePeX mounting medium (Gurr, BDH Limited, 
Poole, England).
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Mixed leukocyte reaction (MLR)
Allogeneic MLRs were performed in order to measure the accessory capability of the various 
APC populations generated. Responder T lymphocytes were obtained from healthy donors 
and isolated following standard procedures with Ficoll-isopaque, Percoll density gradient 
centrifugation, and nylon wool adherence (Leuko-Pak, Fenwall Laboratories, IL, USA). Non-
adhering cells recovered were greater than 90% CD3 positive. 1.5x105 responder cells were 
cultured in 96-well, flat-bottom microtitre plates (Nalgene Nunc International, Rochester, NY, 
USA) with different numbers of irradiated (2000 rad) stimulator cells (monocytes, VC or DC) 
to achieve stimulator-to-T cell ratios of 1:5, 1:10, 1:20 and 1:40. The culture medium used 
was RPMI 1640 with 25 mM HEPES and L-glutamine, supplemented with 100 U/ml penicillin 
G, 0.1 mg/ml streptomycin and 10% human A+ serum, in a total volume of 200 µl per well. 
Controls used were monocytes, VC or DC alone, and lymphocytes in the presence of 10-50 
µg/ml phytoheamagglutinin (PHA) (Wellcome Diagnostics, UK). Cultures were performed in 
triplicate. On day 5, thymidine incorporation was measured by adding 0.5 µCi 3H-thymidine 
(specific activity = 185 GBq/mmol) to each well, then harvesting 16 hours later. Scintillation 
was counted on an LKB 1205 Betaplate liquid scintillation counter (Wallac, Turku, Finland).
IL-12/IL-10 production
Monocytes and VC were placed in 24-well plates (Nalgene Nunc) at a concentration of 
5x105 cells/ml and cultured for 24 hours in RPMI+ containing ultraglutamine (2 mM, g/ml, 
Biowhitaker) and �Biowhitaker), penicillin/streptomycin (100 U/ml, 100 serum free medium 
supplement (SF-1; Corning Costar Europe, Badhoevedorp, the Netherlands). To stimulate 
IL-10 production, the culture fluid contained staphylococcus aureus cowan 1 strain (SAC) 
(1:5000, Calbiochem, La Jolla, CA, USA). The IL-12 production was stimulated by SAC (1:5000) 
and γ-IFN (1000 U/ml, Biomedical Primate Research Centre, Rijswijk, the Netherlands). The 
production was measured by ELISA as indicated by the manufacturer (IL-10: ELISA Pelikine, 
CLB, Amsterdam, the Netherlands and the IL-12 (p 70): Eli-pair, Diaclone, Besançon, France).
RESULTS
Exposing monocytes shortly to 1,25(OH)2D3 prior to an overnight non-adherent culture 
resulted (similarly to T3 and dexamethasone) in a stimulation of cells forming veils and 
interestingly the number of cells forming veils after the overnight culture was higher in the 
case of the pulse with 1,25(OH)2D3 as compared to the pulse with T3 (Fig 1). Also similarly 
the 1,25(OH)2D3 pulse resulted in a population of CD14 dim/negative and a population of 
CD14 positive VC. As was the case with T3 and dexamethasone exposure, the CD14 positive 
cells were poor stimulators in allogeneic MLR and we therefore concentrated on the CD14 
dim/negative VC.
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Figure 2 shows the FACS analysis of the cells. The 1,25(OH)2D3-exposed cells expressed 
similar levels of HLA-DR, CD1a, CD80 and CD 86 than the T3-exposed cells, however the 
expression level of CD14 tended to be higher (in Figure 2 statistical significance was not 
reached, yet in another small series of experiments, n=4, significance was reached). 
Figure 3 illustrates the allogeneic T cell stimulatory capacity of the VC generated from 
1,25(OH)2D3- and T3-exposed monocytes. At a stimulatory-to-T cell ratio of 1:5 it can be seen 
that T3-VC were better stimulators of T cell proliferation than 1,23(OH)2D3-VC (mean 53013,s.
d 35862 cpm vs mean 34899,s.d 22414 cpm, p=0.01).
Figure 4 shows the IL-10 and IL-12 production of the 1,25(OH)2D3-VC and the T3-VC as 
compared to the cytokine production of the original monocytes. The IL-10 production capa-
bility of both VC populations was higher than that of the original monocytes, but the IL-12 
production capability of both the 1,25(OH)2D3-VC and the T3-VC was lower and that of the 
1,25(OH)2D3-VC the lowest (although not reaching statistical significance. This pattern of IL-
10 and Il-12 production is in keeping with the pattern as described in Chapter 3. 
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Figure 1. This figure shows the percentage of cells (all cells, or MACS separated CD14- and CD14 + cells) with long, cytoplasmic, moving 
extensions after an overnight culture of either T3 (white bars) or D3 (black bars) pulsed monocytes (n=11, mean and standard deviations are 
shown, differences between T3 and D3 are in all cases signficant, i.e. p<0.05, Wilcoxon)
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Figure 2. This figure shows the mean fluorescence intensity (MFI) of the CD14 negative monocyte-derived cells (MACS separated) after 
overnight culture and a T3 (white) or D3 (black) pulse (n=7, mean and standard deviations are shown)
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Figure 3. The accessory capability of CD14 negative monocyte-derived cells (MACS separated) after overnight culture and a T3 (white) or D3 
(black) pulse as measured in allogeneic MLR (n=10, mean and standard deviations are shown). P<0.01 at a ratio of 1:5 (VC:T cell)
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CONCLUSIONS
Exposure of monocytes to 1,25(OH)2D3 prior to a non-adherent overnight culture resulted 
in veiled cells that
a. tended to express higher levels of CD14
b. had a lower accessory capability in allogeneic MLR and
c. a very low IL-12 production capability
(as compared to T3-exposed cells)
These results are compatible with other reports that 1,25(OH)2D3 hampers the generation 
of fully immunostimulatory APC from monocytes and is engaged in suppressive activities in 
cell-mediated immunity (see chapter 5).
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Figure 4. The IL-10 (white) and IL-12 (black) production of original monocytes, CD14 negative D3-VC and T3-VC (n=4, means and standard 
deviations are shown)
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A defective adherence of monocytes to fibronectin in thyroid 
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ABSTRACT
Blood monocytes of patients with thyroid autoimmune disease (TAID) show a defective 
capability to rearrange their cortical actomyosin cytoskeleton (‘polarize’) in response to 
chemoattractants. Since such cytoskeletal rearrangements also take place after adherence 
of monocytes to fibers of the extracellular matrix (ECM), it is not surprising that monocytes 
are primed for chemoattractant stimulation after fibronectin (FN) adherence, showing an 
enhanced polarization toward chemoattractants.
We investigated the adherence capability of blood monocytes of TAID patients to a FN 
matrix, and their integrin expression and chemoattractant-induced polarization both before 
and after FN adherence. Since cytoskeletal rearrangements are also needed for the develop-
ment of veils during the transition of monocytes into veiled antigen-presenting (VCs), we 
additionally investigated such transition of FN-adherence monocytes of TAID patients.
Adherent and non-adherent monocyte populations from TAID patients and healthy con-
trols were subjected to a polarization test with the chemoattractant fMLP (or MCP-1), FACS 
analyses (FITC-labelled FN, CD29, CD49e, d, b, and a) and tested for their capability to develop 
into veiled APC.
Monocytes of healthy individuals showed an improved chemoattractant-induced cell 
polarization after FN adherence, not reflected by TAID monocytes, in which chemoattractant-
induced polarization worsened. Monocytes of healthy individuals upregulated CD49e and d 
integrins and their capability to bind FITC-labelled FN after adherence to a FN-coated plate, 
as well as enhancing their capability to generate T cell-stimulatory VCs. Monocytes of TAID 
patients did not.
These data indicate that integrin- (and chemokine)-mediated functions are hampered in 
monocytes of TAID patients. Because, integrin action is pivotal to processes such as monocyte 
adherence to endothelial cells, uropod formation, migration into tissues and differentiation 
into APC and macrophages, these defects might underly immune dysbalances important in 
thyroid autoimmune development.
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INTRODUCTION
We previously reported in patients with thyroid autoimmune disease (1,2) a hampered 
response of monocytes to change shape from a round to a triangular motile form when 
stimulated with the chemoattractant N-formyl-methionyl-leucyl-phenalanine (fMLP). The 
process of shape change, also called cell polarization, is based on a rearrangement of the 
interior cytoskeleton of the cell (3). Chemoattractants and chemokines such as fMLP induce 
such rearrangement by binding to serpentine G-protein coupled receptors in the cytomem-
brane of monocytes. This stimulates a complex cascade of 2nd messenger systems including 
the phosphatidyl inositol (PI) cycle and the Rho-family of GTP-ases, which results - amongst 
other things - in a coupling of f-actin and other cytoskeletal building blocks to the membrane 
of the cell (4). In this way a submembranous myoactin cell cortex is formed, enabling the cell 
to change shape (5).
A similar formation of submembranous cortical myoactin filaments does occur after 
contact of monocytes with the extracellular matrix (ECM). Monocytes adhere to the ECM 
via integrins (6). The integrins are a family of noncovalent heterodimeric complexes situ-
ated in the cell membrane and consisting of an α and a β chain. Integrins do not only act 
as intermediary molecules linking the ECM fibers to the interior cytoskeleton, they also act 
as receptors triggering 2nd messenger systems like the PI cycle and the Rho-family of GTP-
ases (7). It is thus not surprising that adherence of monocytes to an ECM matrix synergizes 
with chemoattractant signaling. Fibronectin (FN)-adhered monocytes have been reported 
to respond to chemoattractants with an enhanced cell polarization (8,9). A concerted action 
between integrin signaling and chemoattractant stimulation is thus of prime importance for 
the diapedesis of monocytes from the bloodstream into the tissues and their differentiation 
in the various monocyte-derived cells. 
Here we describe an investigation on the chemoattractant-induced cell polarization 
of monocytes from 20 patients with recently diagnosed thyroid autoimmune disease (10 
patients with hyperthyroid Graves’ disease; 10 patients with hypothyroid autoimmune thy-
roiditis). Monocytes had either been or not been adhered to a fibronectin (FN)-coated surface 
prior to fMLP or MCP-1 chemoattractant stimulation.
Several integrins can bind to FN, however of the α chains CD49d and CD49e are primarily 
involved (6,7). Of the β chains CD29 is involved. Because of the molecular heterogeneity of 
integrin receptors for FN binding, we labeled FN with FITC and studied in addition to CD49 
and CD29 expression, the expression of "fibronectin-receptors", i.e. the binding of FITC-
labeled FN to patient and control monocytes before and after FN adherence.
Since rearrangements of the cortical actomyosin cytoskeleton are also needed for the 
development of the cell protrusions characteristic of veiled cells during their differentia-
tion from monocytes (10), we also studied the capability of patient monocytes to develop 
into accessory veiled cells (VCs) before and after FN adherence. We previously reported on 
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a method to generate considerable numbers of VCs from monocytes (11,12). Crucial in this 
method of VC generation is the prevention of monocyte oxidase stimulation, via strictly 
plastic non-adherent culture conditions and the presence of reducing substances like BHA 
or iodinated compounds (e.g. metrizamide, reverse T3 and T3) to improve the yield of VCs 
(11,12). The procedure results in a veiled cell population of which 30-45% of the cells have 
veiled protrusions, starting from a suspension of round or oval-shaped monocytes. These 
generated VCs show a strong MHC class II positivity, a decreased expression of the monocyte 
marker CD14, S100 positivity (a marker of Langerhans dendritic cells), a decreased phagocytic 
capability, and a clearly enhanced stimulator capability in T cell proliferation assays indicating 
their improved accessory cell function (11,12). These in vitro-generated monocyte-derived 
VC thus resemble in many morphological and functional aspects the cells in vivo known to 
belong to the heterogenous group of dendritic cells (DC)(13). We previously showed that the 
generation of VCs from monocytes and their function is disturbed in patients with an organ-
specific autoimmune disease, like autoimmune thyroid disease(1,2,14).
PATIENTS AND METHODS
Patients and controls
Heparinized blood (70 mls) was obtained via venapuncture from the following groups of 
individuals:
a. Ten recently diagnosed hyperthyroid Graves’ patients (9 females, one male, ages 50 ± 
13 (mean ± standard deviation) age-ranges 23-69 years) visiting the Department of 
Internal Medicine of the Zuiderziekenhuis, Rotterdam. None of the patients received 
medication at the time of blood collection. All patients had raised serum free thyroxin 
(fT4) levels and decreased serum thyroid stimulating hormone (TSH) levels. Patients 
had a diffuse non-nodular appearance of the thyroid on palpation, scan or ultrasonog-
raphy. TSH-receptor antibodies (Brahms Diagnostics, Berlin, Germany) were positive 
in 8, thyroid anticytoplasmic antibodies (inhouse indirect immunofluorescence assay) 
were positive in 7.
b. Ten recently diagnosed hypothyroid patients (9 females, one male; ages 53 ± 14 years, 
age ranges 40-75 years) visiting the Department of Internal Medicine of the Zuiderz-
iekenhuis, Rotterdam. None of the patients received medication at the time of blood 
collection. All patients had lowered serum fT4 levels and raised serum TSH levels. All 
had positive thyroid anticytoplasmic antibodies. TSH-receptor antibodies were positive 
in none.
c. Twenty healthy controls (15 females, 5 males) consisting of laboratory and hospital 
staff, ages 34±8 years; age range 21-52 years.
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All patients and controls gave informed consent to donate blood for this investigation. The 
protocol had been approved by the Medical Ethical Committee of the Erasmus University 
Hospital Dijkzigt.
Monocyte isolation
Peripheral blood mononuclear cell separation was performed using Ficoll Paque density gra-
dient centrifugation (density 1.077 g/ml; Pharmacia, Uppsala, Sweden). The cells were washed 
twice in RPMI 1640 culture fluid enriched with 10% fetal calf serum (FCS; Gibco, Breda, the 
Netherlands). Aliquots of 40-80 x 106 cells were stored at −150°C in a solution of 10% DMSO 
(Dimethylsulphoxide) in RPMI 1640 supplemented with 10% FCS.
Monocytes were isolated from the separated and deep-frozen lymphoid cells: an enrich-
ment for the monocytes in the Ficoll-Isopaque isolated fraction was obtained by Percoll 
gradient centrifugation: after washing, the Ficoll-isolated pellet containing both monocytes 
and lymphocytes was resuspended in RPMI 1640 10% FCS and carefully layered on top of an 
equal volume of Percoll 1.063 (Pharmacia, Diagnostics AC, Uppsala, Sweden). After centrifu-
gation (40 min, 450 g) the cells were collected from the interface, washed twice in the culture 
fluid (10 min, 500 g) and counted. The suspension almost always contains 80-95% monocyte-
specific esterase positive cells, and only suspensions showing this yield of monocytes were 
used. The monocyte suspension was either directly used for the monocyte polarization assay 
and for FACS analysis, or for further adherence to fibronectin-coated surfaces.
Preparation of fibronectin-adhered monocytes
Monocytes were suspended at a density of 2x106 cells/ml in supplemented RPMI medium; 
aliquots (2.5 ml) were then dispensed into 50-mm tissue culture dishes (Nunc, Denmark) that 
had been precoated with varying concentrations of human fibronectin (CLB, Amsterdam, the 
Netherlands) in a total volume of 2.0 ml of phosphate buffered saline (PBS) for 2 h at 37°C. A 
coating concentration of 20 µg/ml of fibronectin was found to be optimal, and this concen-
tration was used in subsequent assays. The monocytes were incubated in these fibronectin-
coated wells at 37°C for 1 h in a 5% CO2-95% air atmosphere. Nonadherent monocytes were 
vigorously washed off with ice-cold PBS (2 x 2 ml).
Firmly fibronectin-adherent monocytes were removed by incubating the cells in 2.0 ml 
PBS enriched with 3mM EDTA for 45 min. at 4°C, followed by further removal using a rubber 
policeman. This procedure was repeated twice with RPMI 1640, cells were washed, concen-
trated by centrifugation and counted using a hemocytometer.
We checked the lymphocytic contamination of the fibronectin-adhered cells by studying 
the expression of monocyte-esterase and markers such as CD3 (for contaminating T cells), 
CD19 (for contaminating B cells) and CD56-CD16 (for contaminating NK cells): the lympho-
cytic contamination of the monocytes after fibronectin adherence was very low: the popula-
tion contained >90% of cells staining for monocyte-esterase, while contamination with CD3+ 
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T cells was as low as 2%, and the B- and NK-cell contamination as low as 5%. The fibronectin 
nonadherent monocytes were considerably contaminated with other populations of cells 
(around 15% of T cells and 15% of NK cells) and were not further used in our assays.
The polarization assay
For the polarization assay, aliquots (0.2 ml) of the various suspensions containing 2x105 
monocytes were added to 12x75 mm polypropylene tubes (Falcon Labware Division of Bec-
ton Dickinson, Oxford, CA, USA) containing 0.05 ml of either medium, N-formyl-methionyl-
leucyl-phenylalanine (fMLP) in medium to reach a final concentration of 10 nm, or MCP-1 (gift 
dr. A. Montovani). The tubes were incubated at 37°C in a waterbath for 15 min. The incubation 
was stopped by addition of 0.25 ml ice-cold 10% formaldehyde in 0.05% PBS (pH 7.2). The cell 
suspensions were kept at 4°C until counting of polarized cells in a hemocytometer using an 
ordinary light microscope (magnification 250x). The test was read blindly by two experienced 
persons; 200 cells were counted, manually, from each tube. A monocyte was "polarized" if 
any of the following occurred: a change to an elongated or triangular shape, broadened 
lamallopodia, and/or membrane ruffling. The responsiveness of a monocyte population was 
expressed as the percentage of polarized cells in the presence of the chemoattractant minus 
the percentage of polarized cells in the absence of the chemoattractant. On previous occa-
sions we verified that contaminating lymphocytes (in occasional preparations present in up 
to 20%) do not polarize under these conditions. The percentage of polarized monocytes was 
calculated as follows: (% cells polarized due to chemoattractant / % monocyte-specific esterase 
positive cells) x 100%.
The mean value of the two values recorded blindly by the two experienced observers 
was taken as the final value. Although this method seems to be a subjective microscopical 
quantification, it has been proven to be the most sensitive and reliable polarization assay as 
compared to morphometric and flow cytometric methods (15). This has also been our experi-
ence, with intra- and interassay variation hardly ever exceeding 5% polarization (n>100). If 
the data were discrepant in this way (less than 2% of assays), outcomes were not used and 
the assay was carried out again.
FACS analysis
The various monocyte fractions were analyzed using a FACScan flow cytometer (Becton Dick-
inson) for the following markers using the following monoclonal antibodies: CD49a (VLA1, 
Serotec, Oxford, England); CD49b (VLA2, Serotec); CD49d (VLA4, Serotec); CD49e (VLA5, 
Serotec); CD29 (Beckman Coulter, Hialeah, FL, USA) and FITC-labeled fibronectin. Fibronectin 
had been labeled with FITC (Sigma, St. Louis, USA) according to Bergquist et al. (16). Mono-
nuclear cells were incubated with the FITC-labeled fibronectin and monoclonal antibodies 
for the detection of the membrane-bound integrins according to earlier described standard 
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FACS analysis techniques (17). The monoclonal antibodies had been directly conjugated with 
fluorescein isothiocynate (FITC) or phycoerythrin (PE) by the manufacturer.
Generation of veiled cells (VC) 
Monocytes were suspended under plastic-nonadherent conditions (polypropylene tubes, 
Falcon, Becton Dickinson, USA) at a concentration of 2x106/ml in RPMI 1640 (without FCS). T3 
(Sigma) was added to the cell suspension at a concentration of 2x10-10 M to improve the yield 
of VCs. This suspension was then incubated at 37°C, 5% CO2, 100% humidity for 30 min. This 
was followed by washing in FCS supplemented RPMI 1640 culture fluid (5 min, 500 g), and 
further culturing in the same culture fluid at 37°C, 5% CO2, 100% humidity under non-adher-
ent conditions for 16 hrs (overnight).
Following the 16 hr culture period, cells were centrifuged (5 min, 500 g) and resuspended 
in FCS supplemented RPMI 1640. Cells were then examined under light microscopy at a mag-
nification of 400x. Veiled cells were defined as large cells with actively moving cytoplasmic 
processes or veils, which can easily be identified (see Fig.1). Measurements were performed 
blindly, and intra-assay variation remained below 2% (n>50). Inter-assay variation ranged 
from 1-6%. 
Allogeneic MLRs were performed in order to measure the accessory capability of the 
generated VCs. Responder T lymphocytes were obtained from healthy donors and isolated 
following standard procedures with Ficoll-isopaque, Percoll density gradient centrifugation, 
and nylon wool adherence (Leuko-Pak, Fenwall Laboratories, Il, USA). Non-adhering cells 
recovered were more than 90% CD3 positive. 1.5x105 responder cells were cultured in 96-
well, flat-bottom microtiter plates (NUNC A/S International, Denmark) with different numbers 
of irradiated (2000 rad) stimulator cells (VC) to achieve stimulator-to-T cell ratios of 1:5 and 
1:10. The culture medium used was RPMI 1640 with 25mM HEPES and L-glutamine, supple-
mented with 100U/ml penicillin G, 0.1 mg/ml streptomycin and 10% human A+ serum, in a 
total volume of 200 µl per well. Controls used were VC alone, and lymphocytes in the pres-
ence of 10-50 µg/ml phytoheamagglutinin (PHA) (Wellcome Diagnostics, UK). Cultures were 
performed in triplicate. On day 5, thymidine incorporation was measured by adding 0.5 µCi 
3H-thymidine to each well, then harvesting 16 hrs later. Scintillation was counted on an LKB 
1205 Betaplate liquid scintillation counter (Wallac, Turku, Finland).
Statistical analysis
For statistical testing, the Mann-Whitney test was performed (two-tailed, Instat program). 
P<0.05 was considered significant. 
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Figure 1. Time-lapse cinematographic pictures of a living monocyte-derived veiled cell (a-d) and an unchanged monocyte (e-h) in the same 
suspension (see for generation of these cells materials and methods). Pictures are taken 20-30 seconds apart. Magn. x1000. Note the constant 
changes in shape of the veiled cell extanding and withdrawing long, thin cytosplasmic extensions (a-d), this in contrast to the rigid round shape 
of the unchanged monocyte (e-h).
RESULTS
The chemoattractant-induced cell polarization of monocytes of thyroid autoimmune patients is defective and does 
not improve, but worsens after fibronectin adherence
Monocytes of thyroid autoimmune patients were as capable of adhering to fibronectin (FN)-
coated surfaces as circulating monocytes of healthy control individuals. A mean value of 47% 
± 10% (mean ± standard deviation, n=20) adhering monocytes was found in healthy controls, 
whereas thyroid autoimmune patients showed a value of 48% ± 10% (n=20). There was also 
no difference between the purities of the monocyte suspensions of thyroid autoimmune 
patients and of healthy controls neither before nor after FN adherence, values ranged from 
80-95% monocyte-esterase positive cells before and over 95% monocyte-esterase positive 
cells after FN adherence. 
We went on to test the chemoattractant-induced polarization of monocytes of thyroid 
autoimmune patients and healthy controls before and after FN adherence. As can be seen 
from Fig. 2, percoll-purified monocytes of thyroid autoimmune patients were hampered in 
their polarization response towards fMLP before FN adherence (verifying our earlier data, 
ref. 1): Values of 27% (mean, s.d. 11, n=20) vs. 35% (s.d. 6, n=17) of polarized monocytes were 
found in thyroid autoimmune patients and healthy controls respectively (p=0.005). Both 
hypothyroid and hyperthyroid patients showed this phenomenon.
After adherence to FN, the monocytes of healthy controls had a higher polarization capability 
as compared to the original monocytes: 45% (s.d. 5%, n=17) of the cells now responded to the 
chemoattractant fMLP (Fig. 2). The monocytes of thyroid autoimmune patients, on the contrary, 
became (after FN adherence) extremely poor in their polarization capability, and only 18% of 
polarized monocytes (s.d. 11, n=20) were found when stimulated with fMLP (Fig. 2). 
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In a few experiments we used the chemokine MCP-1 as a polarization-inducing signal. 
Monocytes of healthy controls again showed a good polarization response to MCP-1 (40-
42%, at optimal MCP-1 dosage 20 ng/ml) after FN adherence. In 3 patients tested (2 hypo, 
1 hyper) this response was again very low (11%, 29% and 9% respectively), reinforcing the 
observation of a poor capability of the patient monocytes to rearrange their cytoskeleton 
upon a chemoattractant stimulus, particularly after FN adherence. It must also be noted that 
we found MIP1α and RANTES to be poor inducers of monocyte polarization both in healthy 
controls and patients.
The upregulation of fibronectin receptors on monocytes of thyroid autoimmune patients is hampered after 
fibronectin adherence
Firstly it must be noted that the expression of “fibronectin receptors”, of the various CD49 
markers and of CD29 was “dull” on monocytes and at a moderate Mean Fluorescence Inten-
sity (MFI) level of 60-150 as compared to the MFI expression levels we have seen previously 
on e.g. dendritic cells (MFIs of 500-2000).
Although we had expected that FN-adherence would have acted as a method to separate 
‘fibronectin receptor’ positive monocytes from ‘fibronectin receptor’ negative monocytes, we 
observed (Table I) that the percentage of original monocytes that were capable to adhere 
to a FN-coated surface did not match with the percentage of original monocytes capable of 
binding FITC-labelled FN or expressing the relevant FN-binding CD49d, e and CD29 integrins. 
Also the expression of such binding sites and integrins was still considerable in the fraction 
of FN-nonadhered monocytes (both numerically and regarding the intensity of expression). 
Moreover the number of FITC-FN, CD49d, e and CD29 positive cells in the FN-adhered frac-
tion was certainly not enriched to 90- 100%, though it was significantly increased for FITC-FN, 
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Figure 2. The percentage of monocytes that show a cytoskeletal rearrangement (cell polarization) under the influence of the chemoattractant 
fMLP. Means ± s.d. are shown of monocytes before (open columns) and after (gray dotted columns) fibronectin (FN) adherence of healthy 
controls (n=17) and thyroid autoimmune patients (n=20). *p<0.01 vs monocytes prior to FN adherence, † p<0.01 vs monocytes of healthy 
controls, ‡ p<0.001 vs FN-adhered monocytes of healthy controls
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CD49d and CD49e positive cells (see Table 1). The number of CD29 positive cells was even 
lower in the FN-adhered fraction, but values did not reach statistical significance. There were 
also no difference with regard to the MFI intensity of integrin expression after FN adherence. 
Furthermore, repetitive steps of FN-adherence did not alter these integrin expression data in 
a noteworthy manner. These observations are in line with the previously described plasticity 
of integrin expression with regard to the number and avidity / affinity of these receptors 
after binding to ECM proteins (6, 7). This process of regulation of integrin expression is called 
“inside-out” signalling. 
Table 1 also shows that CD49a and CD49b (α integrin chains important in laminin binding) 
were not significantly upregulated after adherence to FN, though there were significant dif-
ferences with the FN-nonadherent cells for CD49b.
Fig. 3 gives the data for the percentages of patient monocytes with “fibronectin receptors” 
(able to bind FITC-labeled fibronectin) before and after FN adherence in relation to values 
of healthy control monocytes. Also the percentages of monocytes expressing the CD49e, 
CD49d, CD29, CD49b and CD49a integrins are shown. Before FN adherence there were no 
differences between healthy controls and thyroid autoimmune patients with regard to the 
percentage and expression levels of monocytes expressing FITC-FN binding sites or CD49e, 
d, and b integrins. Remarkably, more monocytes of thyroid autoimmune patients expressed 
CD49a. The number of CD29-expressing monocytes was lower, but this did not reach statisti-
cal significance. Fig 3 also shows that - although monocytes of thyroid autoimmune patients 
adhered equally well to FN-coated surfaces (see before) - after FN adherence there were fewer 
monocytes from these patients with “fibronectin receptors” as compared to healthy control 
monocytes. The same phenomenon was seen for CD49e positive monocytes. CD49d expres-
sion was raised to the same extent in patient and control monocytes after FN adherence. 
CD29 and CD49b expression were neither significantly altered before nor after FN adherence 
in patients and controls. CD49a expression stayed high after FN adherence in monocytes of 
thyroid autoimmune patients as compared to those of healthy controls.
Table I. Fibronectin-related integrin expression (percentage of monocytes positive in FACS analysis) of fibronectin-adhered and non-adherent 
monocytes of healthy donors (n=10)
Original monocytes Fibronectin-adhered cells Fibronectin-nonadherent cells
Fibronectin-adhering cells 47 ± 10%
Fibronectin-FITC+ 36 ± 16% 55 ± 20%a 16 ± 10%b
CD49d+ 84 ± 12% 93 ±4%a 68 ± 12%b
CD49e+ 67 ± 18% 86 ± 10%a 42 ± 14%b
CD29 70 ± 23% 51 ± 19% n.t.
CD49b+ 55 ± 17% 73 ± 7% 32 ± 12%b
CD49a+ 14 ± 9% 17 ± 10% 8 ± 5%
a p<0.05 vs original monocytes.
b p<0.05 vs fibronectin-adhered monocytes
n.t. = not tested
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Figure 3. The percentages of monocytes positive in FACS analysis for “fibronectin receptors” (FN-FITC, see text), CD49e, CD49d, CD29, CD49b and 
CD49a integrins. Mean ± s.d. are given of original monocytes (first two columns of a set) and of FN-adhered monocyts (last two dotted columns 
of a set) of healthy controls (open columns) and patients (gray columns). a=p<0.05 vs monocytes before FN adherence, b=p<0.01 vs normal 
monocytes of healthy controls, c=p<0.05 vs FN-adhered monocytes of healthy controls.
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Figure 4. The percentages of veiled cells (VCs) generated from blood monocytes prior to (open columns) and after (gray,dotted columns) FN 
adherence. Means ± s.d. are shown of healthy controls before FN adherence (n=4) and after FN adherence (n=8), and of thyroid autoimmune 
patients under both conditions (n=20). a=p<0.01 vs monocytes before FN adherence, c=p<0.001 vs FN-adhered monocytes of healthy 
controls.
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The development of functionally active veiled cells from fibronectin-adherent monocytes is lower in thyroid 
autoimmune patients
On an earlier occasion we reported that the recovery of veiled cells (VCs) from normal, non-
fibronectin-adhered monocytes is in the same range in Graves’ patients as in healthy controls 
(1). We experienced the same observation in a few patients tested (n=4) in the present series 
of experiments, and values in the range of 22-37% of cells with long, actively moving veils 
could be generated from monocytes both in patients and healthy controls (Fig. 4). Fig. 4 also 
shows that the percentages of VCs that could be generated from monocytes was higher in 
healthy controls after FN adherence of the cells, and values of 46% ± 8% (n=8) were obtained. 
These generated VC were good stimulators of the T cell proliferation in an allogeneic MLR 
(Fig. 5).
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Figure 5. The T cell stimulatory potential of the VC populations generated from FN-adhered monocytes. Data are expressed as the capacity of 
the VCs to induce T cell proliferation in an allogeneic MLR (3H-thyminidine incorporation, cpm, means ± standard errors). Data are given of 7 
healthy controls () and of 18 thyroid autoimmune patients (). The horizontal axis gives the VC toT cell ratios. At both ratios the differences 
between the controls and the patients are significant (p=0.003 for the 1 to 10 and p=0.02 for the 1 to 5 ratio).
When FN-adhered monocytes of thyroid autoimmune patients were used, the recovery of 
VCs was much poorer (Fig. 4, 31% ± 10%, p<0.01 n=20), and the cell population was less 
capable to stimulate T cells in allo-MLR (Fig. 5). 
 It must also be noted that there existed a good correlation between the polarization 
capability of a given population of FN-adhered monocytes on the one side and its capabil-
ity to generate VCs and the capability of that VC population to stimulate T cells in allo-MLR 
on the other side; correlation coefficients of 0.48 and 0.47 were found respectively (n=30, 
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p<0.01). This underlines the notion that the capability of fibronectin-adhered monocytes to 
rearrange their cortical cytoskeleton is closely linked to the capability of that population to 
generate veiled T cell-stimulating APCs. 
DISCUSSION
Integrins and chemoattractant stimuli play a pivotal role when monocytes enter the tissues 
from the bloodstream. Via integrin ligation and integrin signaling monocytes are able to 
firmly adhere to endothelial cells (18), to form uropods (19), to respond more vigorously to 
chemoattractants (8,9), to migrate through the vessel wall and through the connective tissue 
via ECM fibers (20) and to differentiate more efficiently into antigen presenting cells (APCs) 
and macrophages (21). Integrin-induced stimulation of 2nd messengers and rearrangements 
of the cytoskeleton are essential in many of these processes (“outside-in” signaling, 6,7). 
After binding to ECM-fibers, integrin expression itself and the avidity and affinity of inte-
grins to ECM proteins is upregulated (6,7). The significance and biochemical pathways of 
this so-called “inside-out” signaling are poorly understood (6,7). It has been suggested that 
“inside-out” signaling plays a role in the ability of migrating cells to align ECM-fibers (22).
Our experiments indeed show that greater numbers of monocytes from healthy controls 
expressed FN binding sites, CD49e and CD49d integrins after FN adherence. The FN-adhered 
cells also showed an enhanced chemotactic polarization and an enhanced capability to dif-
ferentiate into veiled accessory cells.
With regard to monocyte dysfunction in thyroid autoimmune disease, we show here that 
monocytes of patients with recently diagnosed thyroid autoimmune disease are hampered 
in these integrin - and chemokine - mediated functions: the cells were less able to rearrange 
their cytoskeleton after FN adherence, to upregulate the above-named integrins and to 
generate veiled, T cell-stimulating APCs. Monocytes of both hypo- and hyperthyroid patients 
showed these defects. It is known that the thyroid hormone status is able to influence the 
function of monocytes and monocyte-derived cells (23,24). However since both hyper- and 
hypothyroid patients showed these abnormalities and since we reported on a previous occa-
sion on monocyte cytoskeletal rearrangement disturbances in euthyroid TPO-Ab- positive 
women (2), we presume that our data indicate that the autoimmune status per se and not the 
thyroid hormonal status determines the above described monocyte abnormalities. 
Together with our earlier report on a poor homotypic clustering capability of veiled/den-
dritic cells in thyroid autoimmune disease (1), also a function dependent of integrins (25,26), 
the present data strongly point to the existence of defects in the integrin and chemokine sig-
naling pathways in monocytes and monocyte-derived cells of thyroid autoimmune patients. 
There are previous reports on a defective and altered expression of integrins on leukocytes 
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in thyroid autoimmune disease (27,28). However, these reports mainly focus on a defective 
integrin expression on lymphocytes and the consequences of such defective expression for 
a hampered lymphocytic adherence to endothelial cells, which has indeed been established 
for high endothelial venules in the thyroid-draining lymph nodes of thyroid autoimmune 
patients (29).
It is perhaps difficult to conceive why a general disturbance in monocyte function – as 
described here- should occur in a disease in which the abnormality of the immune system 
is an immune response mainly focused toward thyroid gland antigens. In explaining this, 
the NOD mouse model can be helpful. In the majority of NOD strains, no thyroiditis but only 
autoimmune insulitis occurs. The NOD mouse is – despite a mainly focussed immune reac-
tion towards islet antigens- characterized by a general immune disturbance including an 
abnormal development of DC and other APC from precursors, leading to suppressor T cell 
defects (30-32). Only when the thyroid is manipulated such that monocytes, macrophages 
and DC are attracted to the thyroid (via iodine intoxication, 33) is thyroid autoimmune dis-
ease precipitated. Thus, local factors together with a general immune disturbance lead to 
full-blown thyroiditis in this animal model. This likely also is the case in humans, as iodine also 
precipitates autoimmune thyroid disease here. 
Integrin and chemoattractant signaling activates a plethora of molecules involved in intra-
cellular signal transmission and cytoskeletal rearrangements. In Wiskott-Aldrich syndrome 
(WAS), a rare disease characterized by thrombocytopenia, immune dysregulation and also 
autoimmunity, there is an inherited deficiency of the so-called WAS protein (WASp, reviewed 
in 34). WASp is a molecule important in the signaling cascade from the cell membrane to the 
myoactin cytoskeleton, probably at the level of the Rho GTP-ase CDC42 and the cytoskeletal 
organizing complex Arp2/3. This deficiency leads - amongst other things - to an inability 
of monocytes to respond to a chemoattractant signal with cell polarization (3). Also the 
appropriate maturation of dendritic cells (DC) from monocytes is hampered, and WAS-DC are 
defective in their ability to migrate on ECM matrixes (35). The here-presented data on mono-
cytic defects in thyroid autoimmune patients are reminiscent of those reported in WAS, and 
therefore urge for a more detailed study on putative molecular abnormalities in the signaling 
cascade “integrins and chemokine receptors → cytoskeletal rearrangements" in monocytes 
of patients with thyroid autoimmune disease. Interestingly in the NOD mouse an impaired 
cell membrane targeting of the Grb2-sos complex has been found (36) (The Grb2-sos com-
plex mediates the signal from integrins to the MAP-kinase pathway). In BB-DP rats, another 
animal model of autoimmune thyroiditis, an abnormal expression of vav was found (37) (Vav 
mediates the signal from integrin-activated tyrosine kinases to the Rho-family of GTP-ases).
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The present report also expands our previous observations on abnormalities of monocyte-
derived APCs in thyroid autoimmune patients. Here we show that the generation of VCs 
from fibronectin-adhered monocytes is lower in patients with a recently diagnosed thyroid 
autoimmune disease as compared to healthy controls. The here-used method of generat-
ing VC from monocytes yields a type of APC which is different from the so-called "imma-
ture dendritic cells (DC)" generated according to a method first published by the group of 
Lanzevecchia (38). In the latter method, monocytes are cultured under plastic-adherent 
conditions for one week in the presence of GM-CSF and IL-4. The here-generated VC show 
many characteristics known of dendritic/veiled cells in ex vivo/in vivo situations (13): they are 
MHC class II positive, have various markers known of Langerhans cells (e.g. S100) and have a 
clearly increased capability in stimulating T cells as compared to monocytes. They are almost 
as good as "Lanzavecchia" DC in this respect (11,12). The VCs, however, hardly produce the 
immunostimulating cytokine IL-12. They do produce large quantities of the immunosuppres-
sive and immunomodulating cytokine IL-10 (to be published). It is thus tempting to specu-
late that the here-described defects in VC development from integrin-activated monocytes 
represent defects in the generation of APC with immunosuppressive and tolerating capabili-
ties. Interestingly, similar abnormalities in APC generation exist in BB-DP rats (39) and NOD 
mice (30). In these animals, these defects indeed lead to a faulty activation of T cells with an 
immunosuppressive/regulatory capability (30,31,39). Further research is however needed to 
explore the latter hypothesis.
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INTRODUCTION
Dendritic Cells (DC) form a heterogenous group of antigen presenting cells (APC) with dif-
ferent lineage backgrounds (lymphoid versus myeloid), with different (local) precursors and 
with various stages of differentiation and maturation. In the last decade the idea has gained 
acceptance that DC are not only cells capable of initiating immune responses, but also prime 
inducers of tolerance [4]. There are a number of non-mutually exclusive ideas about the 
characteristics and capabilities of the populations of DC that are capable of performing such 
function [5]: thymus DC [6], so-called “steady state” DC [7] and certain forms of (semi-) mature 
DC [8] have all been described as capable of inducing tolerance.
In chapter 3 of this thesis we described that apart from classical DC also a population of 
veiled accessory macrophages exist which are quite similar to classical DC, yet also show dif-
ferences. Culturing monocytes for 24 hrs while avoiding plastic adherence (polypropylene tubes) 
and avoiding the activation of NADPH oxidase (blocking agents) results in the generation of such 
veiled accessory cells (VC). The generated VC were actively moving cells like lymph-borne VC in 
vivo. The monocyte (mo)-derived VC population existed of CD14dim/- and CD14bright cells. Of these 
the CD14dim/- VC were as good in stimulating allogeneic T cell proliferation as immature DC (iDC) 
obtained after one week of adherent culture of monocytes in granulocyte-macrophage-colony 
stimulating factor (GM-CSF)/interleukin (IL)-4. Although the CD14dim/- VC had a modest expression 
of the DC specific marker CD83 and were positive for S100, expression of the DC specific markers 
CD1a, Langerin, DC-SIGN, and DC-LAMP were absent. This indicates that the generated CD14dim/- 
VC cannot be considered as classical LC/DC. 
It was impossible to turn the CD14dim/- mo-derived VC population into typical DC by culture 
for one week in GM-CSF/IL-4 or LPS. In fact the cells died under such circumstances, gaining 
some macrophage characteristics before dying. We also found that culturing the the CD14dim/- 
mo-derived VC in IL-3 let the cells survive while gaining clear macrophage characteristics 
such as an adhesive capacity and acid phosphatase activity, underscoring the actual macro-
phage character of the cells.
Abnormalities in the differentiation and maturation of VC from fibronectin-adhered mono-
cytes were documented in Chapter 6 in patients with autoimmune thyroid disease. 
Interestingly the non-obese diabetic (NOD) mouse and the BB-DP rat, both models for 
endocrine autoimmune disease, show aberrancies in the generation of classical DC and mac-
rophages from their precursors, and it is thought that such defects might be causal to the 
state of defective tolerance in such animals. 
With regard to the NOD mouse, the group of Haskins showed that a mixture of DC and 
macrophages isolated from the spleen were poor in accessory function [11]. In accord 
with the abnormalities of the DC isolated from the lymph node and spleen of this animal 
are findings on an abnormal differentiation and maturation of DC from NOD bone–marrow 
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precursors, particularly when DC are generated in the presence of GM-CSF alone [12-18]. 
Under such circumstances NOD BM-precursors yield lower numbers of differentiated DC, yet 
show various signs of pro-inflammation, viz. an enhanced expression of NF-κB [19] and a 
higher production of interleukin-12 [20]. 
There exist however also reports for the NOD mouse that doubt these defects in the dif-
ferentiation of DC from their precursors [21-23].
With regard to the BB-DP rat our group previously showed that lymph node and spleen DC 
are less differentiated and have an abnormal (“immature”) phenotype [24], i.e. a relatively low 
expression of MHC class II and of co-stimulatory molecules. These lymph node and spleen DC 
also showed a diminished capability to stimulate the proliferation of T cells, particularly of the 
suppressor T cell population of the rat: the RT6+CD8+ T cells. 
Here we tested monocytes of patients with a recent onset autoimmune thyroiditis (AIT) for 
their capability to generate classical DC in culture with GM-CSF/IL-4.
SUBJECTS AND METHODS
Subjects
Heparinised blood (60 mL) was obtained from
1. Recently diagnosed AIT patients (n=28), who visited the outpatient clinic of the Depart-
ment of Internal Medicine, Medical Center Rijnmond Zuid, Rotterdam, the Netherlands. 
The mean age was 42.7 ± 12.6 years, ranging from 30.9 to 71.2 years. All patients had 
high levels of thyroid peroxidase antibodies (TPO-Abs > 400IU/ml). 
2. Healthy controls with an absent family history of autoimmune diseases. These individu-
als consisted of laboratory personnel and students. The controls were divided for some 
comparisons into two groups to obtain age-matched controls for the two diabetic 
groups (young group, n=41, mean age 28 ± 6.6 years, ranging from 19.4 to 42.5 years; 
older group, n=15, mean age 50.1 ± 9.5 years, ranging from 30 to 60.5 years).
Informed consent was obtained from all participants. The research protocol has been approved 
by the Medical Ethical Committee of the Erasmus MC, Rotterdam, the Netherlands. 
MONOCYTE ISOLATION AND GENERATION OF DCS
Ficoll (Pharmacia, Uppsala, Sweden; density 1.077 g/ml) and Percoll (Pharmacia; density 
1.063 g/ml) density gradient centrifugation were used to isolate monocytes from heparin-
ized blood and buffycoats (Sanquin Blood bank, Rotterdam, the Netherlands) as described in 
detail before by Kabel et al [26]. The monocytes were cultured (according to the methods of 
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Sallusto [27]) at a concentration of 5x105 cells/ml on 24-well culture plates for six days under 
plastic-adherent conditions in RPMI 1640 with 25mM HEPES and L-glutamine (BioWhittaker 
Europe, Verviers, Belgium) (hereafter referred to as RPMI+) containing ultraglutamine (UG) 
(2mM, BioWhittaker), penicillin/streptomycin (P/S) (100U/ml penicillin, 100µg/ml streptomy-
cin, BioWhittaker) and 10% inactivated FCS (FCSi) (BioWhittaker) in the presence of GM-CSF 
400U/106 cells and IL-4 500U/106cells (both Pepro Tech EC, London, England). The cells were 
incubated at 370C, 5% CO2
 and 95% humidity. On day three, half of culture fluid was refreshed 
with GM-CSF 200U/106cells, IL-4 250U/106cells. After six days DC were collected by resus-
pending and washing the wells thoroughly with cold phosphate buffered saline (PBS) pH 
7,4 (Biowittaker), with 0,1% bovine serum albumin (BSA) (Bayer, Kankakee, IL, USA) and 3mM 
ethylene diamine tetraacetic acid (EDTA), pH 8 (Sigma-Aldrich, Steinheim, Switzerland). The 
cells were counted with 0.1% trypan blue (Sigma Chemical co, St Louis, USA) to assess cell 
viability.
T cell isolation was performed by washing the pellet in the Percoll gradient twice with PBS/ 
0,1%BSA and incubating the cells with 20µl/107 cells anti-CD3 microbeads (Miltenyi Biotec, 
Bergisch Gladbach, Germany) for 20 minutes on ice. A magnetic cell sorting system (auto 
MACS sorter, Miltenyi Biotec) was used for the selection of CD3 positive T cells.
Phenotype of DCs 
The following monoclonal antibodies (mAbs) were used for flowcytometry: anti-IgG1 FITC, 
anti-IgG1 PE (both (1:10) Becton Dickinson, San Jose, CA, USA), anti-CD14 FITC (1:250, Beckman 
Coulter, Hialeah, FL, USA), DC-SIGN PE (1:10, R&D systems, Minneapolis, MN, USA), anti-HLA-
DR PE (1:200, Becton Dickinson), anti-CD80 PE (10µl/105 cells, Becton Dickinson), anti-CD86 
FITC (10µl/105 cells, Pharmingen, San Diego, USA), anti-CD40 FITC (10μl/105 cells, Serotec, 
Oxford, England), anti-CD1a PE (1:100, Beckman Coulter), anti-CD18 FITC, anti-CD11b PE (1:5 
and 1:10, Becton Dickinson), anti-CD29 FITC (1:160, Beckman Coulter), anti-CD54 PE (ICAM-1) 
(1:4, Becton Dickinson), anti-CD49a FITC (VLA-1), anti-CD49b FITC (VLA-2), anti-CD49d (VLA-4) 
(10µl/105 cells, Serotec), anti-CD49e FITC (VLA-5) (10µl/105 cells, Immunotech), anti-CD3 FITC 
(1:20, Becton Dickinson), anti-CD19 PE (1:25, Becton Dickinson) and 7AAD (1:250, Molecular 
probes, Eugene, Oregon, USA).
DC were incubated in polypropylene tubes with mAbs for 15 minutes, then washed twice. 
The cells were measured immediately following cell staining using a FACScan flowcytometer 
and analyzed using CellQuestPro (Becton Dickinson, Mountain View, CA, USA). Routinely 
10,000 events were collected. Debris and dead cells were gated out on basis of their light 
scatter properties. In addition, we stained the cells with trypan blue and 7AAD. The gated 
DC population was devoid of CD3+ and CD14+ cells. Data were expressed as mean ± SD of 
percentage of positive cells and mean ± SD of mean fluorescence intensity (MFI). The back-
ground staining was determined by staining of cells with IgG1-FITC and IgG1-PE alone and 
subtracted from the values.
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Mixed Leucocyte Reaction (MLR) 
For the MLR DC were irradiated with 20Gy and placed in flat-bottom 96-wells-plates (Nunc, 
Roskilde, Denmark) at concentration of 3x105, 1.5x105, 0.75x105 cells/ml RPMI+ containing 
UG, P/S and A+-serum. We added 100µl of DC and an equal volume of autologous T-cells at 
concentration of 1.5x106 cells/ml to the wells resulting in a total volume of 200µl per well. 
As positive control these T-cells were stimulated with phytohemagglutamin (PHA) (Sigma). 
Culture of DC or T-cells in medium alone served as negative controls. Proliferation was deter-
mined after 18 hours of 0.5µCi/well 3H-thymidine addition on day 5. Cells were harvested on 
filterpapers and radioactivity was counted in a liquid scintillation analyzer (LKB Betaplate, 
Wallac, Turun, Finland). The values are the mean of triplicates.
STATISTICAL ANALYSIS
Statistical analysis was performed using SpSS 11.0. Paired Student’s T-test was used to detect 
differences between data of untreated and CD54 treated DC experiments. For the other 
experiments the Mann Whitney U-test was used. P–values lower than 0.05 were considered 
significant.
RESULTS
The yields of DC, measured as the percentage of generated viable cells of the original number 
of monocytes put into GM-CSF/IL-4 culture, were comparable for AIT patients and healthy 
controls. After six days of culture the yield of DC was 39% (mean) ± 21% (standard deviation, 
SD) for the healthy controls (n=18) and for AI thyroiditis patients 32% ± 24% (n=12). Differ-
ences between groups and series of experiments were not statistically significant. 
The percentages and expression levels of the markers CD1a, DC-SIGN, HLA-DR, CD80, CD86 
and CD40 on the DC of AIT patients were also comparable to those of the healthy controls 
(Figure 1). 
With regard to DC function, the T cell stimulatory capacity in autologous MLR of the pheno-
typically abnormal DM1 DC was significantly lower. For the DC:T cell ratio 1:10 and 1:20 DM1 
patients showed a significantly lower incorporation of 3H-thymidine (Figure 2). 
When the T cells of the DM1 patients were stimulated with the mitogen PHA in the absence 
of DC, they also showed a lower proliferation as compared to healthy control T cells (8568 ± 
7508 vs 22099 ± 13550, p=0.03). 
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Figure 1. Phenotype of immature DC derived from DM1, DM2, AIT patients and control subjects. The phenotypes (DC markers and costimulatory 
molecules) of DC from DM1, DM2 and AIT patients (thick lines) are shown in histograms. The thin lines are DC from control subjects and the 
dashed lines are DC stained with isotype control Abs. DC of DM1 have lower expression of DC-SIGN, CD80, CD86, CD40 and CD1a. DC of DM2 and 
thyroiditis patients are comparable to controls. 
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Figure 2. Proliferation of autologous T cells measured by 3H-thymidine incorporation and expressed as counts per minute (cpm) are shown. DC 
of DM1 patients (n=6, triangles) have lower autologous T cell stimulatory capacity compared to DC of controls (n=8, diamants). T cells of DM1 
patients have significantly lower proliferation to PHA stimulus compared to T cells of controls. Data are shown as means and standard deviations 
of cpm for triplicate samples per individual (* p=0.03).
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CONCLUSION
We could neither find abnormalities in the generation of mo-DC of recent onset AIT patients, 
nor in the expression of the here studied markers and important immune stimulatory mol-
ecules of their DC. In a previous study (Chapter 6) we did find that monocytes of AIT patients 
had a lower capability to arrange their cyto-skeleton when stimulated with a chemo-attrac-
tant and were less capable in forming veiled accessory macrophages, particularly when FN-
adhered monocytes were used [53]. 
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GENERAL CONCLUSIONS
Regarding veiled accessory macrophages
The studies performed in Chapter 3 on monocytes using oxygen radical blocking agents and 
non-adherent conditions illustrate the plasticity of monocyte-derived APC populations by 
demonstrating that within a period of twenty-four hours, veiled accessory cells (VC) can be 
generated from human monocytes. These VC are actively moving cells and demonstrate the 
morphology and some markers typical of classical monocyte-derived DC (i.e.in S-100 expres-
sion). They also differ from the DC described in peripheral tissues and in the T cell areas of 
lymph nodes (the interdigitating cells) by showing an absence of DC-SIGN and CD1a. 
Despite this difference, our monocyte-derived veiled macrophage-like cells most likely form 
part of the heterogeneous population of veiled/dendritic macrophage-like cells in afferent 
lymph described in the 1970-1980s which drain the peripheral tissues to the draining lymph 
nodes, since cells with a morphology and movement pattern similar to our in vitro obtained 
VC formed part of this heterogeneous lymph-borne population. However, detailed studies 
on such lymph-borne cells using markers developed in the last few decades are required to 
strengthen or refute such a view.
The VC we generated could be divided based upon their expression of CD14. While the 
CD14 bright cells were extremely poor accessory cells, the CD14dim/negative population 
was a very good accessory cell population, able to stimulate T cell proliferation as good as 
classical immature (i) DC obtained after one week of adherent culture in GM-CSF/IL-4. Inter-
estingly, CD14dim/negative VC expressed S100 strongly, like Langerhans cells in the skin and 
DC in interstitial tissues (in fact monocyte-derived DC do not). Like monocyte-derived DC, 
the VC were not reactive to acid phosphatase and expressed MHC Class II, however expres-
sion of the DC-specific marker CD83 was modest, and there was hardly or no expression of 
other DC-specific markers such as CD1a, Langerin, DC-SIGN and DC-LAMP. The production of 
IL-10 and IL-12 by these veiled accessory cells also differed from iDC, with more IL-10 and less 
IL-12 produced, with the result that the T cells that were stimulated by these VC produced less 
IFN-gamma than T cells stimulated by iDC. 
It was impossible to keep the VC in culture, or to differentiate them further into typical DC 
by culturing them with GM-CSF/IL-4 or LPS. Under these conditions, the cells gained some 
characteristics of macrophages before dying. Culturing the CD14dim/negative VC in IL-3 let 
the cells survive; the cells now gained clear macrophage characteristics such as an adhesive 
capacity and acid phosphatase activity, underscoring the actual macrophage character of the 
cells (unpublished results).
Conclusive hypothesis: Avoiding “danger signals” (plastic adherence and radical formation) 
monocytes are capable of rapidly transforming into veiled macrophages with an excellent T 
cell stimulatory capacity. The cytokine profile of these veiled macrophages (high IL-10 and 
low IL-12 production capability) and their capability to skew the T cell response in a Th2 direc-
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tion suggests that the cells are “steady state” APC involved in tolerance induction rather than 
in eliciting a cell-mediated immune response.
Regarding the effects of hormones on classical DC and veiled accessory macrophages
The studies described in Chapter 4 and 5 demonstrate clear effects of hormones on the dif-
ferentiation and maturation of classical DC and VC from monocytes, the two APC populations 
studied in this thesis (Table I and II). 
1,25 (OH)2 Vit D3. Specifically, the presence of Vitamin D3 in the cultures caused a down 
regulation of typical DC markers such as CD1a, CD83, CD80, CD40 and HLA-DR, while up 
regulating monocyte markers such as CD14 and CD86. Functionally, the resulting DC were 
less able to stimulate T cell proliferation in the MLR than normal monocyte-derived iDC, and 
produced large amounts of IL-10 (Table I). 
The use of Vitamin D3 in the VC culture resulted in a lower yield of CD14 negative/dim VC 
with a considerable residual CD14 expression. Such VC had a lowered capability to stimulate 
T cells and a poorer IL-12 production (Table I). 
Table I. The effects of 1,25 (OH)2 Vit D3 on monocyte-derived APC
Classical DC CD 14- VC
Yield ↓ (CD1a+, CD83+) ↓
Immune stimulatory molecules (DR, CD80/86) ↓ ~
T cell stimulatory capacity ↓ ↓
Cytokines IL-12    
     IL-10
~
↑
↓
~
Conclusion: This combination of a down regulation of particularly CD1a, CD80 and CD40 in 
DC culture, a high residual CD14 expression for VC and DC, a reduced capability in MLR for 
both APC populations and a high production of IL-10 for iDCs and a low production of IL-12 
for VC clearly illustrate the suppressive influence of this hormone on the stimulation of cell-
mediated immunity and a skewed differentiation of monocytes away from antigen present-
ing cells (APC) and toward phagocytosing macrophages, thus favoring a non-specific innate 
immune response over an antigen-specific response. 
Dexamethasone. The influence of dexamethasone in the DC cultures was clearly seen by a 
down regulation of CD1a, CD40 and CD80 combined with an increase in CD14 expression in 
the resulting plastic-adherent macrophage-like cells (Table II). Although the ability of these 
cells to stimulate T cell proliferation in the MLR was not affected, their production of IL-12 
was virtually shut down, while their production of IL-10 increased. Therefore, the presence of 
dexamethasone in the culture during the generation of monocyte-derived DC directed cell 
development away from DC toward a more macrophage-like cell, possibly indicating a Th-2 
biased response. 
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Exposure of monocytes to dexamethasone also affected their differentiation potential 
towards veiled accessory macrophage-like cells. The resulting CD14 dim/negative VC had a 
low expression of important immune stimulatory molecules such as HLA-DR and CD86, a low 
capability to produce IL-12 and a poor capability to stimulate T cells.
Conclusion: The effects of dexamethasone on the generation of APC population from 
monocytes are therefore clearly inhibitory as was the case for VitD3. 
Table II. The effects of dexamethasme on monocyte-derived APC
Classical DC CD 14- vC
Yield More mø-like ~
Immune stimulatory molecules (DR, CD80/86) ~ (to ↓) ↓
T cell stimulatory capacity ~ ↓
Cytokines IL-12    
     IL-10
↓↓
↑
↓
~
DHEA. Adding DHEA to the cultures during the differentiation process from monocytes to 
DC had a contrasting effect to that of dexamethasone, possibly skewing the immune reac-
tion toward a Th-1 type response. The continuous presence of DHEA resulted in monocyte-
derived iDC possessing similar functional characteristics to typical non-exposed iDC. While 
the presence of DHEA did not significantly alter the ability of the resulting cells to stimulate T 
cell proliferation or their IL-12/IL-10 production, an increase in CD80 expression and decrease 
in the expression of the immaturity marker CD43 may indicate the emergence of a more 
mature DC after exposure to this ‘immunostimulating’ hormone. The effects of DHEA on VC 
development were not tested in depth, but in a few experiments we noted that the T cell 
stimulatory capacity of CD14dim/negative VC generated from DHEA-exposed monocytes 
was stronger than that of T3-exposed monocytes (see addendum 4A).
Conclusion: Our observation supports the view that DHEA has some immuno-stimulatory 
capacity. 
Regarding VC and DC function in patients with autoimmune thyroiditis
The studies in Chapter 6 on monocytes obtained from recently diagnosed thyroid autoim-
mune disease (TAID) patients indicate abnormalities in integrin- and chemokine-mediated 
functions. We found the chemoattractant-induced polarization of monocytes (rearrange-
ment of interior cytoskeleton) to be defective in TAID patients, and this defect was more 
pronounced after fibronectin (FN) adherence. The monocytes of TAID patients were also less 
able to up regulate specific (CD49d and e) integrins and to generate VC (after FN adherence) 
that were functionally active in T cell-stimulation (normally, adherence to FN increases the 
expression of integrins on monocytes and stimulates the VC development from monocytes). 
Interestingly, monocytes of autoimmune thyroiditis patients had a normal capability to 
generate classical monocyte-derived DC when cultured with GM-CSF and IL-4 for one week. 
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Conclusion: These data indicate that there are in particular aberrancies in monocytes of 
TAID patients. These aberrancies are in the signaling pathways downstream of the integrins 
and chemokine-receptors and linked to the cytoskeletal functions of the cell. These aber-
rancies did not affect the in vitro development of classical DC, but did affect the in vitro 
development of VC from TAID monocytes. 
Taken together with the characteristics of monocyte-derived VC described in chapter 
3 (particularly their significant production of IL-10 and the literal shut-down of IL-12), the 
defects in VC development from fibronectin-adherent (=integrin-activated) monocytes of 
TAID patients could represent defects in the generation of a subset of APC with immunosup-
pressive and tolerating capabilities. 
Collectively and answering the questions posed in Chapter II of this thesis we have shown 
here that
a. A population of APC, characterized by veils, could rapidly be generated from mono-
cytes. Such VC were equally potent in stimulating T cells as classical mo-derived 
iDC, yet were different in marker pattern, cytokine production and Th1/Th2 skewing 
capability in that they were less potent to stimulate Th1 cells. The VC were also more 
macrophage-like cells.
b. Hormones modulate the function of both DC and VC. The effects of dexamethasone 
and 1,25 (OH)2 Vit D3 were inhibitory on the generation of both APC populations from 
monocytes (making them actually more macrophage-like), while DHEA had a slight 
immune stimulating effect. 
c. The motility of monocytes and the generation of VC from monocytes was disturbed in 
patients with autoimmune thyroid disease, yet the generation of mo-derived DC was 
intact.
How do our data on monocyte-derieved APC populations relate to a putative pathogenesis of thyroid autoimmune 
disease in the human?
To discuss this question we want to address the following items before trying to construct a 
state of the art hypothesis on the pathogenesis of autoimmune thyroiditis: 
a. The histological evidence for a primary role of APC in the pathogenesis of human auto-
immune thyroiditis
b. The T cell defects that exist in addition to defects in APC function in animal models and 
human autoimmune thyroid disease
The histological evidence for a primary role of APC in the pathogenesis of human autoimmune thyroiditis
For histological studies predominantly thyroids of Graves’ patients have been available. These 
specimens are taken late in disease. Interventions that likely influence the infiltration and 
accumulation of APC, T cells, B cells and scavenger macrophages (such as an anti-thyroid 
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drug treatment) have often been given. Despite that, the histological picture of the leuko-
cyte infiltration into a Graves’ goiter is remarkably similar to that of the late phase leukocyte 
infiltration into the thyroid of the BB-DP rat. In both situations the glands show areas of intra-
thyroidal lymphoid tissue and areas in which the thyroid follicles are largely intact. In Graves’ 
disease such areas of intact parenchyma are composed of hyperplastic and hypertrophic cells 
(1,2), in BB-DP rats of slightly hypertrophic cells only (3). A few Hashimoto glands have also 
been examined. In such glands, areas of intra-thyroidal lymphatic tissue are also present, but 
located next to areas of heavily damaged thyroid parenchyma (1,2). Damage is caused by 
inflammatory infiltrates of CD8+ cytotoxic lymphocytes, CD4+ lymphocytes and scavenger 
macrophages. 
In areas of Graves’ goiters where there are intact follicles, significantly elevated numbers 
of peri-follicularly-located DC/VC are present (1,2). Such cells are often adherent to the basal 
surface of the thyrocytes, sending their long cytoplasmic protrusions deeply into the inter-
cellular space in between the thyrocytes (4). Such peri-follicular DC/VC have an immature 
phenotype with a low expression of the co-stimulatory molecules CD80, CD86 and CD40 (2). 
Mature DC with a high expression of such molecules are predominantly present in the 
larger areas of intra-thyroidal lymphatic tissue and co-localized with activated CD4+ T cells 
(2). In such areas, high endothelial venules (HEV) are also present. Such venules are character-
ized by an up regulated integrin expression of their high columnar endothelial cells (1). HEV 
are responsible for the increased infiltration of (naïve) T and B cells in such areas of intra-
thyroidal lymphatic tissue by virtue of their heightened integrin expression (5). 
With regard to the discussion on the role of thyrocytes as APC, Tandon et al (6) and Mat-
suoka et al (7) showed that normal human thyrocytes are not capable of expressing co-stimu-
latory molecules to a noteworthy extent. There is however some evidence that they might 
express such molecules in Graves disease (8). In addition, while the co-culture of thyrocytes 
and T cells alone resulted in a relatively weak T cell proliferation, addition of low numbers 
of monocytes or APC to the culture led to a clear enhancement of the T cell proliferative 
response (9). 
Collectively, these observations point in the direction of DC/VC and not the thyrocytes 
playing the most important role in the induction of thyroid autoimmunity, not only in the 
animal models (see Chapter 1) but also in the human. 
The T cell defects that exist in addition to defects in APC function in animal models and human autoimmune 
thyroid disease
The defects in T cells in the animal models of spontaneously developing autoimmune thyroid 
disease and/or in autoimmune thyroid patients can be divided into defects in apoptosis and 
defects in the generation of suppressor T cells.
Defects in apoptosis. The BB-DP rat has a profound peripheral (=non-thymic) T cell lym-
phopenia. The peripheral lymphopenia of the BB-DP rat is due to an excessive apoptosis of 
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recent thymus emigrants and is a recessive trait (10). The animals are lymphopenic from birth 
onwards due to a mutation in one of the Immune-associated nucleotide (Ian) genes on rat 
chromosome 4, i.e. the Ian-5 gene (11). Ian-5 codes for a protein, which binds to the mito-
chondrial membrane. The protein protects the cell against apoptosis. Homozygosity for the 
mutation in the Ian-5 molecule leads to a strongly reduced expression of the anti-apoptotic 
Ian-5 molecule in T cells and their consequent vulnerability for apoptosis. Interestingly, this 
affects in particular activated, i.e. RT6+ T cells in the blood and in the peripheral tissues of 
the BB-DP rat. The activated RT6+ T cell population mainly harbors the suppressor T cells of 
the rat. Hence the apoptosis disturbance leads in the BB-DP rat to a massive death of recent 
thymus emigrating T cells but particularly of suppressor T cells.
The T cells of the NOD mouse are also characterized by defects in apoptosis, but –in con-
trast to the BB-DP rat- the T cells are resistant to apoptosis (12,13). Decallone et al (12) found 
that NOD T lymphocytes, when compared to non-obese diabetes-resistant (NOR) and healthy 
control strains, were resistant to activated immune T cell death (AITCD) induced by strong 
activation stimuli (IL-2 and anti-CD3). The AITCD defect of NOD T cells was characterized by 
a low Caspase-8 activity and an aberrant transcriptional expression of several AITCD-related 
molecules in resting NOD T cells (14). Interestingly, this immunological dysfunction of the T 
cells (which is directly related to peripheral tolerance induction) could be counteracted by 
treating the mice with 1,25 (OH)2 Vitamin D3 (14). 
With regard to the T cells of autoimmune thyroid patients, there is a recent report that 
shows that the T cells of autoimmune thyroid patients also have a defective apoptosis, similar 
to the defective apoptosis of the T cells in the NOD mouse model (15). 
Defects in T suppressor cells in animal models of thyroid autoimmune disease. The mouse 
thymectomy models are clear models of the lack of the current most popular regulator T cell 
population, the CD4+CD25+ T reg cells (16,17). Regulatory CD4+CD25+ T cells comprise 5-
10% of all CD4+ T cells, and are further characterized by the constitutive expression of CTLA-4, 
Fox-P3 and GITR. CD4+CD25+ T cells develop in the thymus via a distinct pathway of thymic 
selection requiring the expression of endogenous TCR α chains on the cells for selection since 
CD4+CD25+ T cells are absent in TCR transgenic mice on a RAG-deficient background. In this 
selection process, the cells are selected that are able to recognize self-antigens expressed in 
the thymus. A feature of CD4+CD25+ T cells is that in the periphery the cells are “anergic” to 
TCR ligation, yet capable of suppressing the activation of (bystander) CD4+ and CD8+ cells 
when these cells are approached by their cognate antigens. Ligation of surface molecules 
such as CD152 (CLTA-4) and GITR, as well as secretion of anti-inflammatory cytokines, such as 
TGF-β, IL-4 and IL-10, have all been implicated in the regulation or mediation of the suppres-
sive activity of CD4+ CD25+ T cells (18).
Although relatively little is known about the mechanisms that control the development 
and/or function of CD4+CD25+ T cells, studies in CD7, CD28 and CD40 deficient (knock-out) 
mice have clearly shown that co-stimulation, most likely given by professional APC, is essen-
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tial for their generation in the thymus and expansion in the periphery. In particular, signal-
ing via the CD80-CD28 route seems to be essential. Studies in C57BL/6 mice have shown 
that when such co-stimulation via the CD28 and CD7 pathways are not given, that there are 
decreased numbers of CD4+CD25+ T cells in the periphery and that autoimmune thyroiditis 
will spontaneously develop. Interestingly, the NOD mouse shows a progressive loss of CD4+ 
CD25+ T regulator cells during the development of diabetes, while the pathogenicity of CD4+ 
CD25- effector T cells increases (19). Also, treatment of the NOD mice with Vitamin D receptor 
(VDR) ligands, mimicking the effects of 1,25(OH)2 D3, increases the number of CD4+CD25+ 
T cells in the spleen of NOD mice and prevents the development of autoimmune diabetes. 
There are indications that at least part of the effects are mediated by the effects of the VDR on 
DC (see also this thesis) and that such modified DC are more able to expand the CD4+CD25+ 
T cell population. There is also a report that shows that thyroglobulin-specific CD4+CD25+ T 
cells are activated in mice and experimental autoimmune thyroiditis suppressed, when DC 
generation is stimulated using a treatment with GM-CSF/IL-4, but not with Flt-3 ligand (20). 
Taken together, there is ample evidence that there are defects in the recently discovered new 
sub-set of CD4+CD25+ T regulator cells in the animal models of spontaneously developing 
autoimmune thyroiditis/diabetes and that a faulty function of APC might at least in part be 
instrumental to these defects. 
Defects in T suppressor cells in patients with thyroid autoimmune disease. What about 
CD4+CD25+ T cells in patients with autoimmune thyroiditis? There is one recent Japanese 
report (21) that shows that CD4+ CD25+ T cells are not related to the progression of Hashi-
moto’s disease. Some Japanese patients with Hashimoto’s disease develop hypothyroidism 
and are treated with thyroxine (severe Hashimoto’s disease), but most do not throughout 
their lives (mild Hashimoto’s disease). There was no significant difference in CD4+ CD25+ cells 
between these Hashimoto’s disease groups, but the serum titers of the thyroid autoantibod-
ies and the proportion of CD25+ cells within CD8+ cells (activated T cytotoxic cells) were 
higher in patients with severe Hashimoto’s disease than in those with mild Hashimoto’s dis-
ease. However proper control groups of healthy individuals were not included in this study.
Recently collected data by Strieder et al support a role for CD4+CD25+ T cells in the 
development of human autoimmune thyroiditis (to be published). We showed that s-IL2R 
levels and the percentages of CD4+CD25+ T cells/CD4+CD152+ (CTLA-4) T cells are lower in 
patients with autoimmune thyroiditis and in first degree relatives (FDR) of these autoimmune 
thyroiditis patients as compared to healthy controls. FDR who smoked and FDR who used 
oral contraceptives surprisingly had the lowest risk of developing autoimmune thyroiditis, 
and interestingly these FDR had the highest levels of CD4+CD25+ T cells. 
Taken together evidence is emerging that also in the human CD4+CD25+ T cells might 
play a prominent role in the protection against autoimmune thyroiditis. It is tempting to 
speculate that the APC defects, as found in this thesis, play a role in the defective generation 
and sustenance of the CD4+ CD25+ T cells, as they do in the animal models. It must also be 
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noted that apart from these CD4+CD25+ T regulator cells, there are other T cell populations 
with regulator function, such as the Tr1 cells (producing IL-10) and the TH3 cells of the gut 
(producing TGF-β), and little is known about these populations in patients with endocrine 
autoimmune disease and their regulation by the defective APC.
A state of the art hypothesis on the etio-pathogenic mechanisms of human autoimmune thyroiditis
Taking the data from the literature and the here-presented data together, it can be concluded 
that there exists in animals and patients with autoimmune thyroiditis a plethora of (some-
times subtle) aberrancies in the function of thyrocytes, monocytes, macrophages, DC/VC and 
T cells. From these aberrancies a general blueprint for the etio-pathogenesis of destructive 
autoimmune thyroiditis can be constructed (see Figure 1). In this blueprint the first step is 
that APC are attracted to the thyroid in larger numbers. Instead of staying in a “steady state 
tolerogenic” mode the APC become “activated” as in danger situations and start to trigger T- 
and B-cells to mount an immune response towards auto-antigens after arrival in the draining 
lymph node. The basis for this aberrant switch from “steady state tolerogenic mode” towards 
“danger-associated immune response eliciting mode” lies in the various aberrancies of the 
thyrocytes, monocytes, macrophages, DC/VC and T cells. However it is important to note that 
the various specific thyrocyte, APC and T cell aberrancies clearly differ between the three 
animal models for destructive autoimmune thyroiditis (e.g. T suppressor cell defects in the 
BB-DP rat due to an enhanced T cell apoptosis, AITCD defects in the NOD mouse due to a 
reduced T cell apoptosis). This tells us that there clearly exist different etio-pathogenic routes 
for the development of destructive autoimmune thyroiditis. It is likely that - as in the animal 
models – also in patients different combinations of various and different (and perhaps even 
human-specific) inborn polymorphisms for thyrocyte, APC and T cell function in combination 
with environmental factors contribute to the loss of tolerance to thyroid autoantigens and to 
a susceptibility for thyroid autoimmunity. Interesting in this respect is that we were unable to 
find in patients the defects in DC development so characteristic of the BB-DP rat and the NOD 
mouse. In humans, however, we detected a similar defect in the generation of veiled macro-
phages and perhaps this lead to a similar inability to stimulate T suppressor cells sufficiently. 
Whether a heterogeneity in etio-pathogenesis is also the case for Graves’ disease remains 
unknown. Spontaneously developing animal models of the disease would be helpful in 
unraveling this question.
If there are indeed various and different routes that lead to destructive autoimmune 
thyroiditis, and if one wants to attempt to correct the underlying immune abnormalities to 
prevent the development or progression of destructive autoimmune thyroiditis, then differ-
ent therapeutic approaches need to be carried out in patients who differ in such routes. Obvi-
ously a more precise definition of cellular immune aberrancies is required in individual cases 
of destructive autoimmune thyroiditis, before therapies that aim at correcting the immune 
disturbances could even be tested successfully. With regard to preventive therapies, several 
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are emerging. This thesis shows that interventions with hormones, such as with DHEA and its 
metabolites, with glucocorticoids and with Vitamin D3 analogs (lacking effects on the calcium 
metabolism, but retaining their tolerance-inducing effects) hold promise for the future, as do 
vaccination protocols with “tolerogenic” DC or approaches to stimulate regulator T cells.
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Figure 1. The general blueprint for the pathogenesis of the various phases of autoimmune thyroiditis 
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Two polar forms of autoimmune reactivity to the thyroid gland are known, a catabolic and 
an anabolic form. The catabolic form is best known as destructive autoimmune thyroiditis 
subdivided in Hashimoto goiter and atrophic thyroiditis, while the anabolic form is generally 
referred to as Graves’ disease. Immune responses to thyroid specific autoantigens form the 
basis of these autoimmune thyroid diseases. The most important antigens are thyroperoxidase 
(TPO), thyroglobulin (Tg) and the TSH receptor. Antibodies to TPO and Tg are found in high 
titres in the serum of the majority of patients with the catabolic forms of autoimmune thyroid 
disease, i.e. Hashimoto goiter and atrophic thyroiditis. Although such antibodies to TPO and 
Tg are good markers of Hashimoto goiter and atrophic thyroiditis, macrophages activated by 
TPO- and Tg-specific T helper-1 (Th 1) cells, cytotoxic CD8+ T cells and apoptotic interactions 
between thyrocytes and these inflammatory cells are believed to play a more prominent role 
in the actual destruction of the thyroid parenchyma. Antibodies to the TSH receptor are a 
hallmark of the anabolic form of autoimmune thyroid disease, i.e. Graves´disease, and cause 
the stimulation of thyrocytes resulting in the hyperfunction and growth of thyrocytes char-
acteristic of this autoimmune disorder.
Prior to the disease development and autosensitization an accumulation of antigen 
presenting cells (APC), i.e. of dendritic cells (DC) and macrophages (mφ) is observed in the 
thyroid gland around the follicles (as observed in the animal models of the disease). It is 
generally thought that these APC originate from blood monocytes that have entered the thy-
roid gland and have differentiated into DC or mφ. On the basis of their normal physiological 
role, these cells presumably take up self-antigens (TPO, Tg and the TSH receptor) and process 
these into peptides, which they present, after a so-called “steady-state” or “homeostatic” 
trafficking to the draining lymph nodes, to T lymphocytes in the para-cortical area of these 
nodes. Normally this leads to tolerance induction (an immunological non-reactivity) to these 
self antigens via the induction of T regulatory cells. However in the case of thyroid autosen-
sitization and the development of thyroid autoimmune disease, not T regulatory cells, but 
erroneously T effector lymphocytes and B cells become activated to these self antigens and 
thyroid autoimmunity is induced. 
The focus of this thesis is on the role of APC in autoimmune thyroid disease. Although 
almost all cells can act as antigen presenting cells to some degree, there are cells in the 
immune system that excel in this function, specifically B cells, accessory macrophages and 
above all, the dendritic cell. Dendritic cells are critically involved in the initiation of primary T 
cell responses and the generation of T cell dependent autoantibody formation. 
Langerhans cells in the skin are prototypic DC and it is now well accepted that the Langer-
hans cells of the skin pick up foreign antigens, process these antigens and travel with these 
– as so-called veiled cells - via the lymph to draining lymph nodes to populate the T cell areas 
of these nodes as interdigitating cells. The interdigitating cells act in presenting the trans-
ported and processed antigens to the surrounding T cells, and stimulate these lymphocytes 
to proliferate and to differentiate. In the case of a foreign (“danger”) signal the T cells are 
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programmed for an effector response, in the case of self-antigens (“non-danger”) the T cells 
are programmed for a tolerogenic response. 
Langerhans cells, veiled cells, interdigitating cells and similar antigen transporting and 
presenting cells from other sites are generally referred to as dendritic cells (DC) since these 
cells share many morphological and functional characteristics with the so-called dendritic 
cells initially described by Steinman in the spleen. Cells belonging to the dendritic cell group 
are the most potent antigen transporting and presenting cells, and have considerable poten-
tial for use in immunotherapy and tolerance induction. The population of dendritic cells is 
heterogeneous. Lymphoid dendritic cells orginate from the thymus whereas plasmacytoid 
dendritic cells have a plasmacytoid precursor in the peripheral blood while myeloid dendritic 
cells originate form CD34+ precursors and from CD14+ circulating monocytes.
In vitro generation of antigen presenting cells from monocytes with a morphology and 
function reminiscent of lymph-borne veiled cells was already described by Drexhage et al. 
in 1989. In chapter 3 this method has been further explored and the impact of diphenylene 
iodonium (DPI) and ascorbate, both nicotinamide adeninedinucleotide phosphate (NADPH) 
inhibitors, to enhance transition of monocytes into veiled cells has been studied. Monocytes 
were cultured for 24 hours while avoiding adherence to polypropylene tubes and avoid-
ing activation of NADPH oxidase. The generated veiled cells were actively moving cells like 
lymph-borne veiled cells in vivo. The monocyte-derived veiled cell population consisted of 
CD14dim/- and CD14bright cells. Of these the CD14dim/- veiled cells were as good in stimulating 
allogeneic T cell proliferation as prototypic immature dendritic cells obtained after one week 
of adherent culture of monocytes in granulocyte-macrophage-colony stimulating factor 
(GM-CSF) and interleukin (IL)-4. This underscores the accessory cell function of the monocyte 
derived CD14dim/- veiled cells. Although the CD14dim/- veiled cells had a modest expression of 
the dendritic cell specific marker CD83 and were positive for the Langerhans cell marker S-100, 
expression of the dendritic cell specific markers CD1a, Langerin, DC-SIGN, and DC-LAMP were 
absent. This indicates that the here generated CD14dim/- veiled cells can not be considered 
as classical dendritic cells. It was not possible to transform the CD14dim/- monocyte-derived 
veiled cells population into typical dendritic cells by culturing for one week in GM-CSF/IL-4 
or LPS. Under these circumstances, all cells died while presenting some characteristics of 
macrophages. 
The IL-12 production from monocyte-derived CD14dim/- veiled cells was lower, whereas the 
production of IL-10 was higher as compared to immature dendritic cells. Consequently the T 
cells which were stimulated by these monocyte-derived veiled cells produced less interferon 
gamma in comparison to T cells stimulated by immature dendritic cells (hence there was a 
skewing of the T cell response away from Th1 cells). 
In conclusion the method described in chapter 3 generates CD14dim/- veiled accessory cells 
which are not classical dendritic cells but appear to be more related to the macrophage series. 
They must thus be considered as a potent subpopulation of the accessory macrophages.
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Chapters 4 and 5 are dealing with the effect of hormones on the generation of classical 
dendritic cells and veiled accessory macrophages. Hormones with a known or suspected 
effect on autoimmune reactivity were selected.
Dehydroepiandrosterone (DHEA) is one of the adrenal steroid hormones. Although no 
major endocrine function has been ascribed to DHEA, it has been suggested that DHEA plays 
a role in age-related processes such as fat depot distribution and neurodegeneration. DHEA 
is considered as an immunostimulating steroid hormone of which the effects on the develop-
ment of dendritic cells are unknown. The effects of DHEA tend to oppose those of the other 
adrenal glucocorticoid hormone cortisol. Glucocorticoids are known to suppress the immune 
response at different levels and have recently been shown to modulate the development of 
dendritic cells, thereby influencing the initiation of the immune response. Variations in the 
duration of exposure to and doses of glucocorticoids however, have resulted in conflicting 
effects on the development of dendritic cells. 
In chapter 4, the effects of a continuous high level of exposure to the adrenal steroid DHEA 
on the generation of immature dendritic cells from monocytes, as well as the effects of the 
opposing steroid dexamethasone (DEX) on this development were studied. 
The continuous presence of DHEA (10-6 M) in GM-CSF/IL-4-induced monocyte-derived den-
dritic cells cultures resulted in immature dendritic cells with a morphology and functional 
capabilities similar to those of typical immature dendritic cells, such as T cell stimulation 
and IL-12/IL-10 production, but with a slightly altered phenotype of increased CD80 and 
decreased CD43 expression which are markers of maturity.
The coninuous presence of DEX at a concentration of 10-6 M in the monocyte/DC cultures 
resulted in the generation of plastic-adherent macrophage-like cells in place of typical imma-
ture dendritic cells, with increased CD14 expression, but decreased expression of the typical 
dendritic cell markers CD1a, CD40 and CD80. These cells were strongly reactive for acid phos-
phatase, but equally capable of stimulating T cell proliferation as immature dendritic cells. 
The production of IL-12 by these macrophage-like cells was virtually shut down, whereas the 
production of IL-10 was significantly higher than that of control immature dendritic cells. 
The continuous presence of a high level of glucocorticoids during the generation of imma-
ture dendritic cells from monocytes thus modulates this development away from dendritic 
cells towards a macrophage-like cell with equally strong accessory capabilities, yet the com-
bination of a low CD80 expression and a shutdown of IL-12 production suggests the possibil-
ity of DEX-generated cells preferably initiating a Th2-biased response. These effects by DEX 
on dendritic cells development contrast with those by DHEA, which resulted in a more typical 
dendritic cell although possessing a phenotype possibly indicating a more mature state of 
the cell.
In chapter 4a the effects of DEX on the generation of veiled accessory macrophages from 
monocytes are described. The findings were compatible with the view expressed above 
that this hormone hampers the generation of Th1 skewing immunostimulatory APC from 
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monocytes; the generated VC were less capable to stimulate T cells and produced less of the 
cytokine IL-12.
1α, 25-Dihydroxyvitamin D3 (1,25(OH)2D3) is a steroid hormone known for its ability to 
regulate calcium metabolism. The presence of the vitamin D3 receptor in almost all types of 
immune cells and the ability of 1,25(OH)2D3 to affect immune cell function in vitro is indicative 
of other actions of this hormone. The ability of 1,25(OH)2D3 to stimulate cell differentiation 
has been well characterized. For instance, this hormone can inhibit proliferation and induce 
differentiation of benign cells such as keratinocytes, malignant cells such as prostate, breast 
and colon adenocarcinoma cells and various leukemic cells. 
In chapter 5, the impact of 1,25(OH)2D3 on the generation of immature dendritic cells from 
monocytes has been studied. Human peripheral blood monocytes were cultured to imma-
ture dendritic cells in the presence of GM-CSF and IL-4 for one week, with or without the extra 
addition of 10-8 M 1,25(OH)2D3 to the culture. Their phenotype (CD14, CD1a, CD83, HLA-DR, 
CD80, CD86 and CD40 expression) was studied by FACS analysis and their T cell stimulatory 
potential in allogeneic mixed lymphocyte reaction (allo-MLR) was assessed. The in vitro pro-
duction of IL-10, IL-12 and TGF-ß by ELISA was investigated.
1,25(OH)2D3, when added to monocytes in culture with GM-CSF and IL-4, hampered 
the maturation of monocytes into immature dendritic cells. Firstly the phenotype of the 
1,25(OH)2D3-differentiated dendritic cells was affected with a impaired down regulation of 
the monocytic marker CD14 and a impaired up regulation of CD1a, CD83, HLA-DR, CD80 and 
CD40. CD86 was expressed on more 1,25(OH)2D3-differentiated dendritic cells. Secondly, the T 
cell stimulatory capability of 1,25(OH)2D3-differentiated dendritic cell was up regulated from 
that of the original monocytes to a lesser degree than dendritic cells differentiated without 
1,25(OH)2D3 when tested in allogenic mixed lymphocyte reaction (MLR). With regard to the 
production of cytokines, SAC-induced IL-10 production, although not enhanced, remained 
considerably high in 1,25(OH)2D3-differentiated dendritic cells, whereas it was strongly down 
regulated in dendritic cells generated in the absence of 1,25(OH)2D3. SAC/IFNγ-induced IL-12 
production was clearly up regulated in both types of dendritic cells from that of the original 
monocytes and TGF-ß production down regulated.
These data confirm earlier reports that 1,25(OH)2D3 hampers the maturation of fully active 
immunostimulatory MHC-classII+,CD1a+,CD80+ dendritic cells from monocytes. Our data 
supplement the other reports in showing that the expression of CD86 was up regulated in 
1,25(OH)2D3-differentiated dendritic cells, while the capability for IL-10 production remained 
high. Collectively, this is in line with earlier descriptions of suppressive activities of this ste-
roid-like hormone regarding the stimulation of cell-mediated immunity. 
In Chapter 5 a the effect of 1,25(OH)2D3 on the generation of veiled accessory macrophages 
from monocytes is described. Exposure of monocytes to 1,25(OH)2D3 prior to an overnight 
non-adherent cell culture resulted in the generation of veiled cells that had a very low IL-
12 production capability and a poor T cell stimulatory capacity as compared to veiled cells 
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generated in the presence of iodinated compounds. These data underscore that 1,25(OH)2D3 
is a hormone hampering the maturation of fully active Th1 skewing APC from monocytes. 
Blood monocytes of patients with thyroid autoimmune disease show a defective capability 
to rearrange their cortical actomyosin cytoskeleton (‘polarize’) in response to chemoattrac-
tants. Since such cytoskeletal rearrangements also take place after adherence of monocytes 
to fibers of the extracellular matrix, it is not surprising that monocytes are primed for che-
moattractant stimulation after fibronectin adherence, showing an enhanced polarization 
toward chemoattractants.
In chapter 6, the adherence capability of blood monocytes from patients with thyroid 
autoimmune disease to a fibronectin matrix, and their integrin expression and chemoattrac-
tant-induced polarization both before and after fibronectin adherence were studied. Since 
cytoskeletal rearrangements are also needed for the development of veils during the transi-
tion of monocytes into veiled accessory macrophages, the transition of fibronectin-adhered 
monocytes of patients with autoimmune disease of the thyroid was investigated as well.
Adherent and non-adherent monocyte populations from patients with autoimmune 
disease of the thyroid and healthy controls were subjected to a polarization test with the 
chemoattractant fMLP (or MCP-1), FACS analyses (FITC-labelled fibronectin, CD29, CD49e, d, 
b, and a) and tested for their capability to develop into veiled antigen presenting cells.
Monocytes of healthy individuals showed an improved chemoattractant-induced cell 
polarization after fibronectin adherence, not reflected by monocytes from patients with 
autoimmune disease of the thyroid, in which chemoattractant-induced polarization wors-
ened. Monocytes of healthy individuals upregulated CD49e and d integrins and their capabil-
ity to bind FITC-labelled fibronectin after adherence to a fibronectin-coated plate, as well as 
enhancing their capability to generate T cell-stimulatory veiled cells. Monocytes of patients 
with autoimmune disease of the thyroid did not.
These data indicate that integrin- (and chemokine)-mediated functions are hampered in 
monocytes from patients with autoimmune disease of the thyroid. Because, integrin action 
is pivotal to processes such as monocyte adherence to endothelial cells, uropod formation, 
migration into tissues and differentiation into antigen presenting cells and macrophages, 
these defects might underly immune dysbalances important in thyroid autoimmune devel-
opment.
In chapter 6a it is described that the generation of prototypic DC from monocytes (via 
culture in GM-CSF and IL-4) was not altered in patients with autoimmune thyroiditis.
In conclusion, a population of antigen presenting cells, characterized by veils, could be 
generated in 24 hours from monocytes. Such veiled cells were equally potent in stimulating 
T cells as classical monocyte-derived immature dendritic cells, yet were different in marker 
pattern, cytokine production and Th1/Th2 skewing capability in that they were less potent to 
stimulate Th1 cells. The veiled cells were also more macrophage-like cells.
162
Su
m
m
ar
y
Hormones modulate the function of both dendritic cells and veiled cells. The effects of 
dexamethasone and 1,25(OH)2D3 were inhibitory on the generation of both antigen present-
ing cells populations from monocytes (rendering them actually more macrophage-like), 
while DHEA had a slight immune stimulating effect.
The motility of monocytes and the generation of veiled accessory macrophages from 
monocytes was disturbed in patients with autoimmune thyroid disease, particularly after 
adherence to fibronectin. The generation of monocyte-derived dendritic cells was intact.
This thesis thus shows aberrancies in the APC function of monocyte-derived veiled mac-
rophages in patients with autoimmune thyroiditis (particularly after fibronectin adherence) 
that may play a role in the erroneous tuning of the immune system towards self reactivity and 
that interventions with hormones, such as with Vitamin D3 analogues, which lack effects on 
the calcium metabolism but retain effects on APC development, holds promise for the future 
of patients with autoimmune thyroid disease.
Samenvatting
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Auto-immuunziektes van de schildklier kunnen zowel een katabole als anabole vorm aan-
nemen. De katabole vorm staat bekend als destructieve auto-immuun thyreoïditis onder te 
verdelen in Hashimoto struma en atrofische thyreoïditis. De anabole vorm van auto-immuun 
thyreoïditis refereert in het algemeen aan de ziekte van Graves. Immuunreacties op schild-
klierspecifieke auto-antigenen vormen de basis van de genoemde schildklierziektes. De 
belangrijkste antigenen zijn thyreoperoxidase (TPO), thyreoglobuline (Tg) en de TSH recep-
tor. Antilichamen tegen TPO en Tg worden in hoge concentraties gevonden in het serum 
van patiënten met katabole vormen van auto-immuunziektes van de schildklier, te weten 
Hashimoto struma en atrofische thyreoïditis. Alhoewel deze antilichamen tegen TPO en Tg 
goede merkstoffen zijn voor Hashimoto struma en atrofische thyreoïditis, spelen macrofagen 
geactiveerd door TPO- en Tg-specifieke T helper 1 (Th1) cellen, cytotoxische CD8+ T cellen en 
apoptotische interacties tussen schildkliercellen en deze inflammatoire cellen een belang-
rijkere rol in de destructie van schildklierparenchym. Antilichamen tegen de TSH-receptor 
zijn de hoeksteen van de anabole vorm van auto-imuunziekten van de schildklier, te weten 
de ziekte van Graves, en stimuleren schildkliercellen leidend tot hyperfunctie en groei van 
schildkliercellen die karakteristiek zijn voor deze auto-immuunaandoening.
Voorafgaand aan het ontstaan van de ziekte en de autosensitisatie vindt een ophoping 
van antigeen presenterende cellen (APC), oftewel dendritische cellen (DC) en macrofagen 
in de schildklier plaats rondom de follikels (althans in diermodellen). In het algemeen wordt 
aangenomen dat deze APC ontstaan uit bloedmonocyten die de schildklier zijn binnen-
gedrongen en zijn gedifferentieerd tot DC of macrofagen. Conform de normale fysiologie 
nemen deze cellen eigen antigenen (TPO, Tg en de TSH receptor) op en verwerken deze tot 
peptiden die worden gepresenteerd, na een zogenaamde “steady state” of “homeostatisch” 
transport naar de drainerende lymfklieren, aan T lymfocyten in de paracorticale velden van 
deze lymfklieren. Normaliter leidt dit tot tolerantie-inductie (immunologische non-reactivi-
teit) voor deze eigen antigenen door middel van inductie van regulerende T-cellen. Echter, 
in het geval van autosensitisatie van de schildklier en het ontstaan van auto-immuunziekten 
van de schildklier, worden in plaats van de regulerende T-cellen, effector T-cellen en B-cellen 
geactiveerd tegen deze eigen antigenen en wordt aldus auto-immuniteit van de schildklier 
geïnduceerd. 
Dit proefschrift richt zich op de rol van antigeen presenterende cellen bij auto-immuun-
ziektes van de schildklier. Alhoewel vrijwel alle cellen in zekere mate kunnen functioneren als 
antigeen presenterende cellen, excelleren sommige cellen van het immuunsysteem hierin, 
dit zijn met name B-cellen, ‘accessory’ macrofagen en bovenal, de dendritische cel. Dendriti-
sche cellen spelen een sleutelrol bij de initiatie van de primaire T-cel reactie en de vorming 
van T-cel afhankelijke auto-antilichamen. 
Langerhans cellen in de huid zijn protoype DC en inmiddels is het algemeen aanvaard 
dat Langerhans cellen in de huid vreemde antigenen oppakken, vervolgens verwerken en 
zich met deze antigenen verplaatsen – als zogenaamde sluiercellen - via de lymfe naar de 
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drainerende lymfklieren om zich te nestelen als interdigiterende cellen in T-cel velden van 
deze lymfklieren. De interdigiterende cellen presenteren de getransporteerde en verwerkte 
antigenen aan de omringende T-cellen aan en stimuleren deze lymfocyten om te prolifereren 
en te differentieren. In het geval van een vreemd (‘danger’) signaal worden de T-cellen gepro-
grammeerd voor een effector respons terwijl in het geval van eigen antigenen (‘non-danger’) 
de T-cellen worden geprogrammeerd voor een tolerantierespons. 
Langerhans cellen, sluiercellen, interdigiterende cellen en vergelijkbare antigeen trans-
porterende en presenterende cellen worden in het algemeen dendritische cellen genoemd 
(DC) omdat deze cellen vele morfologische en functionele eigenschappen delen met de 
zogenaamde dendritische cellen die in eerst instantie werden beschreven door Steinman 
in de milt. Cellen die behoren tot de groep van dendritische cellen zijn de meest krachtige 
antigeen transporterende en presenterende cellen en kunnen potentieel worden toegepast 
in immunotherapie en tolerantie-inductie. De familie van dendritische cellen is heterogeen. 
Lymfoïde dendritische cellen worden gevormd in de thymus in tegenstelling tot plasmacyto-
ide dendritische cellen die een plasmacytoïde voorloper hebben in het perifere bloed terwijl 
myeloïde dendritische cellen afstammen van CD34+ voorlopers en van CD14+ circulerende 
monocyten.
In vitro differentiatie van monocyten tot antigen presenterende cellen met een morfologie 
en functie die zich verhouden tot die van sluiercellen in lymfe werd door Drexhage cum suis 
beschreven in 1989. In hoofdstuk 3 wordt deze methode verder onderzocht en wordt de 
invloed van diphenyleen iodonium (DPI) en ascorbaat, beide nicotinamide adeninedinucle-
otide fosfaat (NADPH) remmers, op de vorming van sluiercellen uit monocyten bestudeerd. 
Monocyten werden gedurende 24 uur gekweekt in polypropyleen reageerbuizen en acti-
vatie van NADPH oxidase werd voorkomen. De gevormde sluiercellen bewogen actief zoals 
‘sluiercellen in lymfe in vivo. De monocyt afgeleide sluiercel populatie bestond uit CD14dim/- 
en CD14bright cellen. De CD14dim/- sluiercellen stimuleerden allogene T-cel proliferatie even 
krachtig als prototype immature dendritische cellen die waren verkregen na een één week 
durende adherente kweek van monocyten in aanwezigheid van granulocyte-macrophage-
colony stimulating factor (GM-CSF) en interleukine 4 (IL-4). Dit benadrukt de ‘accessory’ func-
tie van de van monocyten afgeleide CD14dim/- sluiercellen. Alhoewel de CD14dim/- sluiercellen 
een redelijke expressie vertoonden van de voor dendritische cellen specifieke merkstof CD83 
en een positieve expressie vertoonden van de Langerhans cel specifieke merkstof S-100, was 
expressie van voor dendritische cellen specifieke merkstoffen CD1a, Langerin, DC-SIGN en 
DC-LAMP afwezig. Dit impliceert dat de gevormde CD14dim/- monocyt afgeleide sluiercellen 
niet kunnen worden beschouwd als klassieke dendritische cellen. Het was niet mogelijk om 
de CD14dim/- sluiercellen om te vormen tot typische denritische cellen door middel van een 
één week durende kweek in GM-CSF/IL-4 of LPS. Onder deze omstandigheden gingen alle 
cellen dood nadat ze enkele karakteristieke aspecten van macrofagen hadden vertoond.
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De IL-12 productie van monocyt afgeleide CD14dim/- sluiercellen was lager terwijl de pro-
ductie van IL-10 hoger was dan die van immature dendritische cellen. Als gevolg hiervan 
produceerden de T-cellen die waren gestimuleerd door deze monocytafgeleide sluiercellen 
minder interferon gamma in vergelijking met T-cellen die gestimuleerd waren door imma-
ture dendritische cellen (oftewel de T-cel respons ging voornamelijk in de richting van Th1 
cellen)
Concluderend kan worden gesteld dat de methode die wordt beschreven in hoofdstuk 
3 CD14dim/- gesluierde ‘accessory’ cellen oplevert die geen klassieke dendritische cellen zijn 
maar meer lijken op macrofagen. Deze cellen moeten dus worden beschouwd als een krach-
tige subpopulatie van ‘accessory’ macrofagen.
De hoofdstukken 4 en 5 richten zich op de effecten van hormonen op de vorming van klas-
sieke dendritische cellen en gesluierde ‘accessory’ macrofagen. De onderzochte hormonen 
hebben een bekend of vermoed effect op auto-immuniteit. Dehydroepiandrosteron (DHEA) 
is één van de steroïde hormonen van de bijnier. Alhoewel er geen duidelijke endocriene 
functie wordt toegeschreven aan DHEA, is gesuggereerd dat DHEA een rol speelt in verou-
deringsprocessen zoals vetverdeling en neurodegeneratie. DHEA wordt beschouwd als een 
immuunstimulerend steroïd hormoon waarvan de effecten op de ontwikkeling van dendri-
tische cellen onbekend zijn. DHEA zou de werking van het andere glucocorticoïde hormoon 
van de bijnier, cortisol, tegen gaan. Glucocorticoïden onderdrukken de immuunrespons op 
verschillende niveau’s. Onlangs is aangetoond dat deze hormonen de ontwikkeling van den-
dritische cellen moduleren waardoor de initiatie van de immuunrespons wordt beinvloed. 
Variatie van de blootstelling aan en variatie van de doses glucocorticoïden heeft echter 
geleid tot tegenstrijdige effecten op de ontwikkeling van dendritische cellen. 
In hoofdstuk 4 worden de effecten van een continue hoge spiegel van DHEA en dexame-
thason (DEX) op de ontwikkeling van monocyten tot immature dendritische cellen gerap-
porteerd. 
De continue aanwezigheid van DHEA (10-6 M) in GM-CSF/IL-4 geïnduceerde monocyt afge-
leide dendritische celculturen leidde tot immature dendritische cellen met morfologische en 
functionele aspecten die vergelijkbaar waren met die van typische immature dendritische 
cellen. Hierbij moet worden gedacht aan T-cel stimulatie en IL-12/IL-10 productie. Het feno-
type was enigszins afwijkend zich uitend in verhoogde CD80 expressie en verlaagde CD43 
expressie, beide merkstoffen voor maturiteit.
De continue aanwezigheid van DEX met een concentratie van 10-6 M in de monocyt/DC 
kweken resulteerde in de vorming van aan plastic adherente macrofaagachtige cellen in 
plaats van typische immature dendritische cellen. Deze macrofaagachtige cellen vertoonden 
een verhoogde CD14 expressie maar een verlaagde expressie van typische dendritische cel 
merkstoffen zoals CD1a, CD40 en CD80. Deze cellen vertoonden verder een sterke reactie 
met zure fosfatase maar een capaciteit om T-cellen te stimuleren die vergelijkbaar was met 
die van immature dendritische cellen. De productie van IL-12 door deze macrofaagachtige 
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cellen was vrijwel nihil terwijl de productie van IL-10 significant hoger was dan die van imma-
ture dendritische cellen.
De continue aanwezigheid van een hoge concentratie glucocorticoïden gedurende de vor-
ming van immature dendritische cellen uit monocyten verschuift derhalve de ontwikkeling 
tot dendritische cellen naar een ontwikkeling tot macrofaagachtige cellen met vergelijkbare 
sterke accessoire capaciteiten. Echter, de combinatie van een lage CD80 expressie en een 
afwezige IL-12 productie suggereert de mogelijkheid van DEX-gevormde cellen die bij voor-
keur een Th2 respons initieren. Deze effecten van DEX op de ontwikkeling van dendritische 
cellen contrasteren met die van DHEA die resulteerden in meer typische dendritische cellen 
alhoewel het fenotype mogelijk wees op een meer mature status van de cel.
In hoofdstuk 4a worden de effecten van DEX op de vorming van gesluierde ‘accessory’ 
macrofagen vanuit moncyten bescheven. De bevindingen waren compatibel met het eerder 
beschreven fenomeen dat DEX de vorming belemmert van immuunstimulerende antigen 
presenterende cellen (die de immunrespons in de richting van Th1 cellen sturen) uit mono-
cyten. De gevormde sluiercellen waren minder goed in staat om T-cellen te stimuleren en 
produceerden minder IL-12. 
1α, 25-Dihydroxyvitamin D3 (1,25(OH)2D3) is een steroid hormoon dat het calcium metabo-
lisme reguleert. De aanwezigheid van de vitamine D3 receptor in vrijwel alle immuuncellen 
en het vermogen van 1,25(OH)2D3 om de functie van immuuncellen in vitro te beinvloeden 
zijn duidelijke aanwijzingen dat dit hormoon ook andere functies heeft. Stimulatie van 
celdifferentiatie door 1,25(OH)2D3 is duidelijk vastgelegd. Bijvoorbeeld, dit hormoon kan de 
proliferatie remmen en de differentiatie tot goedaardige cellen induceren van cellen zoals 
keratinocyten, kwaadaardige cellen zoals prostaat-, borst- en dikke darm kanker cellen en 
verscheidene leukemie cellen. 
In hoofdstuk 5 wordt de invloed van 1,25(OH)2D3 op de vorming van immature denritische 
cellen uit monocyten bestudeerd. Humane perifere monocyten uit bloed werden gekweekt 
tot immature dendritische cellen in de aanwezigheid van GM-CSF en IL-4 gedurende één 
week met of zonder toevoeging van 10-8 M 1,25(OH)2D3. Het fenotype van deze cellen, te 
weten CD14, CD1a, CD83, HLA-DR, CD80, CD86 en CD40 expressie, werd bestudeerd middels 
FACS analyse en de T-cel stimulerende potentie werd in een ‘allogenic mixed lymfocytes reac-
tion’ (allo-MLR) bepaald. Verder werd de in vitro productie van IL-10, IL-12 en TGF-β gemeten 
door middel van een ELISA. 
Wanneer 1,25(OH)2D3 werd toegevoegd aan monocyten in een kweek met GM-CSF en 
IL-4, dan werd de rijping van monocyten tot immature dendritische cellen belemmerd. Ten 
eerste was het fenotype van 1,25(OH)2D3 gedifferentieerde dendritische cellen aangedaan 
met een gestoorde ‘down-regulation’ van de monocyt merkstoffen CD14 en een verstoorde 
‘upregulation’ van CD1a, CD83, HLA-DR, CD80 en CD40. Expressie van CD86 was verhoogd in 
1,25(OH)2D3 gedifferentieerde dendritische cellen. Ten tweede, de capaciteit van 1,25(OH)2D3 
gedifferentieerde dendritische cellen om T-cellen te stimuleren (getest in een ‘allogenic 
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mixed lymphocyte reaction’) was in mindere mate verhoogd ten opzichte van de oorspron-
kelijke monocyten dan dendritische cellen gedifferentieerd zonder 1,25(OH)2D3. Ten aanzien 
van de productie van cytokines bleef de SAC geïnduceerde IL-10 productie van 1,25(OH)2D3 
gedifferentieerde dendritische cellen hoog terwijl het duidelijk verlaagd was in dendritische 
cellen gevormd in afwezigheid van 1,25(OH)2D3 . De SAC/IFNγ geïnduceerde IL-12 productie 
was duidelijk verhoogd en de TGF-β productie was verlaagd in beide types dendritische cel-
len in vergelijking met oorspronkelijke monocyten.
Deze gegevens bevestigen eerder publicaties dat 1,25(OH)2D3 de rijping van monocyten 
tot actieve immuunstimulerende MHC-Class II+, CD1a+, CD80+ dendritische cellen belem-
mert. Deze data vullen eerdere publicaties aan door te laten zien dat de expressie van CD86 
hoger was in 1,25(OH)2D3 gedifferentieerde dendritische cellen terwijl de capaciteit om IL-10 
te produceren hoog bleef. Dit bevestigt voorgaande rapportages betreffende de suppressie 
van cellulaire immuniteit door dit type steroidachtige hormonen. 
In hoofdstuk 5a wordt het effect van 1,25(OH)2D3 op de vorming van gesluierde ‘accessory’ 
macrofagen vanuit monocyten beschreven. Blootstelling van monocyten aan 1,25(OH)2D3 
voorafgaande aan een niet-adherente celkweek gedurende de nacht resulteerde in de vor-
ming van sluiercellen met een zeer lage productie van IL-12 en een zwakke T-cel stimulerende 
capaciteit in vergelijking met sluiercellen gevormd in de aanwezigheid van gejodeerde stof-
fen. Deze bevindingen onderstrepen dat 1,25(OH)2D3 de rijping van actieve antigeen pre-
senterende cellen (die de immuunrespons in de richting van Th1 cellen sturen) gevormd uit 
monocyten belemmert.
Monocyten uit het bloed van patiënten met auto-immuunziekten van de schildklier verto-
nen een verminderde capaciteit om hun corticale actomyosine cytoskelet aan te passen (te 
polariseren) als reactie op chemoattractantia. Aangezien dergelijke aanpassingen ook plaats 
vinden nadat monocyten zich hebben vastgekleefd aan de extracellulaire matrix, is het niet 
verbazend dat monocyten verhoogd gevoelig zijn voor chemoattractant stimulatie na adhe-
rentie aan fibronectine zich uitend als een versterkte polarisatie op chemoattractantia.
In hoofdstuk 6 worden de adherentie capaciteit aan een fibronectine matrix, de expres-
sie van integrinen en de chemoattractant geïnduceerde polarisatie van monocyten uit het 
bloed van patiënten met een schildklier auto-immuunziekte bepaald voor en na fibronectine 
adherentie. Aangezien aanpassingen van het cytoskelet ook noodzakelijk zijn tijdens de 
ontwikkeling van sluiercellen vanuit monocyten, werd deze differentiatie van fibronectine 
adherente monocyten van patiënten met autoimmuunziekten van de schildklier eveneens 
bestudeerd.
Adherente en niet-adherente monocyten populaties van patiënten met auto-immuunziek-
ten van de schildklier en gezonde personen werden onderworpen aan een polarisatietest 
met de chemoattractant fMLP (of MCP-1) en aan FACS analyses met FITC-gelabellmerkte 
fibronectin, voor CD29 en voor CD49e, d, b en a). Tevens werd de capaciteit van deze cellen 
om te ontwikkelen tot een gesluierde antigeen presenterende cel getest.
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Monocyten van gezonde personen vertoonden een verbeterde ‘chemoattractant’ geïndu-
ceerde cel polarisatie na adherentie aan fibronectine terwijl de monocyten van patiënten 
met auto-immuunziekten van de schildklier een verslechterde polarisatie lieten zien. Mono-
cyten van gezonde personen regelden CD49e en d integrines op, evenals hun vermogen om 
FITC-gemerkte fibronectine te binden na adherentie aan een plaat bedekt met fibronectine. 
Tevens was de capaciteit om T-cel stimulerende ‘veiled cells’ te vormen versterkt. Monocyten 
van patiënten met auto-immuunziekten van de schildklier vertoonden deze eigenschappen 
niet.
Deze data impliceren dat integrine- (en chemokine)- gemedieerde functies gestoord zijn 
in patiënten met auto-immuunziekten van de schildklier. Aangezien integrine activiteit van 
essentieel belang is voor processen zoals adherentie van monocyten aan endotheliale cellen, 
uropod vorming, migratie in weefsels en differentiatie tot antigeen presenterende cellen en 
macrofagen, zouden deze gestoorde functies ten grondslag kunnen liggen aan belangrijke 
verstoorde immunologische evenwichten in auto-immuunziekten van de schildklier. 
In hoofdstuk 6a wordt beschreven dat de vorming van prototype dendritische cellen uit 
monocyten (door middel van een kweek in GM-CSF en IL-4) niet verschilde tussen patiënten 
met auto-immuunziekten van de schildklier en gezonde personen.
Concluderend kan worden gesteld dat een populatie van antigeen presenterende cellen, 
gekarakteriseerd door sluiers, kon worden gevormd uit monocyten in 24 uur. Dergelijke slui-
ercellen stimuleerden T-cellen even krachtig als klassieke monocyt afgeleide immature den-
dritische cellen. Echter, het patroon van merkstoffen, de cytokine productie en de Th1/Th2 
sturingscapaciteit waren verschillend. De sluiercellen vertoonden minder sterke stimulatie 
van Th1 cellen en ze leken meer op macrofaagachtige cellen.
Hormonen moduleerden zowel de functie van dendritische cellen als sluiercellen. De 
effecten van dexamethason en 1,25(OH)2D3 remden de vorming van zowel antigeen presen-
terende cel populaties vanuit monocyten (veranderden monocyten in macrofaagachtige 
cellen) terwijl DHEA een beperkt immuunstimulerend effect had. 
De motiliteit van monocyten en de vorming van gesluierde ‘accessory’ macrofagen uit 
monocyten was verstoord in patiënten met auto-immuunziekten van de schildklier vooral na 
adherentie aan fibronectine. De vorming van monocyt afgeleide dendritische cellen was nor-
maal. Dergelijke APC afwijkingen spelen mogelijk een rol in de verstoring van het immuun-
systeem richting zelfreactiviteit. Interventies met hormonen, zoals vitamine D3 analogen, die 
geen effect hebben op het calcium metabolisme maar wel op de ontwikkeling van antigeen 
presenterende cellen, bieden een perspectief voor patiënten met auto-immuunziekte van 
de schildklier.
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